Heterologous prime boost vaccine compositions and methods of use
Through the ceDNA vaccine platform and the heterologous primary immunization-enhanced solution of mRNA or peptide, the problems of insufficient immune memory and limited AAV vector packaging capacity in existing vaccine technologies are solved, and the CD8+ T cell response and immune protection effect is improved.
Patent Information
- Application Number
- CN202380033783.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-14
- Filing Date
- 2023-03-14
- Publication Date
- 2024-12-03
AI Technical Summary
Existing vaccine technologies are difficult to trigger long-lasting immune memory, especially in combating more challenging diseases. Traditional homologous primitive-enhanced regimens are inefficient, and the results of heterologous primitive/enhanced regimens are difficult to predict. The packaging capacity of AAV vectors is limited. and strong immunogenicity, resulting in low efficiency of gene therapy.
The ceDNA vaccine platform is used as a primary immune vaccine, and a booster vaccine is combined with mRNA or peptide. Through a heterologous primary immune-enhancing scheme, the immune system is activated by the synergistic effect of DNA vectors and mRNA or peptides to improve CD8+ T cell response.
It achieves stronger antigen synergistic response and lasting immunity, improves the protection effect of antigens, and avoids the low efficiency and immunogenicity of immune responses in traditional vaccines.
Smart Images

Figure BDA0005080038450000501 
Figure BDA0005080038450000511 
Figure BDA0005080038450000521
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 319,505, filed on March 14, 2022, the entire contents of which are expressly incorporated herein by reference. Background Art
[0003] Generates a large number of antigen-specific memory CD8 + T cells are the desired target of vaccine design for various animal and human diseases to induce lasting immune memory. Generally, vaccines need more than one immunization to induce efficient protection, and usually effective vaccines need to be immunized more than once in the form of primary immunity-enhancement. For example, for pediatric populations, up to five immunizations may be needed, such as the diphtheria, tetanus and pertussis (DTP) vaccine given three times in the first six months after birth, followed by the fourth dose in the second year, and the final reinforcement between four and six years old. Nevertheless, some vaccines even need additional reinforcement in adults who have received a complete immune series, such as tetanus-diphtheria vaccine, which is recommended to be strengthened once every 10 years in the life span of the person. Such further application can be carried out with the same vaccine (homologous reinforcement) or with different vaccines (heterologous reinforcement). Since the initial development of the vaccine, the homologous primary immunity-enhancement immunization using the re-application of the same immunizing agent has been used. The classical vaccination method relies on the homologous primary immunity-enhancement scheme, and traditionally cannot induce the immune response that is strong enough to solve more challenging diseases. For example, although this approach is generally effective in boosting humoral responses to antigen, it is generally considered ineffective in generating increased numbers of CD8 + The efficiency of T cells is much lower. One strategy to overcome this limitation is to administer the vaccine sequentially using different antigen delivery systems. This approach is called heterologous prime / boost.
[0004] Although heterologous prime-boost has been reported to increase responses in certain settings, not all combinations show improved immunity, demonstrating the importance of determining which combinations are effective. Many factors, including the choice of antigen, type of vector, route of delivery, dose, adjuvant, boosting regimen, sequence of vector injections, and time intervals between different vaccinations, influence the outcome of the prime-boost immunization approach, making the results difficult to predict. Finding a vaccine combination that elicits broad, durable, and long-lasting immunity is important for conferring robust protection.
[0005] Recombinant AAV (rAAV) is probably the best research vector for human gene transfer, and hundreds of clinical trials have confirmed the safety of transduction. Adeno-associated virus (AAV) belongs to the family Parvoviridae, and more specifically constitutes the genus Dependoviridae. A vector derived from AAV (i.e., rAVV or AAV vector) is attractive for delivering genetic material because (i) it can infect (transduce) a variety of non-dividing and dividing cell types, including muscle cells and neurons; (ii) it lacks viral structural genes, thereby weakening the host cell's response to viral infection, for example, interferon-mediated response; (iii) wild-type virus is considered non-pathogenic in humans; (iv) compared to wild-type AAV that can be integrated into the host cell genome, replication-defective AAV vectors lack replication (rep) genes and usually persist as episomes, thereby limiting the risk of insertional mutagenesis or genotoxicity; and (v) compared to other vector systems, AAV vectors are generally considered to be relatively weak immunogens, and therefore do not trigger a significant immune response (see (ii)), thereby obtaining the persistence of vector DNA and the potential long-term expression of therapeutic transgenes.
[0006] However, there are several major drawbacks to using AAV particles as gene delivery vectors. One major drawback associated with rAAV is its limited viral packaging capacity of about 4.5 kb of heterologous DNA (Dong et al., 1996; Athanasopoulos et al., 2004; Lai et al., 2010), and therefore, the use of AAV vectors is limited to less than 150,000 Da protein coding capacity. Specifically related to antibody delivery, the packaging restrictions of AAV represent a significant challenge to the efficient delivery of both heavy and light chains that form the structure of natural antibodies. The second disadvantage is that, due to the prevalence of wild-type AAV infection in the population, the presence of neutralizing antibodies that eliminate the vector from the patient must be screened in rAAV gene therapy candidates. The third disadvantage is related to capsid immunogenicity, which prevents re-administration of patients who have not been excluded from initial treatment. The patient's immune system can respond to the vector that effectively acts as a "booster" injection to stimulate the immune system to produce high titers of anti-AAV antibodies, thereby eliminating further treatment. Pre-existing immunity may severely limit the efficiency of transduction. Some recent reports have pointed out concerns about immunogenicity at high doses. Another disadvantage worth noting is that the initiation of AAV-mediated gene expression is relatively slow, given that the single-stranded AAV DNA must be converted to double-stranded DNA before heterologous gene expression.
[0007] Adenovirus vectors expressing unknown antigenic proteins by such vectors have been fully studied for gene and cancer therapy and vaccines. In addition to its extensive safety characteristics, the advantage of using adenovirus vectors is that it is relatively stable, easy to obtain high titers and can infect multiple cell lines attributed to its effectiveness. Even if recombinant adenovirus vectors are widely used today due to their high transduction efficiency and transgenic expression, there is a pre-existing possibility of immunity to the vector because most populations have been exposed to adenovirus (Id). This has been shown to be harmful in human immunodeficiency virus (HIV-1) IIb phase vaccine trials, where vector-based vaccines provide favorable conditions for HIV-1 replication (Smaill, F. et al., " Science Translational Medicine (Sci.Transl.Med.) " (2013) 5:205).
[0008] There remains a need in the art for heterologous prime-boost regimens that provide robust immunogenicity without inducing anti-vector immunity. Summary of the invention
[0009] The present disclosure provides a prime-boost composition and method, the prime-boost composition and method comprising: a prime vaccine, the prime vaccine comprising a first peptide encoded by DNA; and a booster vaccine, the booster vaccine comprising a second peptide. In some embodiments, the second peptide is encoded by mRNA. According to some embodiments, the DNA can be in the following forms: for example, a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (linear covalently closed DNA vector), an end-closed linear duplex DNA (CELiD or ceDNA), a doggybone (dbDNA TM )DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector. According to some embodiments, the priming vaccine comprises plasmid DNA. According to some embodiments, the priming vaccine comprises end-blocked linear duplex DNA (ceDNA).
[0010] As demonstrated in the examples herein, the ceDNA vaccine platform can be successfully used as a priming vaccine in a heterologous prime / boost scheme to elicit and enhance both humoral and cellular responses to encoded model antigens. The results presented herein show that a heterologous prime-boost scheme can confer a more synergistic response to the antigen and has greater protection than immunization with the same vaccine alone. The discovery of the present disclosure is that immune responses can be improved by priming with a DNA priming platform, such as a ceDNA vector platform, and boosting with an mRNA-based or peptide-based platform (heterologous prime-boost scheme). Heterologous prime-boost using two immunologically different platforms as described herein advantageously uses DNA (e.g., ceDNA) as a priming vaccine for engineering, so that subsequent administration (boosting) activates the immune system in a different manner that synergizes with the initial administration (priming). Further, the priming boost compositions and methods described herein produce increased CD8 + Memory T cell responses.
[0011] Use of the prime-boost compositions and methods described herein, wherein the prime vaccine comprises DNA (e.g., minicircle, plasmid, bacmid, minigene, ministring DNA (linear covalently closed DNA vector), end-blocked linear duplex DNA (CELiD or ceDNA), doggybone (dbDNA TM )DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vectors, viral vectors or non-viral vectors), wherein the DNA encodes a first peptide, and a booster vaccine comprising RNA encoding a second peptide or the second peptide can be used to: treat, prevent or reduce the severity of a disease or condition in a subject, is minimally invasive in delivery, is repeatable and dose-effective, has a rapid onset of therapeutic effect, and / or produces sustained expression of an antigenic or immunogenic peptide.
[0012] Unlike traditional vaccines that are prepared in vitro and may trigger unwanted cellular responses, the ceDNA vaccine used as a primary vaccine herein is presented to the cell system in a more natural way. By using a ceDNA vector to deliver a transgenic (e.g., nucleic acid sequence) encoding an antigen to a cell or tissue, the adaptive immune response is bypassed, and the desired antibody specificity is produced without using immunity or passive transfer. In other words, the ceDNA vector enters the cell by endocytosis, then escapes from the endosomal compartment and is transported to the nucleus. Transcriptionally active ceDNA free bodies cause the expression of antigens, which can then be secreted from cells into the circulation. Therefore, ceDNA vectors can achieve continuous, continuous and long-term delivery of antibodies (e.g., therapeutic antibodies or antigen-binding fragments thereof described herein) administered by a single injection. This is particularly advantageous in the context of the described nucleic acid vaccine composition, wherein compared with mRNA vaccines, DNA primary vaccines show that expression increases more slowly and expression continues to be more persistent, although the mRNA vaccine can show that the initial expression increases more, but the expression is not continuous, and it decreases faster.
[0013] According to some aspects, the present disclosure provides a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering a priming vaccine to the subject, the priming vaccine comprising deoxyribonucleic acid (DNA), wherein the DNA encodes the first peptide; and administering a boosting vaccine to the subject, the boosting vaccine comprising (i) ribonucleic acid (RNA), wherein the RNA encodes the second peptide, or (ii) the second peptide, thereby inducing the immune response in the subject against the first peptide and the second peptide. According to some embodiments, the priming vaccine comprises DNA encoding the first peptide, and the boosting vaccine comprises RNA encoding the second peptide. According to some embodiments, the priming vaccine comprises DNA encoding the first peptide, and the boosting vaccine comprises the second peptide. According to further embodiments of any of the embodiments herein, the DNA comprises a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (linear covalently closed DNA vector), an end-closed linear duplex DNA (CELiD or ceDNA), a doggybone (dbDNA TM)DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector. According to further embodiments of any embodiment of the embodiments herein, the first peptide and the second peptide are derived from bacteria, viruses, fungi or parasitic infectious agents. According to further embodiments of any embodiment of the embodiments herein, the first peptide and the second peptide are derived from the same pathogenic organism. According to further embodiments of any embodiment of the embodiments herein, the first peptide and the second peptide are the same in the primary vaccine and the booster vaccine. According to further embodiments of any embodiment of the embodiments herein, at least one of the epitopes of the first peptide and the second peptide is different in the primary vaccine and the booster vaccine. According to some embodiments, wherein the DNA includes a capsid-free end-closed DNA (ceDNA) vector, the ceDNA vector includes at least one nucleic acid sequence located between flanking inverted terminal repeats (ITRs), wherein the at least one nucleic acid sequence encodes the peptide. According to some embodiments, the first peptide and / or the second peptide are tumor-associated antigens or are associated with autoimmune conditions. According to further embodiments of any aspect or embodiment of the aspects or embodiments herein, the first peptide or the second peptide is selected from one or more of those shown in Tables 1-8. According to further embodiments of any of the embodiments herein, the ceDNA vector further comprises a promoter sequence connected to the at least one nucleic acid sequence. According to further embodiments of any of the embodiments herein, the ceDNA vector comprises at least one poly A sequence. According to further embodiments of any of the embodiments herein, the ceDNA vector comprises a 5'UTR and / or intron sequence. According to further embodiments of any of the embodiments herein, wherein the ceDNA vector comprises a 3'UTR sequence. According to further embodiments of any of the embodiments herein, the ceDNA vector comprises an enhancer sequence. According to further embodiments of any of the embodiments herein, at least one of the ITRs comprises a functional terminal resolution site and a Rep binding site. According to further embodiments of any of the embodiments herein, at least one or two of the ITRs are from a virus selected from the group consisting of: a parvovirus, a dependent virus, and an adeno-associated virus (AAV). According to further embodiments of any of the embodiments herein, the flanking ITRs are symmetrical or asymmetrical relative to each other. According to some embodiments, the flanking ITRs are symmetrical or substantially symmetrical. According to some embodiments, the flanking ITRs are asymmetrical. According to further embodiments of any of the embodiments herein, one of the flanking ITRs is wild-type, or two of the flanking ITRs are wild-type ITRs.According to further embodiments of any of the embodiments herein, the flanking ITRs are derived from different viral serotypes. According to further embodiments of any of the embodiments herein, the flanking ITRs are selected from any pair of viral serotypes shown in Table 8. According to further embodiments of any of the embodiments herein, one or both of the ITRs include a sequence selected from one or more of the sequences in Table 9. According to further embodiments of any of the embodiments herein, at least one of the flanking ITRs is changed from a wild-type AAV ITR sequence by a deletion, addition or substitution that affects the overall three-dimensional conformation of the ITR. According to further embodiments of any of the embodiments herein, one or both of the flanking ITRs are derived from an AAV serotype, and the AAV serotype is selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12. According to further embodiments of any of the embodiments herein, one or more of the flanking ITRs are synthetic. According to further embodiments of any embodiment of the embodiments herein, one of the flanking ITRs is not a wild-type ITR, or two of the flanking ITRs are not wild-type ITRs. According to further embodiments of any embodiment of the embodiments herein, one or two of the flanking ITRs are modified by deletion, insertion and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D and D'. According to some embodiments, the deletion, insertion and / or substitution causes the deletion of all or part of the stem-loop structure formed by A, A', B, B', C or C' regions. According to further embodiments of any embodiment of the embodiments herein, one or two of the flanking ITRs are modified by deletion, insertion and / or substitution, and the deletion, insertion and / or substitution causes the deletion of all or part of the stem-loop structure formed by the B and B' regions. According to further embodiments of any embodiment of the embodiments herein, one or two of the flanking ITRs are modified by deletion, insertion and / or substitution, and the deletion, insertion and / or substitution causes the deletion of all or part of the stem-loop structure formed by the C and C' regions. According to further embodiments of any of the embodiments herein, one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of part of the stem-loop structure formed by the B and B' regions and / or part of the stem-loop structure formed by the C and C' regions.According to further embodiments of any of the embodiments herein, one or both of the flanking ITRs include a single stem-loop structure in the region, and in the wild-type ITR, the single stem-loop structure will include a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. According to further embodiments of any of the embodiments herein, one or both of the flanking ITRs include a single stem and two loops in the region, and in the wild-type ITR, the single stem and the two loops will include a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. According to further embodiments of any of the embodiments herein, one or both of the flanking ITRs include a single stem and a single loop in the region, and in the wild-type ITR, the single stem and the single loop will include a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions. According to further embodiments of any embodiment of the embodiments herein, when the flanking ITRs are reversed relative to each other, the ITRs are changed in a manner that produces overall three-dimensional symmetry. According to further embodiments of any embodiment of the embodiments herein, the DNA is delivered in lipid nanoparticles (LNP). According to further embodiments of any embodiment of the embodiments herein, the RNA is delivered in lipid nanoparticles (LNP). According to further embodiments of any embodiment of the embodiments herein, the RNA is messenger RNA (mRNA). According to further embodiments, the RNA includes at least one nucleotide analog. According to further embodiments of any embodiment of the embodiments herein, the immune response is an antibody response. According to further embodiments of any embodiment of the embodiments herein, the immune response is a T cell response. According to other further embodiments, the immune response is a memory (CD8. +) T cell response. According to some embodiments of aspects and embodiments described herein, the method includes administering the booster vaccine at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 9 weeks, at least about 10 weeks, at least about 11 weeks, at least about 12 weeks, at least about 14 weeks, at least about 16 weeks, at least about 1-2 weeks, at least about 2-3 weeks, at least about 3-4 weeks, at least about 4-5 weeks, at least about 5-6 weeks, at least about 6-7 weeks, at least about 7-8 weeks, at least about 8-9 weeks, at least about 9-10 weeks, at least about 10-11 weeks, at least about 11-12 weeks, at least about 12-13 weeks, at least about 13-14 weeks, at least about 14-15 weeks, or at least about 15-16 weeks after administering the primary vaccine. According to other further embodiments of any embodiment in the embodiments herein, the method is included in the administration of the booster vaccine at least 8 weeks after the administration of the primary vaccine. According to other embodiments of any embodiment in the embodiments herein, the method is included in the administration of the booster vaccine about 8 weeks after the administration of the primary vaccine.According to some embodiments of the aspects and embodiments described herein, the time interval between the administration of the priming vaccine and the administration of the boosting vaccine is at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days. , at least about 29 days, at least about 30 days, at least about 31 days, at least about 32 days, at least about 33 days, at least about 34 days, at least about 35 days, at least about 36 days, at least about 37 days, at least about 38 days, at least about 39 days, at least about 40 days, at least about 41 days, at least about 42 days, at least about 43 days, at least about 44 days, at least about 45 days, at least about 46 days, at least about 47 days, at least about 48 days, at least about 49 days, at least about 50 days, at least about 51 days, at least about 52 days, at least about 53 days, at least about 54 days, at least about 55 days, at least about 56 days, at least about 57 days 7 days, at least about 58 days, at least about 59 days, at least about 60 days, at least about 61 days, at least about 62 days, at least about 63 days, at least about 64 days, at least about 65 days, at least about 66 days, at least about 67 days, at least about 68 days, at least about 69 days, at least about 70 days, at least about 71 days, at least about 72 days, at least about 73 days, at least about 74 days, at least about 75 days, at least about 76 days, at least about 77 days, at least about 78 days, at least about 79 days, at least about 80 days, at least about 81 days, at least about 82 days, at least about 83 days, at least about 84 days, at least about 85 days, at least about 86 days, at least about 87 days, at least about 88 days, at least about 89 days, at least about 90 days In some embodiments, the method comprises administering two or more doses of the booster vaccine to the subject.According to some embodiments of the aspects and embodiments described herein, the method comprises administering each dose of a booster vaccine at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 9 weeks, at least about 10 weeks, at least about 11 weeks, at least about 12 weeks, at least about 14 weeks, at least about 16 weeks, at least about 1-2 weeks, at least about 2-3 weeks, at least about 3-4 weeks, at least about 4-5 weeks, at least about 5-6 weeks, at least about 6-7 weeks, at least about 7-8 weeks, at least about 8-9 weeks, at least about 9-10 weeks, at least about 10-11 weeks, at least about 11-12 weeks, at least about 12-13 weeks, at least about 13-14 weeks, at least about 14-15 weeks, or at least about 15-16 weeks after administration of a previous vaccine.According to some embodiments of the aspects and embodiments described herein, the time interval between administering each dose of the booster vaccine and administering the previous vaccine is at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, at least about 31 days, at least about 32 days, at least about 33 days, at least about 34 days, at least about 35 days, at least about 36 days, at least about 37 days, at least about 38 days, at least about 39 days, at least about 40 days, at least about 41 days, at least about 42 days, at least about 43 days, at least about 44 days about 28 days, at least about 29 days, at least about 30 days, at least about 31 days, at least about 32 days, at least about 33 days, at least about 34 days, at least about 35 days, at least about 36 days, at least about 37 days, at least about 38 days, at least about 39 days, at least about 40 days, at least about 41 days, at least about 42 days, at least about 43 days, at least about 44 days, at least about 45 days, at least about 46 days, at least about 47 days, at least about 48 days, at least about 49 days, at least about 50 days, at least about 51 days, at least about 52 days, at least about 53 days, at least about 54 days, at least about 55 days, at least about 56 days, at least about 57 days, at least about 58 days, at least about 59 days, at least about 60 days, at least about 61 days, at least about 62 days, at least about 63 days, at least about 64 days, at least about 65 days, at least about 66 days, at least about 67 days, at least about 68 days at least about 57 days, at least about 58 days, at least about 59 days, at least about 60 days, at least about 61 days, at least about 62 days, at least about 63 days, at least about 64 days, at least about 65 days, at least about 66 days, at least about 67 days, at least about 68 days, at least about 69 days, at least about 70 days, at least about 71 days, at least about 72 days, at least about 73 days, at least about 74 days, at least about 75 days, at least about 76 days, at least about 77 days, at least about 78 days, at least about 79 days, at least about 80 days, at least about 81 days, at least about 82 days, at least about 83 days, at least about 84 days, at least about 85 days, At least about 86 days, at least about 87 days, at least about 88 days, at least about 89 days, at least about 90 days, at least about 91 days, at least about 92 days, at least about 93 days, at least about 94 days, at least about 95 days, at least about 96 days, at least about 97 days, at least about 98 days, at least about 99 days, at least about 100 days, at least about 101 days, at least about 102 days, at least about 103 days, at least about 104 days, at least about 105 days, at least about 106 days, at least about 107 days, at least about 108 days, at least about 109 days, at least about 110 days, at least about 111 days or at least about 113 days. According to the other embodiment of any embodiment in the embodiments herein, the subject suffers from bacterial infection, viral infection, parasitic infection or fungal infection. According to the other embodiment of any embodiment in the embodiments herein, the subject suffers from cancer. According to the other embodiment of any embodiment in the embodiments herein, the subject suffers from autoimmune disease or illness. According to further embodiments of any of the embodiments herein, one or more of the priming vaccine or the boosting vaccine comprises a pharmaceutically acceptable carrier.According to some embodiments, at least one of the priming vaccine and the boosting vaccine composition further comprises an adjuvant. According to further embodiments of any of the embodiments herein, at least one of the priming vaccine and the boosting vaccine is administered by a route selected from the group consisting of intramuscular, intraperitoneal, buccal, inhalation, intranasal, intrathecal, intravenous, subcutaneous, intradermal, and intratumoral, or administered to the interstitial space of a tissue.
[0014] According to some aspects, the present disclosure provides a vaccine regimen, the vaccine regimen comprising: a priming vaccine, the priming vaccine comprising deoxyribonucleic acid (DNA), wherein the DNA encodes a first peptide; followed by a boosting vaccine, the boosting vaccine comprising (i) ribonucleic acid (RNA) encoding a second peptide or (ii) a second peptide. According to some embodiments, the priming vaccine comprises a certain amount of DNA encoding an immunologically effective amount of the first peptide, and the boosting vaccine comprises an immunologically effective amount of RNA encoding the second peptide. According to some embodiments, the priming vaccine comprises a certain amount of DNA encoding an immunologically effective amount of the first peptide, and the boosting vaccine comprises an immunologically effective amount of the second peptide. According to further embodiments of any of the embodiments herein, the DNA comprises a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (linear covalently closed DNA vector), an end-closed linear duplex DNA (CELiD or ceDNA), a doggybone (dbDNA TM )DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector. According to another embodiment of any embodiment in the embodiments herein, the first peptide and the second peptide are derived from a bacterial infectious agent, a viral infectious agent, a fungal infectious agent or a parasitic infectious agent. According to another embodiment of any embodiment in the embodiments herein, the first peptide and the second peptide are derived from the same pathogenic organism. According to another embodiment of any embodiment in the embodiments herein, the first peptide and the second peptide are the same in the primary vaccine and the booster vaccine. According to another embodiment of any embodiment in the embodiments herein, at least one of the epitopes of the first peptide and the second peptide is different in the primary vaccine and the booster vaccine. According to some embodiments, the DNA includes a capsid-free end-closed DNA (ceDNA) vector, the ceDNA vector includes at least one nucleic acid sequence located between the flanking reverse ends (ITRs), wherein the at least one nucleic acid sequence encodes the first peptide. According to some embodiments, the first peptide and / or the second peptide are tumor-associated antigens. According to some embodiments, the first peptide and / or the second peptide are associated with autoimmune conditions. According to further embodiments of any of the embodiments herein, the first peptide or the second peptide is selected from one or more of those shown in Tables 1-8.
[0015] The disclosure also features a method of treating a subject having a bacterial, viral, parasitic, or fungal infection, the method comprising performing the method of any of the aspects or embodiments herein or administering to the subject the vaccine regimen of any of the aspects and embodiments herein.
[0016] The disclosure also features a method of treating a subject having cancer, the method comprising performing the method of any of the aspects or embodiments herein or administering to the subject the vaccine regimen of any of the aspects and embodiments herein.
[0017] The disclosure also features a method of treating a subject having an autoimmune disease or condition, the method comprising performing the method of any of the aspects or embodiments herein or administering to the subject the vaccine regimen of any of the aspects and embodiments herein.
[0018] The present disclosure also features a method of preventing a bacterial infection, a viral infection, a parasitic infection, or a fungal infection in a subject, the method comprising performing the method of any of the aspects or embodiments herein or administering to the subject a vaccine regimen of any of the aspects and embodiments herein.
[0019] The disclosure also features a method of preventing cancer in a subject, the method comprising performing the method of any of the aspects or embodiments herein or administering to the subject the vaccine regimen of any of the aspects and embodiments herein.
[0020] The disclosure also features a method of preventing an autoimmune disease in a subject, the method comprising performing the method of any of the aspects or embodiments herein or administering to the subject the vaccine regimen of any of the aspects and embodiments herein.
[0021] According to another embodiment of any embodiment in the embodiments herein, the method includes administering two or more doses of the booster vaccine to the subject. According to another embodiment of any embodiment in the embodiments herein, the method includes administering the booster vaccine about 8 weeks after administering the primary vaccine. According to another embodiment of any embodiment in the embodiments herein, the method further includes administering one or more additional therapeutic agents to the subject.
[0022] According to other aspects, the primary vaccine and the booster vaccine are each formulated in a pharmaceutical composition. According to some embodiments, one or both of the primary vaccine and the booster vaccine further include one or more additional therapeutic agents. According to other further embodiments, one or both of the primary vaccine and the booster vaccine further include lipids. According to some embodiments, the lipids are lipid nanoparticles (LNP). According to other embodiments, one or both of the primary vaccine and the booster vaccine are freeze-dried.
[0023] The disclosure also features a pharmaceutical composition comprising the vaccine regimen of any one of the aspects and embodiments herein. In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutic agents.
[0024] The present disclosure is also characterized in that a kind of composition, described composition comprises the vaccine scheme and lipid of any one aspect and embodiment in aspect and embodiment herein.According to some embodiments, described lipid is lipid nanoparticle (LNP).According to the other embodiment of any embodiment in the embodiment herein, described composition is lyophilized.
[0025] In other aspects, the present disclosure provides a kit, the kit includes any aspect and embodiment of the vaccine scheme and instructions for use of the aspects and embodiments herein. In other aspects, the present disclosure provides a kit, the kit includes any aspect and embodiment of the primary vaccine and the booster vaccine and one or both and instructions for use of the primary vaccine and the booster vaccine of any aspect and embodiment herein. In some embodiments, the kit includes lipids.
[0026] These and other aspects of the disclosure are described in further detail below. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Embodiments of the present disclosure, briefly summarized above and discussed in more detail below, can be understood by reference to the illustrative embodiments of the present disclosure depicted in the accompanying drawings. However, the drawings illustrate only typical embodiments of the present disclosure and are therefore not to be considered limiting of the scope, as the present disclosure may admit to other equally effective embodiments.
[0028] Figure 1 is a graph depicting the spike protein antibody titers determined on day 49 of the study described in Example 5.
[0029] Figure 2 is a graph depicting the spike protein antibody titers determined on day 77 of the study described in Example 5.
[0030] Figure 3is a graph depicting the spike protein antibody titers determined on day 105 of the study described in Example 5.
[0031] Figure 4 The CD8 + T cells are IFNγ + IFNγ + and CD107 + IFNγ + and TNFα + or IL4 + Percentage graph.
[0032] Figure 5 is a graph depicting spike protein antibody titers determined at Day 21 and Day 49 of the study as described in Example 6.
[0033] Figure 6 Figure 1 depicts IFNγ in mouse spleen cell suspensions 8 weeks after immunization with mRNA, ceDNA, or plasmid encoding the COVID spike protein. + Antigen-specific memory CD8 + Graph of the percentage of T cells.
[0034] Figure 7 Figure 3 is a graph depicting IFNγ in mice primed and boosted with ceDNA-ceDNA, mRNA-mRNA, or ceDNA-mRNA regimens at 4, 6, or 8 week intervals. + Antigen-specific memory CD8 + Graph of the percentage of T cells.
[0035] Figure 8 Figure 5 is a graph depicting IFNγ after heterologous prime-boost regimens of 0.3 μg mRNA-3 μg mRNA, 1 μg mRNA-3 μg mRNA, 3 μg mRNA-3 μg mRNA, 3 μg ceDNA-3 μg mRNA, and 10 μg ceDNA-3 μg mRNA. + Antigen-specific memory CD8 + Graph of the percentage of T cells. DETAILED DESCRIPTION
[0036] The present disclosure generally relates to the use of compositions and methods for inducing an immune response in a subject using a heterologous prime-boost immunization scheme. This article includes a method for inducing an immune response of a subject to a first peptide and a second peptide, the method comprising: administering a primary vaccine to the subject, the primary vaccine comprising deoxyribonucleic acid (DNA) DNA, wherein the DNA encodes a first peptide; and administering a booster vaccine to the subject, the booster vaccine comprising (i) ribonucleic acid (RNA) or (ii) a second peptide, wherein the RNA encodes the second peptide, thereby inducing an immune response of the subject to the first peptide and the second peptide, which can be used prophylactically and / or therapeutically. In some embodiments, the compositions and methods disclosed herein can be used to produce molecules of interest, such as therapeutic polypeptides, in a subject.
[0037] I. Definitions
[0038] Unless otherwise defined herein, scientific and technical terms used in conjunction with this application should have the meanings commonly understood by those of ordinary skill in the art of the present disclosure. It should be understood that the present disclosure is not limited to the particular methods, protocols, and reagents described herein, etc. and can therefore vary. The terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of the present disclosure, which is limited only by the claims. Definitions of commonly used terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th edition, Merck Sharp & Dohme Corp., 2011 (ISBN 978-0-911910-19-3); Robert S. Porter et al. (eds.), Fields Virology, 6th edition, Lippincott Williams & Wilkins, Philadelphia, PA, USA (2013); Knipe, DM and Howley, PM (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, Blackwell Science Ltd. (2013). Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, VCH Publishers, Inc.), 1995 (ISBN 1-56081-569-8); Immunology, Werner Luttmann, Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor & Francis Limited, 2014 (ISBN 0815345305, 9780815345305); Lewin's Genes XI, Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual =Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.), Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology, Frederick M. Ausubel (ed.), John Wiley & Sons, 2013 (ISBN 0124199542); and Current Protocols in Molecular Biology, Frederick M. Ausubel (ed.), John Wiley & Sons, 2013 (ISBN 0124199542). and Sons), 2014 (ISBN047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E.Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADAM Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are incorporated herein by reference in their entirety.
[0039] As used herein, the term "immunity" or "active immunity" refers to the generation of active immunity, meaning immunity resulting from a naturally acquired infection or deliberate vaccination (artificial active immunity).
[0040] The term "adjuvant" as used herein means an agent that, when used in combination with a specific immunogen in a formulation, will enhance or otherwise alter or modify the resulting immune response. Modification of the immune response includes enhancing or expanding the specificity of the immune response (e.g., either or both of an antibody and a cellular immune response). Modification of the immune response can also mean reducing or inhibiting certain antigen-specific immune responses.
[0041] As used herein, the term "antigen" means a molecule containing one or more epitopes (linear, conformational or both) that will stimulate the host's immune system to produce humoral and / or cellular antigen-specific responses. The term is used interchangeably with the term "immunogen". Typically, a B cell epitope will contain at least about 5 amino acids, but can be as small as 3-4 amino acids. T cell epitopes such as CTL epitopes will contain at least about 7-9 amino acids and at least about 12-20 amino acids of helper T cell epitopes. Typically, an epitope will contain about 7 to 15 amino acids, including, for example, 9, 10, 11, 12, 13, 14 or 15 amino acids. The term includes polypeptides that include modifications compared to the native sequence, such as deletions, additions and substitutions (generally conservative in nature), as long as the protein maintains the ability to elicit an immune response, as defined herein. These modifications may be intentional, such as by site-directed mutagenesis, or may be accidental, such as by mutations in the host that produces the antigen.
[0042] The term "epitope" may also be referred to as an antigenic determinant, which is a molecular determinant (e.g., a polypeptide determinant) that can be specifically bound by a binding agent, an immunoglobulin, or a T cell receptor. Epitope determinants include chemically active surface groups of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural properties and / or specific charge properties. Epitopes may be defined as structural or functional. Functional epitopes are typically subsets of structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes may be linear or conformational, i.e., composed of nonlinear amino acids. The epitope recognized by an antibody or an antigen-binding fragment of an antibody is a structural element of an antigen that interacts with the CDR (e.g., complementary site) of an antibody or fragment. An epitope may be formed by the contribution of several amino acid residues that interact with the CDR of an antibody to produce specificity. An antigen fragment may contain more than one epitope. In certain embodiments, when an antibody recognizes its target antigen in a complex mixture of proteins and / or macromolecules, the antibody specifically binds to the antigen. For example, antibodies are said to "bind to the same epitope" if they cross-compete (one prevents the binding or modulating effect of the other).
[0043] As used herein, the term "autoimmune disorder" generally refers to a condition in which a subject's immune system attacks the body's own cells, resulting in tissue destruction. Blood tests, cerebrospinal fluid analysis, electromyography (measurement of muscle function), and brain magnetic resonance imaging can be used to diagnose autoimmune disorders, but antibody tests in the blood are particularly useful for self-antibodies or auto-antibodies. Typically, IgG class antibodies are associated with autoimmune diseases.
[0044] The term "B lymphocyte" or "B cell" is used interchangeably to refer to a broad class of lymphocytes, which are precursors of antibody-secreting cells that express cloned cell surface immunoglobulin (Ig) receptors (BCRs) that recognize specific antigenic epitopes. Mammalian B cell development encompasses a continuum of stages that begin in primary lymphoid tissues (e.g., human fetal liver and fetal / adult bone marrow), followed by functional maturation in secondary lymphoid tissues (e.g., human lymph nodes and spleen). The functional / protective endpoint is the antibody produced by terminally differentiated plasma cells. Mature B cells can be activated by encountering antigens expressing epitopes recognized by their cell surface immunoglobulins (Ig). The activation process can be direct, depending on the cross-linking of antigens to membrane Ig molecules (cross-linking-dependent B cell activation), or can be indirect, occurring most efficiently in the case of close interaction with helper T cells ("homologous help process"). (LeBien, TW and TF Tedder, B lymphocytes: how they develop and function. Blood (2008) 112(5): 1570-80).
[0045] As used herein, the term "cancer" refers to a disease in which abnormal cells divide without control and are able to invade other tissues. There are more than 100 different types of cancer. Most cancers are named after the organ or cell type in which they begin, for example, cancer that begins in the colon is called colon cancer; cancer that begins in the melanocytes of the skin is called melanoma. Cancer types can be divided into broader categories. The major categories of cancer include: carcinoma (meaning cancer that begins in the skin or in the tissues lining or covering the internal organs, and its subtypes, including adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, and transitional cell carcinoma); sarcoma (meaning cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supporting tissue); leukemia (meaning cancer that begins in blood-forming tissues (e.g., bone marrow) and causes large numbers of abnormal blood cells to be produced and enter the blood; lymphoma and myeloma (meaning cancer that begins in cells of the immune system); and central nervous system (CNS) cancer (meaning cancer that begins in brain and spinal cord tissue). The term "myelodysplastic syndrome" refers to a type of cancer in which the bone marrow does not produce enough healthy blood cells (white blood cells, red blood cells, and platelets) and abnormal cells are present in the blood and / or bone marrow. Myelodysplastic syndrome can become acute myeloid leukemia (AML). In certain embodiments, the cancer is selected from cancers including, but not limited to, acute lymphoblastic leukemia (ALL), acute myeloid Leukemia (AML), Anal cancer, Bile duct cancer, Bladder cancer, Bone cancer, Bowel cancer, Brain tumor, Breast cancer, Cancer of unknown primary, Cancer spread to bone, Cancer spread to brain, Cancer spread to liver, Cancer spread to lung, Carcinoid, Cervical cancer, Chronic lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML), Colon cancer, Colorectal cancer, Endometrial cancer, Eye cancer, Gallbladder cancer, Stomach cancer, Gestational trophoblastic tumor (GTT), Hairy cell leukemia, Head and neck cancer, Hodgkin lymphoma , Kidney cancer, Laryngeal cancer, Leukemia, Liver cancer, Lung cancer, Lymphoma, Melanoma skin cancer, Mesothelioma, Male cancer, Molar pregnancy, Mouth and oropharyngeal cancer, Myeloma, Nose and sinus cancer, Nasopharyngeal cancer, Non-Hodgkin lymphoma (NHL), Esophageal cancer, Ovarian cancer, Pancreatic cancer, Penile cancer, Prostate cancer, Rare cancers, Rectal cancer, Salivary gland cancer, Secondary cancers, Skin cancer (non-melanoma), Soft tissue sarcoma, Stomach cancer, Testicular cancer, Thyroid cancer, Unknown primary cancer, Uterine cancer, Vaginal cancer, and Vulvar cancer.
[0046] As used herein, the term "cross-protection" is used to describe immunity against at least two subgroups, subtypes, strains and / or variants of a virus, bacteria, parasite or other pathogen, where a single vaccination is with one subgroup, subtype, strain and / or variant thereof.
[0047] The term "cytokine" as used herein refers to a small soluble protein substance secreted by cells that has a variety of effects on other cells. Cytokines mediate many important physiological functions, including growth, development, wound healing and immune response. The cytokine acts by binding to its cell-specific receptor located in the cell membrane, which allows different signal transduction cascades to be started in the cell, which will eventually lead to biochemical and phenotypic changes in the target cell. Typically, cytokines act locally. The cytokines include: type I cytokines, which cover many interleukins and several hematopoietic growth factors; type II cytokines, which include interferons and interleukin-10; tumor necrosis factor ("TNF") related molecules, which include TNFα and lymphotoxin; immunoglobulin superfamily members, which include interleukin 1 ("IL-1"); and chemokines, a family of molecules that play a key role in a variety of immune and inflammatory functions. Depending on the state of the cell, the same cytokine may have different effects on the cell. Cytokines generally regulate the expression of other cytokines and trigger cascades of other cytokines.
[0048] As used herein, the term "detectable response" means any signal or response that can be detected in an assay, which can be performed with or without a detection agent. Detectable responses include, but are not limited to, radioactive decay and energy (e.g., fluorescence, ultraviolet, infrared, visible) emission, absorption, polarization, fluorescence, phosphorescence, transmission, reflection, or resonance transfer. Detectable responses also include chromatographic mobility, turbidity, electrophoretic mobility, mass spectrometry, ultraviolet spectrum, infrared spectrum, nuclear magnetic resonance spectrum, and x-ray diffraction. Alternatively, a detectable response can be the result of an assay that measures one or more properties of a biomaterial, such as melting point, density, electrical conductivity, surface acoustic wave, catalytic activity, or elemental composition. A "detection agent" is any molecule that produces a detectable response that indicates the presence or absence of a substance of interest. Detection agents include any of a variety of molecules, such as antibodies, nucleic acid sequences, and enzymes. In order to facilitate detection, a detection agent may include a marker.
[0049] As used herein, the term "effector cell" refers to a cell that carries out a final response or function. For example, the main effector cells of the immune system are activated lymphocytes and phagocytes.
[0050] The term "herd immunity" as used herein refers to the protection conferred to unvaccinated individuals in a population generated by vaccinating others and reducing natural reservoir infection.
[0051] As used herein, the term "heterosubtypic immunity" ("HSI") refers to immunity based on the immune recognition of antigens that are conserved among all viral strains.
[0052] As used herein, the term "heterotypic" is used to refer to being of a different or abnormal type or form (eg, a different subgroup, subtype, strain, and / or variant of a virus, bacteria, parasite, or other pathogen).
[0053] As used herein, the term "homotypic" is used to refer to being of the same type or form, for example, the same subgroup, subtype, strain and / or variant of a virus, bacteria, parasite or other pathogen.
[0054] As used herein, the terms "immune response" and "immune-mediated" are used interchangeably herein to refer to any functional expression of a subject's immune system against exogenous antigens or self-antigens, whether the consequences of these responses are beneficial or harmful to the subject. As used herein, the term "immunological response" to an antigen or composition means the development of a subject's humoral and / or cellular immune response to an antigen present in the composition of interest. For the purposes of this disclosure, a "humoral immune response" refers to an immune response mediated by antibody molecules, while a "cellular immune response" is an immune response mediated by T lymphocytes and / or other leukocytes. An important aspect of cellular immunity involves the antigen-specific response of cytolytic T cells ("CTL"). CTLs are specific for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the cell surface. CTLs help induce and promote the destruction of intracellular microorganisms, or the lysis of cells infected with such microorganisms. Another aspect of cellular immunity involves the antigen-specific response of helper T cells. Helper T cells act to help stimulate function and focus the activity of nonspecific effector cells on cells displaying peptide antigens associated with MHC molecules on their surface. "Cellular immune response" also refers to the production of cytokines, chemokines and other such molecules produced by activated T cells and / or other leukocytes, including those derived from CD4 + and CD8 + Those of T cells. Thus, the immune response may include one or more of the following effects: B cells produce antibodies; and / or activation of suppressive T cells and / or γδT cells, which are specifically directed against one or more antigens present in the composition or vaccine of interest. These responses can be used to neutralize infectivity, and / or mediate antibody complement, or antibody-dependent cellular cytotoxicity (ADCC) to provide protection for the immunized host. Such responses can be determined using standard immunoassays and neutralization assays well known in the art.
[0055] As used herein, the term "immunophenotype" or "immunotype" refers to the collective frequency of various immune cell populations and their functional responses (cell signaling and antibody responses) to stimulation. (See Kaczorowski, KJ et al., Proc. Nat. Acad. Sci. USA (2017)).
[0056] As used herein, the term "immune system" refers to the disease defense system of the body, which includes the innate immune system and the adaptive immune system. The innate immune system provides a non-specific first line of defense against pathogens. It includes both physical barriers (e.g., skin) and cell (granulocytes, natural killer cells) and humoral (complement system) defense mechanisms. The response of the innate immune system is immediate, but unlike the adaptive immune system, it does not provide permanent immunity to pathogens. The adaptive immune response is the response of the vertebrate immune system to specific antigens that usually produce immune memory.
[0057] As used herein, the term "immunodominant epitope" refers to an epitope to which most antibodies are directed, or to which most T cells respond.
[0058] As used herein, the term "immunogenic amount" or "immunologically effective amount" refers to an amount of an active component (such as an immunogenic peptide) sufficient to elicit an antibody or T cell response or both, which is sufficient to have a beneficial effect on a subject, such as a prophylactic or therapeutic effect.
[0059] The term "immune library" refers to a collection of transmembrane antigen receptor proteins located on the surface of T and B cells. (Benichou, J. et al. "Immunology" (2011) 135: 183-191). The combinatorial mechanism responsible for encoding receptors is achieved by reorganizing the genetic code, and it is possible to produce more than 1018 different T cell receptors (TCR) in humans (Venturi, Y. et al. "Natural Review of Immunology (Nat. Rev. Immunol.)" (2008) 8: 231-8) and more diverse B cell libraries. These sequences are then transcribed and then translated into proteins to be presented on the cell surface. The recombinant process of rearranging the gene segments for constructing receptors is key to the development of immune responses, and the correct formation of rearranged receptors is essential for their future binding affinity to antigens.
[0060] Peptides, oligopeptides, polypeptides, proteins or polynucleotides encoding such molecules are "immunogenic", and therefore within the present disclosure are immunogens if they are able to induce an immune response. In the present disclosure, immunogenicity is more specifically defined as the ability to induce a CTL-mediated response. Thus, an immunogen will be a molecule capable of inducing an immune response, and in the present disclosure is a molecule capable of inducing a CTL response. An immunogen may have one or more isoforms, sequence variants or splice variants with equivalent biological and immunological activity, and therefore are also considered to be immunogenic equivalents of the original native polypeptide for the purposes of the present disclosure.
[0061] The term "priming" or "prime" means the administration of a vaccine ("priming vaccine") or an immunogenic composition that induces a higher level of immune response when the same or different vaccine immunogenic composition is subsequently administered, rather than the immune response obtained by administration with a single vaccine or immunogenic composition. According to some embodiments, the "priming vaccine" is a DNA priming vaccine. According to some embodiments, the DNA priming vaccine can be in the form of, for example, minicircles, plasmids, bacmids, minigenes, ministring DNA (linear covalently closed DNA vectors), end-blocked linear duplex DNA (CELiD or ceDNA), doggybone (dbDNA TM )DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector. According to some embodiments, the primary vaccine comprises end-blocked linear duplex DNA (ceDNA). According to some embodiments, the primary vaccine comprises plasmid DNA.
[0062] The term "boosting" or "boost" means the administration of a subsequent vaccine ("boost vaccine") or immunogenic composition after the administration of a primary vaccine or immunogenic composition, wherein the subsequent administration produces a higher level of immune response than the immune response to a single administration of the vaccine or immunogenic composition. The booster vaccine may be the same or different vaccine immunogenic composition as the primary vaccine or immunogenic composition.
[0063] As used herein, the term "heterologous prime boost" means a regimen that includes priming an immune response with an immunogenic peptide or antigen and subsequently boosting the immune response with an immunogenic peptide or an antigen delivered by a different molecule and / or vector. For example, the heterologous prime boost regimen of the present invention includes priming with a ceDNA vector and boosting with an mRNA vector and priming with a ceDNA vector and boosting with an immunogenic peptide. The heterologous prime boost regimen of the present invention may also include, for example, priming with a plasmid DNA and boosting with an mRNA vector and priming with a plasmid DNA and boosting with an immunogenic peptide.
[0064] As used herein, the term "specific binding" refers to the ability of a polypeptide or polypeptide complex to recognize and bind to a ligand in vitro or in vivo without substantially recognizing or binding to other molecules in the surrounding environment. In some embodiments, specific binding can be at least about 1×10 6 An equilibrium dissociation constant of M or less is characterized (eg, a smaller equilibrium dissociation constant indicates tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.
[0065] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows real-time biospecific interactions to be analyzed by detecting changes in protein concentration within a biosensor matrix, for example using a BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). For further description, see Examples 1 and 2 of U.S. Pat. No. 6,258,562. et al. (1993) Ann. Biol. Clin. 51:19; et al. (1991) Biotechniques 11:620-627; Johnsson et al. (1995) J. Mol. Recognit. 8:125; and Johnnson et al. (1991) Anal. Biochem. 198:268.
[0066] As used herein, the terms "heterologous nucleic acid sequence" and "transgene" are used interchangeably and refer to a nucleic acid of interest (other than a nucleic acid encoding a capsid polypeptide) that is incorporated into a ceDNA vector as disclosed herein and can be delivered and expressed by it. According to some embodiments, the term "heterologous nucleic acid" means a nucleic acid (or transgene) that is not present in, expressed by, or derived from a cell or subject with which it is contacted.
[0067] As used herein, the terms "expression cassette" and "transcription cassette" are used interchangeably and refer to a linear nucleic acid comprising a transgene operably linked to one or more promoters or other regulatory sequences sufficient to direct transcription of the transgene, but excluding capsid coding sequences, other vector sequences, or inverted terminal repeats. The expression cassette may additionally include one or more cis-acting sequences (e.g., promoters, enhancers, or repressors), one or more introns, and one or more post-transcriptional regulatory elements.
[0068] The terms "polynucleotide" and "nucleic acid" used interchangeably herein refer to nucleotides of any length, polymer forms of ribonucleotides or deoxyribonucleotides. Therefore, this term includes single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids or polymers comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases. "Oligonucleotide" generally refers to a polynucleotide between about 5 to about 100 nucleotides of a single-stranded or double-stranded DNA. However, for the purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides are also referred to as "oligomers" or "oligomers", and can be isolated from a gene, or chemically synthesized by methods known in the art. It should be understood that the terms "polynucleosides" and "nucleic acids" include single-stranded (such as sense or antisense) and double-stranded polynucleotides, if the described embodiments are applicable.
[0069] The terms DNA and DNA molecule are used interchangeably herein and mean DNA that can be in the form of, for example, an antisense molecule, plasmid DNA, DNA-DNA duplex, precondensed DNA, PCR product, vector (P1, PAC, BAC, YAC, artificial chromosome), expression cassette, chimeric sequence, chromosomal DNA, or derivatives and combinations of these groups. DNA can be in the form of minicircle, plasmid, bacmid, minigene, ministring DNA (linear covalently closed DNA vector), end-closed linear duplex DNA (CELiD or ceDNA), doggybone (dbDNA), or a combination of these groups. TM ) DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector. RNA can be in the following forms: small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, rRNA, tRNA, viral RNA (vRNA) and combinations thereof. According to a preferred embodiment, the DNA of the primary vaccine includes minicircle, plasmid, bacmid, minigene, ministring DNA (linear covalently closed DNA vector), end-closed linear duplex DNA (CELiD or ceDNA), doggybone (dbDNA TM) DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vectors, viral vectors or non-viral vectors. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring and non-naturally occurring, and which have similar binding properties to reference nucleic acids. Examples of such analogs and / or modified residues include, but are not limited to, phosphorothioates, diamidophosphorothioate morpholino oligomers (morpholinos), phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2'-O-methyl ribonucleotides, locked nucleic acids (LNAs), and the like. TM ) and peptide nucleic acid (PNA). Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides with similar binding properties to the reference nucleic acid. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as sequences explicitly indicated.
[0070] As used herein, a "nucleotide" contains the sugar deoxynucleoside (DNA) or ribose (RNA), a base, and a phosphate group. The nucleotides are linked together by the phosphate groups.
[0071] "Bases" include purines and pyrimidines, and further include the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, as well as synthetic derivatives of purines and pyrimidines, including but not limited to modifications that place new reactive groups such as but not limited to amines, alcohols, thiols, carboxylates, and alkyl halides.
[0072] As used herein, the term "nucleic acid construct" refers to a single-stranded or double-stranded nucleic acid molecule that is isolated from a natural gene or modified to contain a segment of nucleic acid in a manner that does not otherwise exist or synthesize in nature. When the nucleic acid construct contains control sequences required for expressing the coding sequence of the present disclosure, the term nucleic acid construct is synonymous with the term "expression cassette." An "expression cassette" contains a DNA coding sequence operably linked to a promoter.
[0073] "Hybridizable" or "complementary" or "substantially complementary" means that a nucleic acid (e.g., RNA) comprises a nucleotide sequence that enables it to non-covalently bind to another nucleic acid sequence under conditions of appropriate temperature and solution ionic strength in vitro and / or in vivo, i.e., to form Watson-Crick base pairs and / or G / U base pairs, "anneal" or "hybridize" in a sequence-specific antiparallel manner (i.e., a nucleic acid that specifically binds to a complementary nucleic acid). As known in the art, standard Watson-Crick base pairs comprise: adenine (A) pairs with thymidine (T), adenine (A) pairs with uracil (U), and guanine (G) pairs with cytosine (C). In addition, it is also known in the art that for hybridization between two RNA molecules (e.g., dsRNA), a guanine (G) base pairs with uracil (U). For example, in the case of tRNA anticodon base pairing with codons in mRNA, G / U base pairing is partially responsible for the degeneracy (i.e., redundancy) of the genetic code. In the context of the present disclosure, the guanine (G) of the protein binding segment (dsRNA duplex) of the RNA molecule targeting the subject DNA is considered to be complementary to uracil (U), and vice versa. Thus, when a G / U base pair can be formed at a given nucleotide position of the protein binding segment (dsRNA duplex) of the RNA molecule targeting the subject DNA, the position is not considered to be non-complementary, but rather is considered to be complementary.
[0074] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymeric form of amino acids of any length, which may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides with modified peptide backbones.
[0075] A DNA sequence that "encodes" a specific antigen or immunogenic peptide is a DNA nucleic acid sequence that is transcribed into a specific RNA and / or protein. A DNA polynucleotide may encode an RNA (mRNA) that is translated into a protein, or a DNA polynucleotide may encode an RNA that is not translated into a protein (e.g., tRNA, rRNA, or DNA targeting RNA; also referred to as "non-coding" RNA or "ncRNA").
[0076] As used herein, the term "terminal repeat sequence" or "TR" includes any viral terminal repeat or synthetic sequence that includes at least one minimum required replication origin and a region including a palindromic hairpin structure. The Rep binding sequence ("RBS") (also known as RBE (Rep binding element)) and the terminal resolution site ("TRS") together constitute the "minimum required replication origin", and thus the TR includes at least one RBS and at least one TRS. TRs that are reverse complementary to each other within a given polynucleotide sequence are generally each referred to as "inverted terminal repeat sequences" or "ITRs". In the context of viruses, ITRs mediate replication, viral packaging, integration, and proviral rescue. As unexpectedly discovered, TRs that are not reverse complementary sequences in full length can still perform the traditional functions of ITRs, so the term ITR is used herein to refer to TRs that can mediate ceDNA vector replication in ceDNA genomes or ceDNA vectors. Those of ordinary skill in the art will appreciate that in complex ceDNA vector configurations, there may be more than two ITRs or asymmetric ITR pairs. ITRs may be AAV ITRs or non-AAV ITRs, or may be derived from AAV ITRs or non-AAV ITRs. For example, the ITRs can be derived from the Parvoviridae family, which encompasses parvoviruses and dependoviruses (e.g., canine parvovirus, bovine parvovirus, mouse parvovirus, porcine parvovirus, human parvovirus B-19), or the SV40 hairpin, which serves as the SV40 origin of replication, can be used as an ITR, which can be further modified by truncation, substitution, deletion, insertion, and / or addition. The Parvoviridae family of viruses consists of two subfamilies: the Parvovirinae, which infects vertebrates, and the Densovirinae, which infects invertebrates. The Dependoviridae genus is a family of viruses that includes adeno-associated viruses (AAVs), which are able to replicate in vertebrate hosts, including, but not limited to, humans, primates, cattle, dogs, horses, and sheep species. For convenience herein, the ITR located 5' (upstream) of the expression cassette in the ceDNA vector is referred to as "5' ITR" or "left ITR", and the ITR located 3' (downstream) of the expression cassette in the ceDNA vector is referred to as "3' ITR" or "right ITR".
[0077] "Wild-type ITR" or "WT-ITR" refers to the sequence of the naturally occurring ITR sequence in AAV or other dependent viruses, which retains, for example, Rep binding activity and Rep nicking ability. Due to the degeneracy or drift of the genetic code, the nucleic acid sequence of the WT-ITR from any AAV serotype may differ slightly from the typical naturally occurring sequence, and therefore, the WT-ITR sequences contemplated for use herein include WT-ITR sequences generated due to naturally occurring changes (e.g., replication errors) that occur during the production process.
[0078] As used herein, the term "substantially symmetrical WT-ITR" or "substantially symmetrical WT-ITR pair" refers to a pair of WT-ITRs in a single ceDNA genome or ceDNA vector that are wild-type ITRs that have reverse complementary sequences throughout their entire length. For example, an ITR may be considered a wild-type sequence even if it has one or more nucleotides that deviate from a typical naturally occurring sequence, as long as the change does not affect the properties and overall three-dimensional structure of the sequence. According to some aspects, the deviated nucleotides represent conservative sequence changes. As a non-limiting example, a sequence has at least 95%, 96%, 97%, 98% or 99% sequence identity with a typical sequence (as measured, for example, using BLAST under default settings), and also has a symmetrical three-dimensional spatial organization with another WT-ITR, so that its 3D structure has the same shape in geometric space. Substantially symmetrical WT-ITRs have identical A, C-C' and B-B' loops in 3D space. Substantially symmetric WT-ITRs can be functionally confirmed to be WT by confirming that they have an operable Rep binding site (RBE or RBE') and a terminal resolution site (trs) that are paired with the appropriate Rep protein.Other functions can optionally be tested, including transgene expression under permissive conditions.
[0079] As used herein, the phrases "modified ITR" or "mod-ITR" or "mutant ITR" are used interchangeably herein and refer to an ITR having a mutation in at least one or more nucleotides compared to a WT-ITR from the same serotype. The mutation may cause a change in some or more of the A, C, C', B, B' regions in the ITR and may cause a change in the three-dimensional spatial organization (i.e., its 3D structure in geometric space) compared to the 3D spatial organization of the WT-ITR of the same serotype.
[0080] As used herein, the term "asymmetric ITR", also referred to as "asymmetric ITR pair", refers to a pair of ITRs that are not reverse complementary over their entire length within a single ceDNA genome or ceDNA vector. As a non-limiting example, an asymmetric ITR does not have a symmetrical three-dimensional spatial organization with its homologous ITR, so that its 3D structure has a different shape in geometric space. In other words, the asymmetric ITR pair has a different overall geometric structure, that is, it has a different A, C-C' and B-B' loop organization in 3D space (for example, one ITR may have a short C-C' arm and / or a short B-B' arm compared to the homologous ITR). The sequence difference between the two ITRs may be due to one or more nucleotide additions, deletions, truncations or point mutations. According to some embodiments, one ITR in the asymmetric ITR pair may be a wild-type AAV ITR sequence, and the other ITR is a modified ITR as defined herein (e.g., a non-wild-type or synthetic ITR sequence). In another embodiment, neither ITR in the asymmetric ITR pair is a wild-type AAV sequence, and the two ITRs are modified ITRs having different shapes in geometric space (i.e., different overall geometric structures). According to some embodiments, one mod-ITR in the asymmetric ITR pair may have a short C-C' arm, and the other ITR may have a different modification (e.g., a single arm or a short B-B' arm, etc.) such that it has a different three-dimensional spatial organization than the homologous asymmetric mod-ITR.
[0081] As used herein, the term "symmetrical ITR" refers to a pair of ITRs within a single ceDNA genome or ceDNA vector that are mutated or modified relative to the wild-type dependent virus ITR sequence and are reverse complementary over their entire length. Neither of these two ITRs is a wild-type ITR AAV2 sequence (i.e., it is a modified ITR, also referred to as a mutant ITR), and differs in sequence from the wild-type ITR due to the addition, deletion, substitution, truncation or point mutation of nucleotides. For convenience herein, the ITR located at the 5' (upstream) of the expression cassette in the ceDNA vector is referred to as the "5' ITR" or "left ITR", and the ITR located at the 3' (downstream) of the expression cassette in the ceDNA vector is referred to as the "3' ITR" or "right ITR".
[0082] As used herein, the term "substantially symmetrical modified ITR" or "substantially symmetrical mod-ITR pair" refers to a pair of modified ITRs in a single ceDNA genome or ceDNA vector that have reverse complementary sequences over their entire length. For example, even if the modified ITR has some nucleotide sequence that deviates from the reverse complementary sequence, it can be considered to be substantially symmetrical as long as these changes do not affect the properties and overall shape. As a non-limiting example, the sequence has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the typical sequence (as measured using BLAST under default settings), and also has a symmetrical three-dimensional spatial organization with its homologous modified ITR, so that its 3D structure has the same shape in geometric space. In other words, a substantially symmetrical modified ITR pair has the same A, C-C' and B-B' loops organized in 3D space. According to some embodiments, the ITRs from a mod-ITR pair can have different reverse complementary nucleotide sequences, but still have the same symmetrical three-dimensional spatial organization, i.e., both ITRs have mutations that produce the same overall 3D shape. For example, one ITR (e.g., 5'ITR) in a mod-ITR pair can be from one serotype, while the other ITR (e.g., 3'ITR) can be from a different serotype, but both can have the same corresponding mutations (e.g., if the 5'ITR has a deletion in the C region, then the homologously modified 3'ITR from a different serotype also has a deletion at the corresponding position in the C' region), so that the modified ITR pair has the same symmetrical three-dimensional spatial organization. In such embodiments, each ITR in the modified ITR pair can be from a different serotype (e.g., AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12), such as a combination of AAV2 and AAV6, wherein modifications according to some of the ITRs are reflected in corresponding positions in the homologous ITRs from different serotypes. According to some embodiments, a substantially symmetrical modified ITR pair refers to a pair of modified ITRs (mod-ITRs) as long as the difference in nucleotide sequence between the ITRs does not affect the properties or overall shape and they have substantially the same shape in 3D space. As a non-limiting example, the mod-ITRs have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with a typical mod-ITR as determined by standard methods well known in the art, such as BLAST (Basic Local Alignment Search Tool) or BLASTN under default settings, and also have a symmetrical three-dimensional spatial organization so that their 3D structures have the same shape in geometric space.A substantially symmetric mod-ITR pair has identical A, C-C', and B-B' loops in 3D space, for example, if a modified ITR in a substantially symmetric mod-ITR pair lacks the C-C' arm, then the corresponding homologous mod-ITR lacks the C-C' loop and also has a similar 3D structure with the remaining A and B-B' loops being the same shape in the geometric space of its homologous mod-ITR.
[0083] As used herein, "internal ribosome entry site" (IRES) refers to a nucleotide sequence (>500 nucleotides) that allows translation initiation in the middle of an mRNA sequence (Kirn, JIT. et al., 2011. PLoS One 6(4):8556; the contents of which are incorporated herein by reference in their entirety. The use of an IRES sequence ensures co-expression of genes before and after the IRES, but the sequence after the IRES can be transcribed and translated at a lower level than the sequence before the IRES sequence.
[0084] As used herein, "2A peptide" is intended to refer to a small self-cleaving peptide derived from a virus, such as foot-and-mouth disease virus (F2A), porcine Teschovirus-1 (P2A), Trichodorus leucoderma virus (T2A), or equine rhinitis A virus (E2A). The 2A designation specifically refers to a region of the picornavirus polyprotein that causes ribosomal jumping at a glycyl-prolyl bond in the O-terminus of the 2A peptide (Kim, J. IT. et al. 2011. PLoS One 6(4); the contents of which are incorporated herein by reference in their entirety. This jump causes cleavage between the 2A peptide and its immediately downstream peptide.
[0085] The term "flanking" refers to the relative position of one nucleic acid sequence relative to another nucleic acid sequence. Typically, in the sequence ABC, B is flanked by A and C. The same is true for the arrangement AxBxC. Thus, the flanking sequence precedes or follows the flanked sequence, but is not necessarily adjacent to or immediately adjacent to the flanked sequence. According to some embodiments, the term flanking refers to the terminal repeat sequences at each end of a linear duplex ceDNA vector.
[0086] As used herein, the term "ceDNA genome" refers to an expression cassette that also incorporates at least one inverted terminal repeat region. The ceDNA genome may further include one or more spacer regions. According to some embodiments, the ceDNA genome is incorporated into a plasmid or viral genome as an intermolecular duplex polynucleotide of DNA.
[0087] As used herein, the term "ceDNA spacer region" refers to an intervening sequence that separates functional elements in a ceDNA vector or ceDNA genome. According to some embodiments, the ceDNA spacer region maintains two functional elements at a distance desired for optimal functionality. According to some embodiments, the ceDNA spacer region provides or increases the genetic stability of the ceDNA genome in, for example, a plasmid or baculovirus. According to some embodiments, the ceDNA spacer region promotes the ready gene manipulation of the ceDNA genome by providing a convenient location for a cloning site, etc. For example, in some aspects, an oligonucleotide "polylinker" containing several restriction endonuclease sites or a non-open reading frame sequence designed to have no known protein (e.g., transcription factor) binding site can be positioned in the ceDNA genome to separate cis-acting factors, such as 6-mers, 12-mers, 18-mers, 24-mers, 48-mers, 86-mers, 176-mers, etc. are inserted between the terminal resolution site and the upstream transcriptional regulatory element. Similarly, a spacer can be incorporated between the polyadenylation signal sequence and the 3' terminal resolution site.
[0088] As used herein, the terms "Rep binding site," "Rep binding element," "RBE," and "RBS" are used interchangeably and refer to a binding site of a Rep protein (e.g., AAV Rep 78 or AAV Rep 68) that, upon binding of the Rep protein, allows the Rep protein to exert its site-specific endonuclease activity on the sequence into which the RBS is incorporated. The RBS sequence and its reverse complement together form a single RBS. RBS sequences are known in the art and include, for example, 5'-GCGCGCTCGCTCGCTC-3', which is an RBS sequence identified in AAV2. Any known RBS sequence may be used in the embodiments of the present disclosure, including other known AAV RBS sequences and other naturally known or synthetic RBS sequences. Without being bound by theory, it is believed that the nuclease domain of the Rep protein binds to the duplex nucleic acid sequence GCTC, and thus the two known AAV Rep proteins directly bind to the duplex oligonucleotide 5'-(GCGC)(GCTC)(GCTC)(GCTC)-3' and are stably assembled thereon. In addition, soluble aggregating conformers (i.e., an undetermined number of mutually associated Rep proteins) dissociate and bind to oligonucleotides containing Rep binding sites. Each Rep protein interacts with both the nitrogenous bases and the phosphodiester backbone on each chain. The interaction with the nitrogenous bases provides sequence specificity, while the interaction with the phosphodiester backbone is non- or less sequence specific and stabilizes the protein-DNA complex.
[0089] As used herein, the terms "terminal resolution site" and "TRS" are used interchangeably herein and refer to a region in which Rep forms a tyrosine-phosphodiester bond with a 5' thymidine, producing a 3' OH that serves as a substrate for DNA extension by a DNA polymerase, such as DNA pol δ or DNA pol ε. Alternatively, the Rep-thymidine complex can participate in a coordinated ligation reaction. According to some embodiments, the TRS minimally encompasses non-base paired thymidines. According to some embodiments, the efficiency of nicking of the TRS can be controlled at least in part by its distance from the RBS within the same molecule. When the acceptor substrate is a complementary ITR, the product produced is an intramolecular duplex. TRS sequences are known in the art and include, for example, 5'-GGTTGA-3', which is a hexanucleotide sequence identified in AAV2. Any known TRS sequence can be used in embodiments of the present disclosure, including other known AAV TRS sequences and other naturally known or synthetic TRS sequences, such as AGTT, GGTTGG, AGTTGG, AGTTGA, and other motifs, such as RRTTRR.
[0090] As used herein, the term "ceDNA" refers to a linear double-stranded (ds) duplex DNA without capsid end closure for non-viral gene transfer, synthesis or other forms. A detailed description of ceDNA is described in the international application PCT / US2017 / 020828 filed on March 3, 2017, the entire contents of which are expressly incorporated herein by reference. Certain methods for producing ceDNA including various inverted terminal repeat (ITR) sequences and configurations using cell-based methods are described in Example 1 of International Applications PCT / US18 / 49996 filed on September 7, 2018 and PCT / US2018 / 064242 filed on December 6, 2018, each of which is incorporated herein by reference in its entirety. Certain methods for producing synthetic ceDNA vectors including various ITR sequences and configurations are described, for example, in International Applications PCT / US2019 / 14122 filed on January 18, 2019, the entire contents of which are incorporated herein by reference. As used herein, the term "ceDNA vector" is used interchangeably with "ceDNA" and refers to an end-closed DNA vector comprising at least one terminal palindrome. According to some embodiments, the ceDNA comprises two covalently closed ends.
[0091] As used herein, the term "ceDNA-plasmid" refers to a plasmid comprising a ceDNA genome as an intermolecular duplex.
[0092] As used herein, the term "ceDNA-bacmid" refers to an infectious baculovirus genome comprising the ceDNA genome as an intermolecular duplex, which is capable of propagation as a plasmid in E. coli and can therefore be operated as a baculovirus shuttle vector.
[0093] As used herein, the term "ceDNA-baculovirus" refers to a baculovirus that includes a ceDNA genome as an intermolecular duplex within the baculovirus genome.
[0094] As used herein, the terms "ceDNA-baculovirus-infected insect cells" and "ceDNA-BIIC" are used interchangeably and refer to invertebrate host cells (including but not limited to insect cells (eg, Sf9 cells)) infected by ceDNA-baculovirus.
[0095] As used herein, the term "end-blocked DNA vector" refers to a capsid-free DNA vector having at least one covalently blocked end, wherein at least a portion of the vector has an intramolecular duplex structure.
[0096] As defined herein, "reporter molecule" refers to a protein that can be used to provide a detectable readout number. Reporter molecules generally produce measurable signals, such as fluorescence, color or luminescence. The reporter protein coding sequence encodes a protein that is easily observed in a cell or organism. For example, fluorescent proteins can cause cells to fluoresce when excited by light of a specific wavelength, luciferase causes a cell to catalyze the reaction of producing light, and enzymes such as beta-galactosidase convert substrates into colored products. Exemplary reporter polypeptides that can be used for experimental or diagnostic purposes include but are not limited to beta-lactamase, beta-galactosidase (LacZ), alkaline phosphatase (AP), thymidine kinase (TK), green fluorescent protein (GFP) and other fluorescent proteins, chloramphenicol acetyltransferase (CAT), luciferase and other reporter polypeptides well known in the art.
[0097] As used herein, the term "effector protein" refers to a polypeptide that provides a detectable readout, such as a reporter polypeptide, or more appropriately, as a cell-killing polypeptide, such as a toxin, or an agent that renders a cell susceptible to a selected agent or killed by the lack of a selected agent. Effector proteins include any protein or peptide that directly targets or damages the DNA and / or RNA of a host cell. For example, effector proteins may include, but are not limited to, restriction endonucleases that target host cell DNA sequences (whether genomic or on extrachromosomal elements); proteases that degrade polypeptide targets necessary for cell survival; DNA gyrase inhibitors; and ribonuclease-type toxins. According to some embodiments, the expression of an effector protein controlled by a synthetic biological circuit as described herein can participate as a factor in another synthetic biological circuit, thereby expanding the response range and complexity of the biological circuit system.
[0098] Transcriptional regulatory factors refer to transcriptional activators and repressors that activate or inhibit the transcription of a transgene (e.g., a nucleic acid encoding an antibody or its antigen-binding fragment as described herein). A promoter is a nucleic acid region that initiates transcription of a specific gene. Transcriptional activators typically bind to and recruit RNA polymerase near a transcriptional promoter to directly initiate transcription. Repressors bind to transcriptional promoters and spatially hinder RNA polymerase from initiating transcription. Other transcriptional regulatory factors may act as activators or repressors depending on their binding position and cell and environmental conditions. Non-limiting examples of transcriptional regulatory factor categories include, but are not limited to, homeodomain proteins, zinc finger proteins, winged helix (forkhead) proteins, and leucine zipper proteins.
[0099] As used herein, a "repressor protein" or "inducer protein" is a protein that binds to a regulatory sequence element and represses or activates transcription of a sequence operably linked to the regulatory sequence element, respectively. Preferred repressor and inducer proteins as described herein are sensitive to the presence or absence of at least one input agent or environmental input. Preferred proteins as described herein are in modular form, including, for example, separable DNA binding and input agent binding or responsive elements or domains.
[0100] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active ingredients may also be incorporated into the composition. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce toxic, allergic or similar adverse reactions when administered to a host.
[0101] As used herein, an "input responsive domain" is a domain of a transcription factor that binds to or otherwise responds to a condition or input agent in a manner that causes an attached DNA binding fusion domain to respond to the presence of the condition or input agent. According to some embodiments, the presence of a condition or input causes a conformational change in the input agent responsive domain or a protein fused thereto that alters the transcriptional modulatory activity of the transcription factor.
[0102] The term "in vivo" refers to an assay or process performed in or within an organism such as a multicellular animal. According to some of the aspects described herein, when a unicellular organism such as a bacterium is used, the method or use can be said to occur "in vivo". The term "ex vivo" refers to methods and uses performed using living cells with intact membranes, which are outside of a multicellular animal or plant, such as explants, cultured cells, including primary cells and cell lines, transformed cell lines, and extracted tissues or cells, including blood cells, etc. The term "in vitro" refers to analyses and methods that do not require the presence of cells with intact membranes, such as cell extracts, and can refer to the introduction of programmable synthetic biological circuits in non-cellular systems, such as media that do not include cells or cell systems, such as cell extracts.
[0103] As used herein, the term "promoter" refers to any nucleic acid sequence that regulates the expression of another nucleic acid sequence by driving the transcription of a nucleic acid sequence, which may be a heterologous target gene encoding a protein or RNA. A promoter may be constitutive, inducible, repressible, tissue-specific, or any combination thereof. A promoter is a control region of a nucleic acid sequence, where the rate of initiation and transcription of the rest of the nucleic acid sequence is controlled. A promoter may also contain genetic elements that can bind to regulatory proteins and molecules such as RNA polymerases and other transcription factors. According to some embodiments of the aspects described herein, a promoter may drive the expression of transcription factors that regulate the expression of the promoter itself. A transcription start site will be found within the promoter sequence, as well as a protein binding domain responsible for RNA polymerase binding. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Various promoters, including inducible promoters, can be used to drive the expression of transgenes in the ceDNA vector disclosed herein. The promoter sequence may be bounded at its 3' end by a transcription start site and extend upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. According to some embodiments, the promoter of the present disclosure is a liver-specific promoter.
[0104] As used herein, the term "enhancer" refers to a cis-acting regulatory sequence (e.g., 10-1,500 base pairs) that binds to one or more proteins (e.g., activator proteins or transcription factors) to enhance transcriptional activation of a nucleic acid sequence. An enhancer can be located up to 1,000,000 base pairs upstream of the gene start site or downstream of the gene start site that it regulates. An enhancer can be located within an intron region, or in an exon region of an unrelated gene.
[0105] A promoter can be considered to drive the expression of the nucleic acid sequence it regulates or to drive its transcription. The phrases "operably connected", "operably positioned", "operably connected", "under control" and "under transcriptional control" indicate that the promoter is in the correct functional position and / or orientation relative to the nucleic acid sequence it regulates, to control the transcription initiation and / or expression of the sequence. As used herein, "reverse promoter" refers to a nucleic acid sequence that is in the opposite orientation, so that the coding strand now becomes the promoter of the non-coding strand, and vice versa. Reverse promoter sequences can be used in various embodiments to regulate the state of the switch. In addition, in various embodiments, the promoter can be used in combination with an enhancer.
[0106] A promoter may be one naturally associated with a gene or sequence, such as may be obtained by isolating 5' non-coding sequences and / or exons of a given gene or sequence upstream of the coding segment. Such promoters may be referred to as "endogenous". Similarly, according to some embodiments, an enhancer may be one naturally associated with a nucleic acid sequence, located downstream or upstream of the sequence.
[0107] According to some embodiments, the coding nucleic acid segment is positioned under the control of a "recombinant promoter" or a "heterologous promoter", both of which refer to promoters that are not usually associated with a coding nucleic acid sequence that is operably linked to it in its natural environment. A recombinant or heterologous enhancer refers to an enhancer that is not usually associated with a given nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes; promoters or enhancers isolated from any other prokaryotic, viral or eukaryotic cells; and non-"naturally occurring", i.e., synthetic promoters or enhancers that include different elements of different transcriptional regulatory regions that change expression and / or mutated by genetic engineering methods known in the art. In addition to synthesizing nucleic acid sequences for promoters and enhancers, promoter sequences may also be generated using recombinant cloning and / or nucleic acid amplification techniques, including PCR, in combination with the synthetic biological circuits and modules disclosed herein (see, e.g., U.S. Pat. No. 4,683,202, U.S. Pat. No. 5,928,906, each of which is incorporated herein by reference). Additionally, it is contemplated that control sequences that direct transcription and / or expression of the sequence in non-nuclear organelles, such as mitochondria, chloroplasts, etc., may also be employed.
[0108] As described herein, an "inducible promoter" is a promoter characterized in that when an inducer or inducer is present, affected by it, or contacted by it, transcriptional activity is initiated or enhanced. As defined herein, an "inducer" or "inducer" may be endogenous, or a generally exogenous compound or protein that is administered in a manner that can induce transcriptional activity from an inducible promoter. According to some embodiments, the inducer or inducer, i.e., a chemical substance, compound, or protein, may itself be the result of transcription or expression of a nucleic acid sequence (i.e., the inducer may be an induced protein expressed by another component or module), and transcription or expression itself may be under the control of an inducible promoter. According to some embodiments, an inducible promoter is induced in the absence of certain agents such as repressors. Examples of inducible promoters include, but are not limited to, tetracycline, metallothionein, ecdysone, mammalian viruses (e.g., adenovirus late promoter; and mouse mammary tumor virus long terminal repeat (MMTV-LTR)) and other steroid response promoters, rapamycin response promoters, and the like.
[0109] The terms "DNA regulatory sequence," "control element," and "regulatory element," used interchangeably herein, refer to transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, protein degradation signals, and the like, that provide and / or regulate the transcription of a non-coding sequence (e.g., a DNA-targeting RNA) or a coding sequence (e.g., a site-directed modifying polypeptide, or a Cas9 / Csn1 polypeptide) and / or regulate the translation of the encoded polypeptide.
[0110] As used herein, the term "open reading frame (ORF)" means a sequence of several nucleotide triplets that can be translated into a peptide or protein. An open reading frame preferably contains a start codon, i.e., three subsequent nucleotides encoding the amino acid methionine (ATG) at its 5' end and a combination of subsequent regions that are generally shown to be a multiple of 3 nucleotides in length. ORF is preferably terminated by a stop codon (e.g., TAA, TAG, TGA). Typically, this is the only stop codon for an open reading frame. Therefore, an open reading frame in the context of the present disclosure is preferably a nucleotide sequence consisting of many nucleotides that can be divided by three, and the nucleotides start with a start codon (e.g., ATG) and preferably terminate with a stop codon (e.g., TAA, TGA or TAG). An open reading frame can be separated, or can be incorporated into a longer nucleic acid sequence, such as incorporated into a ceDNA vector as described herein.
[0111] "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship that permits the components to function in their intended manner. For example, if a promoter affects the transcription or expression of a coding sequence, then the promoter is operably linked to the coding sequence. An "expression cassette" comprises a DNA sequence operably linked to a promoter or other regulatory sequences sufficient to direct transcription of a transgene in a ceDNA vector. Suitable promoters include, for example, tissue-specific promoters. The promoter may also be of AAV origin.
[0112] As used herein, the term "subject" refers to a person or animal to whom treatment with a ceDNA vector according to the present disclosure is provided, including preventive treatment. As used herein, the term "subject" includes humans and other animals. Typically, the subject is a person. For example, the subject may be an adult, a teenager, a child (2 to 14 years old), an infant (born to 2 years old) or a newborn (up to 2 months). In particular aspects, the subject is up to 4 months old, or up to 6 months old. According to some aspects, an adult is an elderly person of about 65 years old or older, or about 60 years old or older. According to some aspects, the subject is a pregnant woman or a woman who intends to become pregnant. In other aspects, the subject is not a person; for example, a non-human primate; such as a baboon, a chimpanzee, a gorilla or a macaque. In some aspects, the subject may be a pet such as a dog or a cat.
[0113] As used herein, the term "host cell" includes any cell type susceptible to transformation, transfection, transduction, etc. of the nucleic acid construct or ceDNA expression vector of the present disclosure. As non-limiting examples, the host cell can be an isolated primary cell, a pluripotent stem cell, a CD34 + Cells, induced pluripotent stem cells or any of a number of immortalized cell lines (e.g., HepG2 cells). Alternatively, the host cell may be an in situ or in vivo cell in a tissue, organ or organism.
[0114] The term "exogenous" refers to a substance present in a cell other than its natural source. When used herein, the term "exogenous" may refer to a nucleic acid (e.g., a nucleic acid encoding a polypeptide) or a polypeptide that has been introduced into a biological system such as a cell or an organism by a process involving human hands, in which the nucleic acid or polypeptide is not normally found, and it is desired to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, "exogenous" may refer to a nucleic acid or polypeptide that has been introduced into a biological system such as a cell or an organism by a process involving human hands, in which the amount of the nucleic acid or polypeptide is found in the cell or organism is relatively low, and it is desired to increase the amount of the nucleic acid or polypeptide in the cell or organism, for example to produce ectopic expression or levels. In contrast, the term "endogenous" refers to a substance that is natural to a biological system or cell.
[0115] The term "sequence identity" refers to the correlation between two nucleotide sequences. For the purpose of the present disclosure, the degree of sequence identity between two deoxyribonucleic acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, the same), the algorithm is as implemented in the EMBOSS software package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, the same), preferably in the Needle programs such as version 3.0.0 or updated versions. The optional parameters used are gap opening penalty 10, gap extension penalty 0.5 and EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of the Needle marked as "longest identity" (obtained using the -nobrief option) is used as the identity percentage, and is calculated as follows: (identical deoxyribonucleotides multiplied by 100) / (total number of gaps in the length-alignment of the comparison). The length of the alignment is preferably at least 10 nucleotides, preferably at least 25 nucleotides, more preferably at least 50 nucleotides and most preferably at least 100 nucleotides.
[0116] As used herein, the term "homology" or "homology" is defined as the percentage of nucleotide residues identical to the nucleotide residues in the corresponding sequence on the target chromosome after the alignment sequences and, if necessary, the introduction of gaps to achieve the maximum sequence identity percentage. The comparison for the purpose of determining the nucleotide sequence homology percentage can be achieved in a variety of ways within the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, ClustalW2 or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for the alignment sequence, including any algorithm required for achieving maximum alignment over the full length of the sequence being compared. According to some embodiments, a nucleic acid sequence (e.g., a DNA sequence), for example, of a homology arm is considered "homologous" when it has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identity to a corresponding native or unedited nucleic acid sequence (e.g., a genomic sequence) of a host cell.
[0117] As used herein, the term "heterologous" means a nucleotide or polypeptide sequence that is not present in a natural nucleic acid or protein, respectively. A heterologous nucleic acid sequence can be connected (e.g., by genetic engineering) to a naturally occurring nucleic acid sequence (or variant thereof) to produce a chimeric nucleotide sequence encoding a chimeric polypeptide. A heterologous nucleic acid sequence can be connected (e.g., by genetic engineering) to a variant polypeptide to produce a nucleic acid sequence encoding a fusion variant polypeptide. Alternatively, the term "heterologous" can refer to a nucleic acid sequence that is not naturally present in a cell or subject.
[0118] A "vector" or "expression vector" is another DNA segment, i.e., a replicon, such as a plasmid, bacmid, phage, virus, virion, or cosmid, to which an "insert" can be connected, so as to cause replication of the connected segment within a cell. A vector can be a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be of viral or non-viral origin and / or final form, however, for the purposes of this disclosure, a "vector" generally refers to a ceDNA vector as the term is used herein. The term "vector" encompasses any genetic element that is capable of replication when associated with appropriate control elements and can transfer a gene sequence to a cell. According to some embodiments, a vector can be an expression vector or a recombinant vector.
[0119] As used herein, the term "expression vector" refers to a vector that guides the expression of RNA or polypeptides from sequences connected to the transcriptional regulatory sequences on the vector. The expressed sequence will usually but not necessarily be heterologous to the cell. The expression vector may include additional elements, for example, the expression vector may have two replication systems so that it can be maintained in two organisms, such as expressed in human cells and cloned and amplified in prokaryotic hosts. The term "expression" refers to the cellular process involved in producing RNA and protein and secreting proteins when appropriate, and when applicable, it includes but is not limited to, for example, transcription, transcript processing, translation and protein folding, modification and processing." Expression product" includes RNA transcribed from a gene and polypeptides obtained by translating mRNA transcribed from a gene. The term "gene" means a nucleic acid sequence that is transcribed (DNA) into RNA in vitro or in vivo when operably connected to an appropriate regulatory sequence. A gene may or may not include regions preceding and following the coding region, for example, a 5' untranslated (5'UTR) or "leader" sequence and a 3'UTR or "trailer" sequence, as well as intervening sequences (introns) between individual coding segments (exons).
[0120] "Recombinant vector" means a vector comprising a heterologous nucleic acid sequence or "transgene" that can be expressed in vivo. It should be understood that, according to some embodiments, the vectors described herein can be combined with other suitable compositions and therapies. According to some embodiments, the vector is episomal. The use of suitable episomal vectors provides a method for maintaining nucleotides of interest to a subject in a high copy number of extrachromosomal DNA, thereby eliminating the potential effects of chromosome fusions.
[0121] As used herein, the term "administration / administering" and variants thereof refer to the introduction of a composition or agent (e.g., ceDNA as described herein) into an individual and include the simultaneous and sequential introduction of one or more compositions or agents. "Administration" may refer to, for example, treatment, pharmacokinetics, diagnosis, research, placebo, and experimental methods. "Administration" also encompasses in vitro and ex vivo treatments. Compositions or agents are introduced into an individual by any suitable route, including oral, pulmonary, nasal, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous), rectal, intralymphatic, intratumoral or local. Administration includes self-administration and administration by others. Administration may be performed by any suitable route. Suitable routes of administration allow compositions or agents to perform their intended functions. For example, if the suitable route is intravenous, the composition is administered by introducing the composition or agent into the vein of the individual.
[0122] As used herein, administering a composition "following" administering a composition indicates that a time interval has elapsed between administering the first composition and administering the second composition, whether the first composition and the second composition are the same or different.
[0123] As used herein, the term "infection" refers to the initial entry of a pathogen into a host; as well as the condition in which a pathogen has established itself in or on cells or tissues of the host; such condition does not necessarily constitute or result in disease.
[0124] As used herein, the term "biological sample" refers to any type of biological source material separated from a subject, including, for example, DNA, RNA, lipids, carbohydrates and proteins. The term "biological sample" includes tissues, cells and biological fluids separated from a subject. Biological samples include, for example, but not limited to, whole blood, plasma, serum, semen, saliva, tears, urine, feces, sweat, cheek fluid, skin, cerebrospinal fluid, bone marrow, bile, hair, muscle biopsy, organ tissue or other materials of biological origin known to those of ordinary skill in the art. Biological samples can be obtained from subjects for diagnosis or research, or can be obtained from healthy subjects as a control or for basic research. As used herein, the term "dose" refers to the amount of a substance (e.g., ceDNA as described herein) taken or administered to a subject at one time.
[0125] As used herein, the term "administering" refers to administering a substance (eg, ceDNA as described herein) to achieve a therapeutic goal (eg, treatment).
[0126] The term "combination" as in the phrase "a first agent is combined with a second agent" includes co-administration of a first agent and a second agent, which may be dissolved or mixed in the same pharmaceutically acceptable carrier, for example, or administration of the first agent followed by administration of the second agent, or administration of the second agent followed by administration of the first agent. Thus, the present disclosure includes methods of combined therapeutic treatments and combined pharmaceutical compositions.
[0127] The term "concomitant" as in the phrase "concomitant therapeutic treatment" includes administering an agent in the presence of a second agent. Concomitant therapeutic treatment methods include methods in which a first, second, third or additional agent is co-administered. Concomitant therapeutic treatment methods also include methods in which a first agent or additional agent is administered in the presence of a second agent or additional agent, wherein the second agent or additional agent may have been previously administered, for example. Concomitant therapeutic treatment methods can be performed stepwise by different participants. For example, one participant can administer a first agent to a subject and a second agent can administer a second agent to a subject, and the administration steps can be performed simultaneously or nearly simultaneously or at a distant time, as long as the first agent (and additional agent) is administered after the second agent (and additional agent) is administered. The participant and the subject can be the same entity (e.g., a person).
[0128] As used herein, the term "combination therapy" refers to the administration of two or more therapeutic substances, e.g., an antigen or immunogenic protein as described herein, and another drug. The other drug can be administered simultaneously with, before, or after the antigen or immunogenic protein is administered, as described herein.
[0129] As used herein, the phrases "nucleic acid therapeutics," "therapeutic nucleic acids," and "TNAs" are used interchangeably and refer to any modality of therapy that uses nucleic acids as the active component of a therapeutic agent for treating a disease or condition. As used herein, these phrases refer to RNA-based therapeutics and DNA-based therapeutics. Non-limiting examples of RNA-based therapeutics include mRNA, antisense RNA and oligonucleotides, ribozymes, aptamers, interfering RNA (RNAi), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), or guide RNA (gRNA). Non-limiting examples of DNA-based therapeutics include minicircle DNA, minigenes, viral DNA (e.g., lentiviral or AAV genomes) or non-viral synthetic DNA vectors, end-blocked linear duplex DNA (ceDNA / CELiD), plasmids, bacmids, doggybone TM DNA vector, Minimalistic Immunologically Defined Gene Expression (MIDGE) vector, non-viral ministring DNA vector (linear covalently closed DNA vector) or dumbbell-shaped DNA minimal vector ("dumbbell DNA"). According to some embodiments, the therapeutic nucleic acid is ceDNA.
[0130] As used herein, the term "therapeutic effect" refers to the results of treatment, which are judged to be desirable and beneficial. Therapeutic effect can directly or indirectly include the containment, reduction or elimination of disease manifestations. Therapeutic effect can also directly or indirectly include the containment, reduction or elimination of the progression of disease manifestations.
[0131] For any therapeutic agent described herein, the therapeutically effective amount can be initially determined according to preliminary in vitro studies and / or animal models. The therapeutically effective dose can also be determined according to human data. The dosage administered can be adjusted based on the relative bioavailability and the efficacy of the compound administered. It is within the ability of ordinary technicians to adjust the dosage based on the above methods and other well-known methods to achieve maximum efficacy. The following summarizes the general principles for determining the effectiveness of treatment, which can be found in Chapter 1 of Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edition, McGraw-Hill (New York) (2001), which is incorporated herein by reference.
[0132] Pharmacokinetic principles provide the basis for modifying the dosage regimen to obtain the desired degree of therapeutic efficacy with minimal unacceptable side effects. Additional guidance for dosage modifications can be obtained where plasma concentrations of the drug can be measured and related to the therapeutic window.
[0133] As used herein, "viral infection" means the invasion and proliferation of a virus in a subject.
[0134] As used herein, the term "treatment" means any of: (i) prevention of infection or reinfection, as in traditional vaccines, (ii) alleviation or elimination of symptoms, and (iii) substantial or complete elimination of the pathogen in question. Treatment may be induced prophylactically (before infection) or therapeutically (after infection). Treatment may further refer to achieving one or more of: (a) reducing the severity of a condition; (b) limiting worsening of symptoms characteristic of the condition being treated; (c) limiting recurrence of a condition in a patient previously suffering from the condition; and (d) limiting recurrence of symptoms in a patient previously asymptomatic for the condition.
[0135] Beneficial or desired clinical results, such as pharmacological and / or physiological effects, include, but are not limited to: preventing the onset of a disease, disorder or condition in an individual who may be susceptible to the disease, disorder or condition but does not yet experience or display symptoms of the disease (prophylactic or preventive treatment); alleviating the symptoms of the disease, disorder or condition; reducing the extent of the disease, disorder or condition; stabilizing the disease, disorder or condition (i.e., not worsening); preventing the spread of the disease, disorder or condition; delaying or slowing the progression of the disease, disorder or condition; ameliorating or palliating the disease, disorder or condition; and combinations thereof, and prolonging survival as compared to expected survival if not receiving treatment.
[0136] The term "vaccinated" as used herein means treating with a vaccine.
[0137] The term "vaccination" as used herein means treatment with a vaccine.
[0138] The term "vaccine" as used herein means a formulation that is in a form that can be administered to a vertebrate and induces a protective immune response sufficient to induce immunity and / or prevent and / or improve infection and / or alleviate at least one symptom of infection and / or enhance the efficacy of another dose of the formulation. Typically, the vaccine includes a conventional saline or buffered aqueous solution medium in which the composition of the present disclosure is suspended or dissolved. In this form, the composition of the present disclosure can be conveniently used to prevent, improve or otherwise treat viral infections. When introduced into a host, the vaccine can elicit an immune response, including but not limited to the production of antibodies and / or cytokines and / or the activation of cytotoxic T cells, antigen presenting cells, helper T cells, dendritic cells and / or other cellular responses.
[0139] As used herein, the term "vaccine therapy" means a type of treatment that uses a substance or group of substances to stimulate the immune system to destroy tumors or infectious microorganisms.
[0140] Those "in need of treatment" include mammals such as humans already suffering from a disease or disorder, infection or cancer.
[0141] As used herein, the terms "increase," "enhance," "elevate" (and similar terms) generally refer to the act of directly or indirectly increasing the concentration, level, function, activity or behavior relative to native conditions, expected conditions or average conditions, or relative to control conditions.
[0142] As used herein, the terms "suppress," "reduce," "interfere," "inhibit," and / or "reduce" (and similar terms) generally refer to the act of directly or indirectly reducing the concentration, level, function, activity, or behavior relative to natural, expected, or average conditions, or relative to control conditions.
[0143] As used herein, "control" means reference standard. According to some embodiments, the control is a negative control sample obtained from a healthy patient. In other embodiments, the control is a positive control sample obtained from a patient diagnosed with a disease or illness, infection or cancer. In still other embodiments, the control is a historical control or a standard reference value or a range of values (such as a control sample previously tested, or a group of samples representing a baseline or normal value). The difference between the test sample and the control can be an increase or an opposite decrease. The difference can be a qualitative difference or a quantitative difference, such as a statistically significant difference. According to some examples, the difference is to increase or decrease at least about 5% relative to the control, such as at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least about 300%, at least about 350%, at least about 400%, at least about 500% or more than 500%.
[0144] As used herein, the terms "comprising" or "comprises" are used when referring to compositions, methods, and their respective components that are essential to the methods or compositions, but remain open to including unspecified elements, whether essential or not.
[0145] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristics of the embodiment. The use of "comprising" means inclusion rather than limitation.
[0146] The term "consisting of" refers to the compositions, methods, and corresponding components thereof as described herein, excluding any elements not recited in the description of the embodiment.
[0147] As used in this specification and the appended claims, the singular forms "a / an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to a "method" includes one or more methods and / or steps of the type described herein and / or that will become apparent to a person skilled in the art after reading this disclosure, etc. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used to implement or test the present disclosure, suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin exempli gratia and is used herein to indicate a non-limiting example. Therefore, the abbreviation "eg" is synonymous with the term "for example".
[0148] Except in the operating examples, or where otherwise indicated, all numbers used herein to represent the quantity of ingredients or reaction conditions should be understood as being modified by the term "about" in all cases. The term "about" can represent ±1% when used with a percentage. The following examples further explain the present disclosure in detail, but the scope of the present disclosure should not be limited thereto.
[0149] The grouping of alternative elements or embodiments of the present disclosure disclosed herein should not be construed as limiting. Each group member can be mentioned and claimed individually or in any combination with other members of the group or other elements found herein. For convenience and / or patentability reasons, one or more members in a group can be included in or deleted from a group. When any such inclusion or deletion occurs, the description described in this article is considered to contain the group of modification, thereby satisfying the written description of all Markush groups (Markush group) used in the appended claims.
[0150] Additional terms are defined herein within the description of various aspects of the disclosure.
[0151] The description of the embodiments of the present disclosure is not intended to be exhaustive or to limit the present disclosure to the precise form disclosed. Although the specific embodiments and examples of the present disclosure are described herein for illustrative purposes, various equivalent modifications can be made within the scope of the present disclosure as will be appreciated by those skilled in the relevant art. For example, although the method steps or functions are presented in a given order, alternative embodiments can perform functions in different orders or can perform functions substantially simultaneously. The teachings of the present disclosure provided herein can be appropriately applied to other processes or methods. The various embodiments described herein can be combined to provide additional embodiments. If necessary, various aspects of the present disclosure can be modified to provide another embodiment of the present disclosure using the compositions, functions and concepts in the above-mentioned references and applications. In addition, due to considerations of biological functional equivalence, some changes can be made in the protein structure without affecting the type or quantity of the biological effect. These and other changes can be made to the present disclosure according to the detailed description. All such modifications are intended to be included within the scope of the appended claims.
[0152] The specific elements of any of the foregoing embodiments may be combined with or replace elements in other embodiments. In addition, although the advantages associated with certain embodiments of the present disclosure have been described in the context of these embodiments, other embodiments may also exhibit these advantages and not all embodiments must exhibit these advantages to fall within the scope of the present disclosure.
[0153] The technology described herein is further illustrated by the following examples, but these examples should never be construed as further limiting. It should be understood that the present disclosure is not limited to the specific methods, protocols, reagents, etc. described herein and can therefore vary. The terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of the present disclosure, which is limited only by the claims.
[0154] II. Cells of the Immune System
[0155] There are a large number of cellular interactions that include the immune system. These interactions occur through specific receptor-ligand pairs that signal in both directions, so each cell receives instructions based on the temporal and spatial distribution of these signals.
[0156] Murine models have been extremely useful in the discovery of immunomodulatory pathways, but the clinical utility of these pathways does not always translate from hybrid mouse strains to outbred human populations, which may have individuals with varying degrees of reliance on individual immunomodulatory pathways.
[0157] The cells of the immune system include lymphocytes, monocytes / macrophages, dendritic cells, closely related Langerhans cells (Langerhans cell), natural killer (NK) cells, mast cells, basophils and other members of the myeloid cell lineage. In addition, a series of dedicated epithelial cells and stromal cells provide the anatomical environment for immune occurrence, which is usually provided by secreting key factors for growth and / or gene activation in the regulation immune system cells, and the key factors also play a direct role in the induction and effector stages of the response. (Paul, WE, "Chapter 1: The immune system: an introduction", "Fundamental Immunology", 4th edition, Paul, WE editor, Lippicott-Raven Publishers, Philadelphia, (1999), page 102).
[0158] The cells of the immune system are present in peripheral tissues such as the spleen, lymph nodes, Peyer'spatches of the intestine, and tonsils. Lymphocytes are also present in the central lymphoid organs, thymus, and bone marrow, where they undergo developmental steps that enable them to mediate the myriad responses of the mature immune system. Most lymphocytes and macrophages include a cell recycling pool present in the blood and lymph, providing a means of delivering immune competent cells to sites where they are needed and allowing locally generated immunity to become universal. (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999), p. 102).
[0159] The term "lymphocyte" refers to a small white blood cell formed in the lymphatic tissues of the whole body, and in normal adults, it accounts for about 22-28% of the total number of white blood cells in the circulating blood, which plays an important role in protecting the body from disease. The specialization of a single lymphocyte is that it is committed to responding to a limited set of structurally related antigens (for example, to produce T cell receptors and B cell receptors) through the recombination of its genetic material. This commitment, which exists before the immune system first contacts a given antigen, is expressed by the presence of receptors that are specific to the determinants (epitopes) on the antigens on the surface membrane of the lymphocyte. Each lymphocyte has a unique receptor population, all of which have the same combination site. A group or clone of lymphocytes differs from another clone in the structure of the combination region of its receptor, and therefore differs in the epitopes that it can recognize. Lymphocytes differ from each other not only in the specificity of their receptors, but also in their functions. (Paul, WE, "Chapter 1: The Immune System: An Introduction", Fundamental Immunology, 4th edition, Paul, WE ed., Lippincott-Raven, Philadelphia, (1999), p. 102).
[0160] Two broad classes of lymphocytes are recognized: B lymphocytes (B cells), which are precursors of antibody-secreting cells, and T lymphocytes (T cells).
[0161] B lymphocytes
[0162] B lymphocytes are derived from hematopoietic cells of the bone marrow. Mature B cells can be activated with antigens expressing epitopes recognized by their cell surfaces. The activation process can be direct, depending on the cross-linking of antigens to membrane Ig molecules (cross-linking-dependent B cell activation), or indirect through the interaction with helper T cells in the process known as homologous help. In many physiological situations, receptor cross-linking stimulation and homologous help synergistically produce more intense B cell responses (Paul, WE, "Chapter 1: Immune System: Introduction", "Basic Immunology", 4th edition, Paul, WE edited, Lippincott-Raven Publishers in Philadelphia, (1999)).
[0163] Cross-linking-dependent B cell activation requires antigen expression of multiple copies of epitopes complementary to the binding sites of cell surface receptors, because each B cell expresses Ig molecules with identical variable regions. Other antigens with repeated epitopes, such as microbial capsular polysaccharides or viral envelope proteins, meet such requirements. Cross-linking-dependent B cell activation is the main protective immune response against these microorganisms (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0164] Homologous help allows B cells to respond to antigens that cannot cross-link receptors, and at the same time provides a co-stimulatory signal that protects B cells from inactivation when they are stimulated by weak cross-linking events. Homologous help depends on the binding of antigens by membrane immunoglobulins (Ig) of B cells, endocytosis of antigens, and their fragmentation into peptides within the endosomal / lysosomal compartments of cells. Some of the resulting peptides are loaded into grooves in a group of specialized cell surface proteins known as class II major histocompatibility complex (MHC) molecules. The resulting class II / peptide complexes are expressed on the cell surface and act as a cytosolic receptor designated as CD4 + T cells are a group of T cell antigen-specific receptor ligands. CD4 + T cells carry receptors specific for class II / peptide complexes of B cells on their surfaces. B cell activation depends not only on the binding of T cells through their T cell receptors (TCRs), but also on the binding of activation ligands (CD40 ligands) on T cells to receptors (CD40) on their B cells, thereby signaling B cell activation. In addition, helper T cells secrete several cytokines that regulate the growth and differentiation of stimulated B cells by binding to cytokine receptors on B cells (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE editor, Lippincott-Raven Publishers in Philadelphia, (1999)).
[0165] During cognate help of antibody production, CD40 ligand is expressed in activated CD4 + It is transiently expressed on T helper cells, and it binds to CD40 on antigen-specific B cells, thereby transducing a second co-stimulatory signal. The latter signal is crucial for B cell growth and differentiation and for producing memory B cells by preventing apoptosis of germinal center B cells that have encountered antigens. The high expression of CD40 ligands in both B and T cells is related to the production of pathogenic autoantibodies in human SLE patients (Desai-Mehta, A. et al., "Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production", Journal of Clinical Research (J.Clin.Invest.) Vol. 97 (9), 2063-2073, (1996)).
[0166] T lymphocytes
[0167] T lymphocytes derived from precursors in hematopoietic tissues undergo differentiation in the thymus, and are then inoculated into peripheral lymphoid tissues and lymphocyte recirculation pools. T lymphocytes or T cells mediate a wide range of immune functions. These include the ability to help B cells develop into cells that produce antibodies, the ability to increase the microbicidal effects of monocytes / macrophages, the suppression of certain types of immune responses, the direct killing of target cells, and the mobilization of inflammatory responses. These effects depend on the secretion of T cells and cytokines expressed by specific cell surface molecules (Paul, WE, "Chapter 1: Immune System: Introduction", "Basic Immunology", 4th edition, Paul, WE edited, Lippincott-Raven Publishers in Philadelphia, (1999)).
[0168] T cells are different from B cells in their antigen recognition mechanism. The receptor immunoglobulin of B cells binds to each epitope on the surface of soluble molecules or particles. B cell receptors refer to epitopes expressed on the surface of natural molecules. Although antibodies and B cell receptors evolve to bind to microorganisms in extracellular fluids and prevent microorganisms in the extracellular fluid, T cells recognize antigens on the surface of other cells and mediate their functions by interacting with these antigen presenting cells (APCs) and changing the behavior of the antigen presenting cells. There are three main types of APCs that can activate T cells in peripheral lymphoid organs: dendritic cells, macrophages and B cells. Among them, the most effective is dendritic cells, whose only function is to present exogenous antigens to T cells. Immature dendritic cells are located in systemic tissues, including skin, intestines and respiratory tract. When the immature dendritic cells encounter invading microorganisms at these sites, they endocytose pathogens and their products, and carry the pathogens and their products to local lymph nodes or intestinal-related lymphoid organs through lymph. Encounter with pathogens induces dendritic cells to mature from antigen-capturing cells to APCs that can activate T cells. APCs display three types of protein molecules on their surfaces that play a role in activating T cells to become effector cells: (1) MHC proteins, which present foreign antigens to the T cell receptor; (2) co-stimulatory proteins, which bind to complementary receptors on the T cell surface; and (3) cell-cell adhesion molecules, which enable T cells to bind to APCs long enough to activate ("Chapter 24: The adaptive immune system", Molecular Biology of the Cell, Alberts, B. et al., Garland Science, NY, (2002)).
[0169] T cells are subdivided into two distinct classes based on the cell surface receptors they express. Most T cells express a T cell receptor (TCR) composed of alpha and beta chains. A small group of T cells express receptors composed of gamma and delta chains. There are two sublineages of alpha / beta T cells: a sublineage that expresses the co-receptor molecule CD4 (CD4 + T cells); and sublineages expressing CD8 (CD8 + T cells). These cells differ in the way they recognize antigens and in their effector and regulatory functions.
[0170] CD4 + T cells are the main regulatory cells of the immune system. Their regulatory function depends on the expression of molecules on their cell surface, such as the CD40 ligand induced when T cells are activated, and the various cytokines they secrete when activated.
[0171] T cells also mediate important effector functions, some of which are determined by the pattern of cytokines they secrete. Cytokines can be directly toxic to target cells and can mobilize potent inflammatory mechanisms.
[0172] In addition, T cells, specifically CD8 + T cells can develop into cytotoxic T lymphocytes (CTLs) that can effectively lyse target cells expressing antigens recognized by CTLs (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0173] The T cell receptor (TCR) recognizes a complex composed of peptides derived by proteolysis of antigens bound to a dedicated groove of class II or class I MHC proteins. + T cells only recognize peptide / class II complexes, while CD8 + T cells recognize peptide / class I complexes (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0174] Ligands for the TCR (i.e., peptide / MHC protein complexes) are produced within the APC. Typically, class II MHC molecules bind to peptides derived from proteins that have been taken up by the APC through a process called endocytosis. These peptide-loaded class II molecules are then expressed on the cell surface, where they can be expressed by binding to CD4 T cells with TCRs that are able to recognize the expressed cell surface complexes. + T cells bind. Therefore, CD4 +T cells are specialized to react to antigens derived from extracellular sources (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0175] In contrast, class I MHC molecules are loaded primarily with peptides derived from internally synthesized proteins, such as viral proteins. These peptides are generated from cytoplasmic proteins by proteolysis by proteosomes and translocated to the rough endoplasmic reticulum. Such peptides, which are typically nine amino acids in length, are bound to class I MHC molecules and brought to the cell surface, where they can be expressed by CD8 + This enables the T cell system, specifically CD8 + T cells are able to detect cells that express proteins that are different from or produced in much greater amounts than the rest of the organism (e.g., viral antigens) or mutant antigens (such as active oncogene products), even though these proteins in their intact form are neither expressed on the cell surface nor secreted (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0176] T cells can also be classified based on their function into helper T cells; T cells involved in the induction of cellular immunity; suppressor T cells; and cytotoxic T cells.
[0177] Helper T cells
[0178] Helper T cells are T cells that stimulate B cells to make antibody responses to proteins and other T cell-dependent antigens. T cell-dependent antigens are membrane immunoglobulins (Ig) or inefficient immunogens in which a single epitope appears only once or a limited number of times so that it cannot crosslink B cells. B cells bind to antigens through their membrane Ig, and the complex undergoes endocytosis. In the endosome and lysosome compartments, antigens are fragmented into peptides by proteolytic enzymes, and one or more of the produced peptides are loaded into class II MHC molecules, which are transported through the vesicle compartment. The resulting peptide / class II MHC complex is then exported to the B cell surface membrane. T cells with receptors specific for the peptide / class II molecule complex recognize this complex on the B cell surface. (Paul, WE, "Chapter 1: The Immune System: An Introduction", "Basic Immunology", 4th edition, Paul, WE editor, Lippincott-Raven Publishers in Philadelphia (1999)).
[0179] B cell activation depends on both the binding of T cells through their TCR and the interaction of T cell CD40 ligand (CD40L) with CD40 on B cells. T cells do not constitutively express CD40L. Instead, CD40L expression is induced by the interaction with APCs expressing both cognate antigens recognized by the TCR of T cells and CD80 or CD86. CD80 / CD86 is usually expressed by activated rather than resting B cells, so that the auxiliary interaction involving activated B cells and T cells can lead to efficient antibody production. However, in many cases, the initial induction of CD40L on T cells depends on its recognition of antigens on the surface of APCs constitutively expressing CD80 / 86 such as dendritic cells. Then, such activated helper T cells can efficiently interact with B cells and help B cells. The cross-linking of membrane Ig on B cells, even if inefficient, can also interact with CD40L / CD40 to produce violent B cell activation in coordination. Subsequent events in the B cell response including proliferation, Ig secretion and class switching of the Ig class being expressed are dependent on or augmented by the action of T cell-derived cytokines (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th ed., Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0180] CD4 + T cells tend to differentiate into cells that mainly secrete cytokines IL-4, IL-5, IL-6, and IL-10 (TH2 cells) or differentiate into cells that mainly produce IL-2, IFN-γ, and lymphotoxin (TH1 cells). TH2 cells are very effective in helping B cells develop into antibody-producing cells, while TH1 cells are potent inducers of cellular immune responses, involving enhancement of the microbicidal activity of monocytes and macrophages, and thus increasing the efficiency of lysing microorganisms in intracellular vesicle compartments. Although CD4 + T cells (i.e., IL-4, IL-5, IL-6, and IL-10) are highly efficient helper cells, but TH1 cells also have the ability to become helper cells (Paul, WE, "Chapter 1: The Immune System: An Introduction", Basic Immunology, 4th edition, Paul, WE ed., Lippincott-Raven Publishers, Philadelphia, (1999)).
[0181] T cells participate in the induction of cellular immunity
[0182] T cells can also be used to enhance the ability of monocytes and macrophages to destroy intracellular microorganisms. Specifically, interferon-γ (IFN-γ) produced by helper T cells enhances several mechanisms of mononuclear phagocytes to destroy intracellular bacteria and parasites, including the generation of nitric oxide and the induction of tumor necrosis factor (TNF) production. TH1 cells are effective in enhancing microbicidal effects because they produce IFN-γ. In contrast, two major cytokines IL-4 and IL-10 produced by TH2 cells block these activities (Paul, WE, "Chapter 1: Immune System: Introduction", "Basic Immunology", 4th edition, Paul, WE edited, Lippincott-Raven Publishers in Philadelphia, (1999)).
[0183] Regulatory T (Treg) cells
[0184] Immune homeostasis is maintained by a controlled balance between initiation and downregulation of immune responses. Both apoptosis and T cell anergy (a tolerance mechanism in which T cells are essentially functionally inactivated after antigen encounter (Schwartz, RH, "T cell anergy", Annu. Rev. Immunol., Vol. 21: 305-334 (2003)) contribute to downregulation of immune responses. Inhibition or regulation of CD4 + Active suppression of activated T cells by T (Treg) cells provides a third mechanism (reviewed in Kronenberg, M. et al., "Regulation of immunity by autoreactive T cells", Nature, Vol. 435: 598-604 (2005)). + CD25 + ) + Tregs are naturally occurring anergic and suppressive T cell subsets (Taams, LS et al., “Human anergic / suppressive CD4 + CD25 + T cells: a highly differentiated and apoptosis-prone population (Human anergic / suppressive CD4+CD25+T cells: a highly differentiated and apoptosis-prone population)", European Journal of Immunology (Eur. J. Immunol.) Vol. 31: 1122-1131 (2001). CD4 + CD25 +Depletion of Tregs induces systemic autoimmune disease in mice. Furthermore, transfer of these Tregs prevents the development of autoimmune disease. + CD25 + Tregs, similar to their murine counterparts, are generated in the thymus and are characterized by the ability to suppress the proliferation of responding T cells through a cell-cell contact-dependent mechanism, the inability to produce IL-2, and an in vitro anergic phenotype. + CD25 + T cells can be divided into suppressor (CD25 高 ) and non-suppressive (CD25 低 ) cells. FOXP3, a member of the forkhead family of transcription factors, has been shown to be expressed in mouse and human CD4 + CD25 + Tregs are expressed and appear to control CD4 + CD25 + Master genes for Treg development (Battaglia, M. et al., "Rapamycin promotes functional CD4 + CD25 + Foxp3 + "Rapamycin promotes expansion of functional CD4+CD25+Foxp3+regulator T cells of both healthy subjects and type 1 diabetic patients", Vol. 177: 8338-8347, (2006)).
[0185] Cytotoxic T lymphocytes
[0186] CD8 that recognizes peptides from proteins produced within target cells + T cells have cytotoxic properties because they cause lysis of target cells. The lysis mechanism induced by CTL involves CTL production of perforin, a molecule that can insert into the membrane of target cells and promote the lysis of the cells. Perforin-mediated lysis is enhanced by granzymes, a series of enzymes produced by activated CTLs. Many active CTLs also express large amounts of fas ligands on their surfaces. The interaction of fas ligands on the CTL surface with fas on the target cell surface triggers apoptosis in the target cells, leading to the death of these cells. CTL-mediated lysis appears to be the main mechanism for destroying virus-infected cells.
[0187] Lymphocyte activation
[0188] The term "activation" or "lymphocyte activation" refers to the stimulation of lymphocytes by specific antigens, nonspecific mitogens or allogeneic cells, resulting in the synthesis of RNA, protein and DNA and the production of lymphokines; this is followed by the proliferation and differentiation of various effector and memory cells. T cell activation depends on the interaction of the TCR / CD3 complex with its cognate ligand, a peptide bound in the groove of a class I or class II MHC molecule. The molecular events set in motion by receptor engagement are complex. Among the earliest steps, there appears to be the activation of tyrosine kinases, resulting in the tyrosine phosphorylation of a set of substrates that control several signal transduction pathways. These include a set of adapter proteins that connect the TCR to the ras pathway, phospholipase Cγ1, whose tyrosine phosphorylation increases its catalytic activity and engages the inositol phospholipid metabolic pathway, resulting in an increase in intracellular free calcium concentration and activation of protein kinase C, as well as a series of other enzymes that control cell growth and differentiation. In addition to receptor engagement, full responsiveness of T cells requires co-stimulatory activity delivered by auxiliary cells, such as the engagement of CD28 on T cells through CD80 and / or CD86 on APCs.
[0189] T memory cells
[0190] After the recognition and eradication of pathogens by the adaptive immune response, the vast majority (90-95%) of T cells undergo apoptosis, with the remaining cells forming a pool of memory T cells, designated central memory T cells (TCM), effector memory T cells (TEM), and resident memory T cells (TRM) (Clark, RA, "Resident memory T cells in human health and disease", Science Translational Medicine (Sci. Transl. Med.), 7, 269rv1, (2015)). CD45RA is expressed on naive T cells and effector cells in both CD4 and CD8. After antigen experience, central and effector memory T cells gain expression of CD45RO and lose expression of CD45RA. Therefore, CD45RA or CD45RO are often used to distinguish between naive and memory populations. CCR7 and CD62L are two other markers that can be used to distinguish between central and effector memory T cells. Naive and central memory cells express CCR7 and CD62L in order to migrate to secondary lymphoid organs. Therefore, naive T cells are CD45RA + CD45RO - CCR7 + CD62L + , central memory T cells are CD45RA - CD45RO + CCR7 + CD62L +, and effector memory T cells are CD45RA - CD45RO + CCR7 - CD62L - .
[0191] Compared with standard T cells, these memory T cells are long-lived and have different phenotypes, such as the expression of specific surface markers, the rapid production of different cytokine profiles, the ability of direct effector cell functions, and a unique homing distribution pattern. Memory T cells exhibit rapid responses when re-exposed to their corresponding antigens in order to eliminate reinfection of the invader and thereby quickly restore the balance of the immune system. Increasing evidence confirms that autoimmune memory T cells have hindered most attempts to treat or cure autoimmune diseases (Clark, RA, "Resident memory T cells in human health and disease", Science Translational Medicine, Vol. 7, 269rv1, (2015)).
[0192] III. Expression of peptides from DNA vectors
[0193] Provided herein is a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject a priming vaccine, the priming vaccine comprising deoxyribonucleic acid (DNA) DNA, wherein the DNA encodes the first peptide; and administering to the subject a boosting vaccine, the boosting vaccine comprising (i) ribonucleic acid (RNA) or (ii) a second peptide, wherein the RNA encodes the second peptide, thereby inducing an immune response in the subject against the first peptide and the second peptide.
[0194] A vaccine regimen is also provided, comprising: a priming vaccine comprising deoxyribonucleic acid (DNA) DNA, wherein the DNA encodes a first peptide; and a boosting vaccine comprising (i) ribonucleic acid (RNA) or (ii) a second peptide, wherein the RNA encodes the second peptide.
[0195] According to some embodiments, the priming vaccine comprises DNA in the form of a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (a linear covalently closed DNA vector), a linear duplex DNA (CELiD or ceDNA) with closed ends, a doggybone (dbDNA), or a DNA vector. TM )DNA, dumbbell-shaped DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector. According to some embodiments, the priming vaccine includes DNA in the form of a plasmid. According to some embodiments, the priming vaccine includes DNA in the form of ceDNA.
[0196] According to some embodiments, the priming vaccine comprises DNA in the form of a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (a linear covalently closed DNA vector), a linear duplex DNA (CELiD or ceDNA) with closed ends, a doggybone (dbDNA), or a DNA vector. TM ) DNA, dumbbell DNA, minimalistic immunologically defined gene expression (MIDGE) vectors, viral vectors or non-viral vectors, and the booster vaccine includes RNA (e.g., mRNA).
[0197] According to some embodiments, the priming vaccine comprises DNA in the form of a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (a linear covalently closed DNA vector), a linear duplex DNA (CELiD or ceDNA) with closed ends, a doggybone (dbDNA), or a DNA vector. TM ) DNA, dumbbell DNA, minimalistic immunologically defined gene expression (MIDGE) vectors, viral vectors or non-viral vectors, and booster vaccines include peptides.
[0198] DNA plasmids
[0199] According to some embodiments, the priming vaccine comprises DNA in the form of a DNA plasmid comprising a nucleic acid sequence encoding a selected antigen to which an immune response is desired. In the plasmid, the selected antigen is under the control of a regulatory sequence directing its expression in a mammalian or vertebrate cell.
[0200] The components of the plasmids themselves are known in the art.
[0201] The non-viral plasmid vectors that can be used for the present invention contain isolated and purified DNA sequences, which include DNA sequences encoding selected antigens, such as antigens described herein. The DNA molecule can be derived from a virus or non-virus, such as a bacterial species that has been designed to encode an exogenous or heterologous nucleic acid sequence. Such plasmids or vectors can include sequences from viruses or phages. Various non-viral vectors are known in the art and can include, but are not limited to, plasmids, bacterial vectors, phage vectors, "naked" DNA, and DNA condensed with cationic lipids or polymers.
[0202] Examples of bacterial vectors include, but are not limited to, sequences derived from Bacillus Calmette-Guerin (BCG), Salmonella, Shigella, Escherichia coli, and Listeria, etc. Suitable plasmid vectors include, for example, pBR322, pBR325, pACYC177, pACYC184, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pK37, pKC101, pAC105, pVA51, pKH47, pUB110, pMB9, pBR325, Col E1, pSC101, pBR313, pML21, RSF2124, pCR1, RP4, pBAD18, and pBR328.
[0203] Examples of suitable inducible E. coli expression vectors include pTrc (Amann et al., 1988 Gene, 69:301-315), arabinose expression vectors (e.g., pBAD18, Guzman et al., 1995 J. Bacteriol., 177:4121-4130), and pETIId (Studier et al., 1990 Methods in Enzymology, 85:60-89).
[0204] The promoter and other regulatory sequences that drive the expression of the antigen in the desired mammalian or vertebrate host can be similarly selected from a wide list of promoters known to be useful for the purpose. A variety of such promoters are disclosed below. Exemplary promoters include, but are not limited to, the human cytomegalovirus (HCMV) promoter / enhancer (described, for example, in U.S. Patents 5,168,062 and 5,385,839) and the SCMV promoter enhancer.
[0205] Additional regulatory sequences for inclusion in nucleic acid sequences, molecules or vectors include, but are not limited to, enhancer sequences, polyadenylation sequences, splice donor and acceptor sequences, transcription initiation and termination sites located at the beginning and end of the polypeptide to be translated, respectively, ribosome binding sites translated in the transcribed region, epitope tags, nuclear localization sequences, IRES elements, Goldberg-Hogness "TATA" elements, restriction enzyme cleavage sites, selective markers, etc. Enhancer sequences include, for example, 72 bp tandem repeats of SV40 DNA or retroviral long terminal repeats or LTRs, etc., and are used to increase transcription efficiency.
[0206] These other components that can be used in the DNA plasmid, including, for example, an origin of replication, a polyadenylation sequence (eg, BGH polyA, SV40 polyA), a drug resistance marker (eg, kanamycin resistance), etc., can also be selected from sequences well known in the art.
[0207] The selection of promoter and other common vector elements is conventional, and many such sequences can be used to design plasmids that can be used for the present invention.See, for example, Sambrook et al., " Molecular Cloning: Laboratory Manual ", Cold Spring Harbor Laboratory (Cold Spring Harbor Laboratory, New York) in New York, (1989) and references cited therein, such as 3.18-3.26 and 16.17-16.27 pages, and Ausubel et al., " Current Molecular Biology Experiment Guide ", John Wiley & Sons (John Wiley & Sons, New York (1989) in New York. The repertoire of plasmids can be easily selected by those skilled in the art from known materials in the art, and can be obtained from the pharmaceutical industry.
[0208] Examples of suitable DNA plasmid constructs that can be used in the priming vaccines described herein are described in detail in the following patent publications, namely International Patent Publication Nos. WO98 / 17799, WO99 / 43839, and WO98 / 17799; and U.S. Pat. Nos. 5,593,972; 5,817,637; 5,830,876; and 5,891,505, which are incorporated herein by reference in their entirety.
[0209] ceDNA vector
[0210] According to some embodiments, the technology described herein generally relates to the expression and / or production of antigens in cells from one or more non-viral DNA vectors, e.g., ceDNA vectors as described herein. ceDNA vectors for antigen expression are described in the section entitled "Overview of ceDNA Vectors". As previously discussed, the different advantages of ceDNA vectors over traditional AAV vectors and even lentiviral vectors are that there is no size limit for one or more nucleic acid sequences encoding peptides (e.g., antigens). Based on the disclosure provided herein, the skilled person will understand that many peptide antigens can be used to produce almost unlimited types of ceDNA vectors once having the teachings provided herein.
[0211] In some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) comprises a pair of ITRs (e.g., symmetrical or asymmetrical as described herein) and is operably linked to a promoter or regulatory sequence between the pair of ITRs, the nucleic acid encoding the antigen, or the immunogenic peptide as described herein. A unique advantage of ceDNA vectors for expressing antigens or immunogenic peptides compared to traditional AAV vectors and even lentiviral vectors is that there is no size limitation for the nucleic acid sequence encoding the desired antigen or immunogenic peptide.
[0212] As will be appreciated, the ceDNA vector technology described herein can be adapted to any level of complexity, or can be used in a modular fashion, where the expression of different components of the ceDNA vector can be controlled in an independent manner. The following embodiments are specifically contemplated herein, and those skilled in the art can adapt these embodiments as needed.
[0213] According to some aspects, the present disclosure provides one or more ceDNA vectors, which include one or more nucleic acid sequences encoding antigens. According to some embodiments, the one or more nucleic acid sequences encode one or more peptides (e.g., antigens) from a variety of pathogens, and the pathogens include, for example, bacteria, viruses, fungi, and parasitic infectious agents. According to some embodiments, the one or more nucleic acid sequences encode one or more peptides (e.g., antigens) as cancer or cancer-associated antigens. According to some embodiments, the antigen or immunogenic peptide is a tumor antigen. According to some embodiments, the one or more nucleic acid sequences encode one or more peptides (e.g., antigens) associated with autoimmune conditions such as rheumatoid arthritis (RA) or multiple sclerosis (MS). According to some embodiments, the antigen is an antigen associated with an autoimmune disorder or condition such as an autoimmune disease triggered by an infectious agent, or an antigen associated with an infectious disease or a pathogen.
[0214] Cancer or tumor-associated antigens
[0215] According to some embodiments, the ceDNA comprises a nucleic acid sequence encoding a cancer or tumor associated antigen. According to some embodiments, the ceDNA comprises a nucleic acid sequence encoding one or more antigens selected from the Cancer Antigen Peptide Database, which is available at caped.icp.ucl.ac.be / about. For each antigen identified, the database contains the peptide sequence and its position in the protein sequence.
[0216] According to some embodiments, the ceDNA comprises a nucleic acid sequence encoding a tumor-associated antigen selected from one or more of the antigens listed in Table 1 below:
[0217] Table 1
[0218]
[0219] Recent analyses of the Cancer Genome Atlas (TCGA) dataset have linked the genomic landscape of tumors to tumor immunity, suggesting that neoantigen load drives T cell responses (Brown et al., Genome Res. 2014 May;24(5):743-50, 2014) and identifying somatic mutations associated with immune infiltration (Rutledge et al., Clin Cancer Res. 2013 Sep 15;19(18):4951-60, 2013). Rooney et al. (2015 Jan 15;160(1-2):48-61) showed that neoantigens and viruses may drive cytolytic activity and revealed known and novel mutations that enable tumors to resist immune attack.
[0220] In some embodiments, the antigen is a neoantigen identified from a cancer cell in a subject. In some embodiments, the neoantigen is a shared neoantigen. Methods for identifying neoantigens are known in the art and are described, for example, in U.S. Pat. No. 10,055,540, which is incorporated herein by reference in its entirety. Neoantigenic polypeptides and shared neoantigenic polypeptides are described, for example, in PCT / US2016 / 033452, U.S. Publication No. 20180055922, Schumacher and Hacohen et al. (Curr Opin Immunol. 2016 Aug;41:98-103), Gubin, MM et al. (Nature. 2014 Nov 27;515(7528):577-81), Schumacher and Schreiber, Science. 2015 Apr 3;348(6230):69-74), Ott PA. et al., Nature. 2017 Jul 13;547(7662):217-221, all of which are incorporated herein by reference in their entirety.
[0221] Therefore, in some embodiments, the antigen is a new antigen polypeptide. In some embodiments, the antigen is a new antigen polypeptide listed in the comprehensive tumor-specific new antigen database (TSNAdb v1.0); available at biopharm.zju.edu.cn / tsnadb, and described in Wu et al., Genomics Proteomics Bioinformatics 16 (2018) 276-282. In some embodiments, the antigen is a new antigen polypeptide shown in U.S. Patent No. 10,055,540, which is incorporated herein by reference in its entirety.
[0222] Autoimmune disease antigens
[0223] According to some embodiments, the antigen is associated with an autoimmune disease. According to some embodiments, the ceDNA comprises a nucleic acid sequence encoding one or more antigens selected from those in Table 2 below.
[0224] Table 2
[0225]
[0226]
[0227] According to some embodiments, the autoimmune disease is triggered by an infectious agent. According to some embodiments, the present disclosure provides a ceDNA as described herein, comprising a nucleic acid sequence encoding one or more peptides (e.g., antigens) for treating an autoimmune disease or condition associated with or triggered by an infectious agent. Exemplary autoimmune diseases or conditions associated with or triggered by an infectious agent are provided in Table 3.
[0228] Table 3
[0229]
[0230] Infectious Diseases
[0231] According to some embodiments, the present disclosure provides a ceDNA as described herein, the ceDNA comprising a nucleic acid sequence encoding one or more peptides (e.g., antigens) for treating infectious diseases. According to some embodiments, the antigen is an antigen of a pathogen or infectious agent (wherein "pathogen" and "infectious agent" are used interchangeably herein), such as a viral pathogen, a bacterial pathogen, a fungal pathogen, or a parasitic pathogen.
[0232] According to some embodiments, the antigen is a viral antigen. According to some embodiments, the present disclosure provides a ceDNA as described herein, comprising a nucleic acid sequence encoding one or more viral antigens.
[0233] Viral infections include adenovirus, coxsackievirus, hepatitis A virus, poliovirus, Epstein-Barr virus, herpes simplex type 1, herpes simplex type 2, human cytomegalovirus, human herpesvirus 8, varicella-zoster virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), influenza virus, measles virus, mumps virus, parainfluenza virus, respiratory syncytial virus, papillomavirus, rabies virus, and rubella virus. Other viral targets include Paramyxoviridae (e.g., pneumovirus, measles virus, metapneumovirus, respiratory virus, or mumps virus), Adenoviridae (e.g., adenovirus), Arenaviridae (e.g., arenaviruses such as lymphocytic choriomeningitis virus), Arteriviridae (e.g., porcine respiratory and reproductive syndrome virus or equine arteritis virus), Bunyaviridae (e.g., phlebovirus or hantavirus), Caliciviridae (e.g., Norwalk virus), Coronaviridae (e.g., coronavirus or aphthous pharyngitis virus), Filoviridae (e.g., Ebola-like virus), Flaviviridae (e.g., trypanovirus or The virus of this invention can be used to treat a variety of diseases, such as influenza, leukemia ...
[0234] Exemplary viral pathogens are shown in Table 4 below.
[0235] Table 4
[0236]
[0237]
[0238] According to some embodiments, the present disclosure provides a ceDNA as described herein, comprising a nucleic acid sequence encoding one or more peptides (e.g., antigens) for treating COVID-19. According to some embodiments, the nucleic acid encodes a SARS-CoV-2 spike protein.
[0239] The spike protein contains the S1 subunit that facilitates the binding of the coronavirus to cell surface proteins. Therefore, the S1 subunit of the spike protein controls which cells are infected by the coronavirus. The spike protein also contains the S2 subunit, which is a transmembrane subunit that facilitates the fusion of the viral and cell membranes.
[0240] The complete genome of severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 is shown in GenBank accession number MN908947.3. The amino acid sequence of the wild-type spike glycoprotein (S) is shown below as SEQ ID NO:__:
[0241] MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVL
[0242] HSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIR
[0243] GWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVY
[0244] SSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQ
[0245] GFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSSGWTAGAAAYYVGYLQPRTFL
[0246] LKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITN
[0247] LCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF
[0248] TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYN
[0249] YLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPY
[0250] RVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFG
[0251] RDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAI
[0252] HADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR
[0253] RARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTM
[0254] YICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFG
[0255] GFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFN
[0256] GLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQN
[0257] VLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGA
[0258] ISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMS
[0259] ECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAH
[0260] FPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELD
[0261] SFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELG
[0262] KYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSE
[0263] PVLKGVKLHYT
[0264] According to some embodiments, the peptide is a stabilized pre-fusion SARS-CoV-2 spike protein (SARS-CoV-2S(2P)).
[0265] According to some embodiments, the peptide is a bacterial antigen. According to some embodiments, the present disclosure provides a ceDNA as described herein, comprising a nucleic acid sequence encoding one or more bacterial antigens.
[0266] Bacterial infections include, but are not limited to, mycobacteria, Rickettsia, Mycoplasma, Neisseria meningitidis, Neisseria gonorrheoeae, Legionella, Vibrio cholerae, Streptococcus, Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Corynebacteria diphtheria, Clostridium spp., enterotoxigenic Eschericia coli, Bacillus anthracis, Rickettsia, Bartonella henselae, Bartonella quinquefolia, quintana), Rickettsia burnetii, Chlamydia, Mycobacterium leprae, Salmonella, Shigella, Yersinia enterocolitica, Yersinia pseudotuberculosis, Legionella pneumophila, Mycobacterium tuberculosis, Listeria monocytogenes, Mycoplasma spp., Pseudomonas fluorescens, Vibrio cholerae, Haemophilus influenzae, Bacillus anthracis, Treponema pallidum, Leptospira, Borrelia, Corynebacterium diphtheriae; Francisella; Brucella melitensis; Campylobacter jejuni; Enterobacter; Proteus mirabilis; Proteus; and Klebsiella pneumoniae.
[0267] Exemplary bacterial infections are shown in Table 5 below.
[0268] Table 5
[0269]
[0270]
[0271]
[0272]
[0273] According to some embodiments, the antigen is a fungal antigen or an immunogenic peptide. According to some embodiments, the present disclosure provides a ceDNA as described herein, comprising a nucleic acid sequence encoding one or more fungal antigens.
[0274] Exemplary fungal infections are shown in Table 6 below.
[0275] Table 6
[0276]
[0277]
[0278]
[0279] According to some embodiments, the peptide is a parasite antigen. According to some embodiments, the present disclosure provides a ceDNA as described herein, comprising a nucleic acid sequence encoding one or more fungal antigens.
[0280] Exemplary parasitic infections are shown in Table 7 below.
[0281] Table 7
[0282]
[0283]
[0284]
[0285]
[0286] Other diseases and disorders are contemplated for treatment by the ceDNA vectors of the present disclosure. Examples include, but are not limited to, cardiovascular disease and immune disease.
[0287] It is well within the capabilities of one skilled in the art to employ known and / or publicly available protein sequences, such as antigens, and reverse engineer cDNA sequences to encode such proteins.
[0288] IV. ceDNA vectors for antigen production
[0289] Embodiments of the present disclosure are based on methods and compositions including a primary vaccine, the primary vaccine including deoxyribonucleic acid (DNA) DNA, wherein the DNA is a linear duplex (ceDNA) vector with closed ends that can express peptides. As described herein, peptides (e.g., antigens) can be selected from a variety of pathogens, including, for example, bacteria, viruses, fungi and parasitic infections, or cancer or cancer-associated antigens, etc. Still other targets can include autoimmune conditions, such as rheumatoid arthritis (RA) or multiple sclerosis (MS).
[0290] According to some embodiments, the transgene is a nucleic acid sequence encoding an antigen. The ceDNA vector is preferably duplexed, e.g., self-complementary, on at least a portion of the molecule, such as the expression cassette (e.g., the ceDNA is not a double-stranded circular molecule). The ceDNA vector has covalently closed ends and is therefore resistant to exonuclease (e.g., exonuclease I or exonuclease III) digestion, e.g., at 37°C for more than one hour.
[0291] Typically, a ceDNA vector for expressing a peptide (e.g., an antigen) as disclosed herein comprises, in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleic acid sequence of interest (e.g., an expression cassette as described herein), and a second AAV ITR. The ITR sequence is selected from any of the following: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat (mod-ITR) (e.g., an asymmetric modified ITR); (ii) two modified ITRs, wherein the mod-ITR pair has a different three-dimensional spatial organization relative to each other (e.g., an asymmetric modified ITR); or (iii) a symmetrical or substantially symmetrical WT-WT ITR pair, wherein each WT-ITR has the same three-dimensional spatial organization; or (iv) a symmetrical or substantially symmetrical modified ITR pair, wherein each mod-ITR has the same three-dimensional spatial organization.
[0292] Contemplated herein are methods and compositions comprising ceDNA vectors for producing peptides (e.g., antigens), which may further comprise a delivery system, such as, but not limited to, a liposome nanoparticle delivery system. Disclosed herein are non-limiting exemplary liposome nanoparticle systems contemplated for use. According to some aspects, the present disclosure provides a lipid nanoparticle comprising ceDNA and an ionizable lipid. For example, a lipid nanoparticle formulation is prepared and loaded with a ceDNA vector obtained by the method disclosed in International Application No. PCT / US2018 / 050042 filed on September 7, 2018, which is incorporated herein.
[0293] The ceDNA vectors as disclosed herein do not have the packaging limitations imposed by the limited space within the viral capsid. In contrast to the encapsulated AAV genome, the ceDNA vectors represent a viable eukaryotically produced alternative to prokaryotically produced plasmid DNA vectors. This allows the insertion of control elements, e.g., regulatory switches, large transgenes, multiple transgenes, etc. as disclosed herein.
[0294] International Publication No. WO / 2019 / 051255 Figure 1 A-1E shows a schematic diagram of a non-limiting exemplary ceDNA vector for expressing a peptide (e.g., an antigen) or a corresponding sequence of a ceDNA plasmid, which is incorporated herein by reference in its entirety. The ceDNA vector for expressing a peptide (e.g., an antigen) is capsid-free and can be obtained from a plasmid that encodes in this order: a first ITR, an expression cassette including a transgene, and a second ITR. The expression cassette can contain one or more regulatory sequences that allow and / or control the expression of the transgene, for example, wherein the expression cassette can include one or more of the following in this order: an enhancer / promoter, an ORF reporter gene (transgene), a post-transcriptional regulatory element (e.g., WPRE), and a polyadenylation and termination signal (e.g., BGH polyA).
[0295] The expression cassette may also include an internal ribosome entry site (IRES) and / or a 2A element. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir-regulatable elements, post-transcriptional regulatory elements, tissue and cell type-specific promoters, and enhancers. According to some embodiments, the ITR may act as a promoter for a transgenic. According to some embodiments, the ceDNA vector includes additional components for regulating the expression of the transgenic, such as a regulatory switch for controlling and regulating the expression of a peptide (e.g., an antigen), and if desired, a regulatory switch (which is a kill switch) may be included to enable controlled cell death of cells comprising the ceDNA vector.
[0296] The expression cassette may include more than 4000 nucleotides, 5000 nucleotides, 10,000 nucleotides, or 20,000 nucleotides, or 30,000 nucleotides, or 40,000 nucleotides, or 50,000 nucleotides, or any range between about 4000-10,000 nucleotides or 10,000-50,000 nucleotides, or more than 50,000 nucleotides. According to some embodiments, the expression cassette may include a transgene with a length ranging from 500 to 50,000 nucleotides. According to some embodiments, the expression cassette may include a transgene with a length ranging from 500 to 75,000 nucleotides. According to some embodiments, the expression cassette may include a transgene with a length ranging from 500 to 10,000 nucleotides. According to some embodiments, the expression cassette may include a transgene with a length ranging from 1000 to 10,000 nucleotides. According to some embodiments, the expression cassette may include a transgene with a length ranging from 500 to 5,000 nucleotides. ceDNA vectors do not have the size limitations of encapsulated AAV vectors and are therefore able to deliver large-sized expression cassettes to provide efficient transgene expression. According to some embodiments, ceDNA vectors lack prokaryotic-specific methylation.
[0297] The sequences provided in the expression cassette, the expression constructs of the ceDNA vectors described herein for expressing peptides (e.g., antigens) can be codon optimized for the target host cell. As used herein, the term "codon optimization" or "codon optimization" refers to the process of modifying the nucleic acid sequence to enhance its expression in the cells of the vertebrate by replacing at least one, more than one or a large number of codons of a native sequence (e.g., a prokaryotic sequence) with codons with a higher or highest frequency of use in the genes of the vertebrate of interest, such as mice or humans. Various species show specific preferences for certain codons for specific amino acids. Typically, codon optimization does not change the amino acid sequence of the original translated protein. The optimized codons can be modified using, for example, Aptagen's GENE The codon optimization and custom gene synthesis platform (Aptagen, Inc., 2190 Fox Mill Rd. Suite 300, Herndon, Va. 20171) or other publicly available databases are determined. According to some embodiments, the nucleic acid is optimized for human expression.
[0298] The transgene expressed by the ceDNA vector for expressing a peptide (e.g., an antigen) as disclosed herein encodes an antigen. There are many structural features of ceDNA vectors that are different from plasmid-based expression vectors. The ceDNA vector may have one or more of the following features: lack of original (i.e., no insert) bacterial DNA; lack of a prokaryotic replication origin; is self-sufficient, i.e., it does not require any sequence other than the two ITRs, including the Rep binding site and the terminal resolution site (RBS and TRS) and exogenous sequences between the ITRs; the presence of ITR sequences that form hairpins; and the absence of bacterial-type DNA methylation or any other methylation that is actually considered abnormal by the mammalian host. Generally, it is preferred that the vectors of the present invention do not contain any prokaryotic DNA, but it is conceivable that some prokaryotic DNA can be inserted as an exogenous sequence, as a non-limiting example in the promoter or enhancer region. Another important feature that distinguishes ceDNA vectors from plasmid expression vectors is that ceDNA vectors are single-stranded linear DNA with closed ends, while plasmids are always double-stranded DNA.
[0299] The ceDNA vectors for expressing peptides (e.g., antigens) produced by the methods provided herein preferably have a linear and continuous structure rather than a discontinuous structure, as determined by restriction enzyme digestion assays (see, e.g., International Publication No. WO / 2019 / 051255). Figure 4 D, which is incorporated herein by reference in its entirety). It is believed that linear and continuous structures are more stable when attacked by cellular endonucleases, and are less likely to reorganize and cause mutagenesis. Therefore, ceDNA vectors of linear and continuous structures are preferred embodiments. Continuous, linear, single-stranded intramolecular duplex ceDNA vectors can have covalently bound ends without sequences encoding AAV capsid proteins. These ceDNA vectors are structurally different from plasmids (including ceDNA plasmids described herein), which are circular duplex nucleic acid molecules of bacterial origin. The complementary strands of the plasmid can be separated after denaturation, thereby producing two nucleic acid molecules, while in contrast, although the ceDNA vector has a complementary strand, it is a single DNA molecule, and therefore even if denatured, it remains a single molecule. According to some embodiments, unlike plasmids, ceDNA vectors as described herein can be produced without prokaryotic type DNA base methylation. Thus, ceDNA vectors and ceDNA-plasmids differ in terms of structure (specifically linear vs. circular) and also in terms of the methods used to produce and purify these different objects, and also in terms of their DNA methylation, i.e. ceDNA-plasmids are of the prokaryotic type and ceDNA vectors are of the eukaryotic type.
[0300] There are several differences between using ceDNA vectors to express peptides (e.g., antigens) and plasmid-based expression vectors, including but not limited to: 1) plasmids contain bacterial DNA sequences and undergo prokaryotic-specific methylation, e.g., 6-methyladenosine and 5-methylcytosine methylation, whereas capsid-less AAV vector sequences are of eukaryotic origin and do not undergo prokaryotic-specific methylation; therefore, capsid-less AAV vectors are less likely to induce inflammatory and immune responses than plasmids; 2) while circular plasmids are not delivered to the nucleus after introduction into cells and require overloading to circumvent degradation by cellular nucleases, ceDNA vectors contain viral cis-elements, i.e., ITRs, which confer nuclease resistance and can be designed to be targeted and delivered to the nucleus.
[0301] Inverted terminal repeats (ITR)
[0302] As disclosed herein, a ceDNA vector for expressing a peptide (e.g., an antigen) contains a transgene or nucleic acid sequence located between two inverted terminal repeat (ITR) sequences, wherein the ITR sequence can be an asymmetric ITR pair or a symmetric or substantially symmetric ITR pair, as these terms are defined herein. The ceDNA vector as disclosed herein can include an ITR sequence selected from any of the following: (i) at least one WT ITR and at least one modified AAV inverted terminal repeat sequence (mod-ITR) (e.g., an asymmetric modified ITR); (ii) two modified ITRs, wherein the mod-ITR pair has a different three-dimensional spatial organization relative to each other (e.g., an asymmetric modified ITR); or (iii) a symmetric or substantially symmetric WT-WT ITR pair, wherein each WT-ITR has the same three-dimensional spatial organization; or (iv) a symmetric or substantially symmetric modified ITR pair, wherein each mod-ITR has the same three-dimensional spatial organization, wherein the method of the present disclosure can further comprise a delivery system, such as, but not limited to, a liposome nanoparticle delivery system.
[0303] According to some embodiments, ITR sequences can be from viruses of the Parvoviridae family, which includes two subfamilies: the Parvovirinae that infects vertebrates and the Densovirinae that infects insects. The Parvovirinae (referred to as Parvovirus) includes the Dependaviridae genus, and its members need to be co-infected with helper viruses such as adenovirus or herpesvirus in most cases to carry out productive infection. The Dependaviridae genus includes adeno-associated viruses (AAVs) that usually infect humans (e.g., serotypes 2, 3A, 3B, 5, and 6) or primates (e.g., serotypes 1 and 4), and related viruses that infect other warm-blooded animals (e.g., adeno-associated viruses of cattle, dogs, horses, and sheep). Parvovirus and other members of the Parvoviridae family are generally described in Kenneth I. Berns, "Field of Virology (FIELDS VIROLOGY)" (3rd Edition 1996) Chapter 69 "Parvoviridae: The Viruses and Their Replication".
[0304] Although the ITRs exemplified in the specification and the examples herein are AAV2 WT-ITRs, one of ordinary skill in the art will appreciate that as described above, ITRs from any known parvovirus, such as dependent viruses such as AAV (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV 5, AAV7, AAV8, AAV9, AAV10, AAV 11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes. For example, NCBI: NC 002077; NC 001401; NC 001729; NC 001829; NC 006152; NC 006260; NC 006261), chimeric ITRs, or ITRs from any synthetic AAVs can be used. According to some embodiments, AAV can infect warm-blooded animals, such as avian (AAAV), bovine (BAAV), canine, equine, and ovine adeno-associated viruses. According to some embodiments, the ITR is from B19 parvovirus (GenBank Accession No. NC 000883), from minute virus of mice (MVM) (GenBank Accession No. NC 001510); goose parvovirus (GenBank Accession No. NC 001701); snake parvovirus 1 (GenBank Accession No. NC 006148). According to some embodiments, the 5' WT-ITR can be from one serotype and the 3' WT-ITR from a different serotype, as discussed herein.
[0305] Ordinary technicians know that ITR sequences have a common structure of a double-stranded Holliday junction, which is usually a T-shaped or Y-shaped hairpin structure (see, for example, International Publication No. WO / 2019 / 051255). Figure 2 A and Figure 3 A), wherein each WT-ITR is formed by two palindromic arms or loops (B-B' and C-C') and a single-stranded D sequence embedded in a larger palindromic arm (A-A'), (wherein the order of these palindromic sequences defines the flip or flip orientation of the ITR). See, for example, the structural analysis and sequence comparison of ITRs from different AAV serotypes (AAV1-AAV6), and described in Grimm et al., J. Virology, 2006; 80(1); 426-439; Yan et al., J. Virology, 2005; 364-379; Duan et al., Virology 1999; 261; 8-14. Based on the exemplary AAV2 ITR sequences provided herein, one skilled in the art can easily determine the WT-ITR sequence from any AAV serotype for use in a ceDNA vector or ceDNA-plasmid. See, e.g., the sequence comparison of ITRs from different AAV serotypes (AAV1-AAV6 and avian AAV (AAAV) and bovine AAV (BAAV)) described in Grimm et al., J. Virol., 2006; 80(1); 426-439; which shows the % identity of the left ITR of AAV2 with the left ITRs from the other serotypes: AAV-1 (84%), AAV-3 (86%), AAV-4 (79%), AAV-5 (58%), AAV-6 (left ITR) (100%), and AAV-6 (right ITR) (82%).
[0306] Symmetrical ITR pair
[0307] According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) as described herein comprises, in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleic acid sequence of interest (e.g., an expression cassette as described herein), and a second AAV ITR, wherein the first ITR (5' ITR) and the second ITR (3' ITR) are symmetrical, or substantially symmetrical to each other - that is, the ceDNA vector may include ITR sequences having a symmetrical three-dimensional spatial organization, such that their structures have the same shape in geometric space, or have the same A, C-C', and B-B' loops in 3D space. In such embodiments, the symmetrical ITR pair or substantially symmetrical ITR pair may be a modified ITR (e.g., mod-ITR), which is not a wild-type ITR. The mod-ITR pair may have the same sequence with one or more modifications relative to the wild-type ITR, and are reverse complementary (inverse) to each other. In alternative embodiments, the modified ITR pair is substantially symmetrical, as defined herein, that is, the modified ITR pair may have different sequences but have corresponding or identical symmetrical three-dimensional shapes.
[0308] (i) Wild-type ITR
[0309] According to some embodiments, the symmetrical ITR or substantially symmetrical ITR is a wild type (WT-ITR) as described herein. That is, the two ITRs have a wild type sequence, but do not necessarily have to be WT-ITRs from the same AAV serotype. That is, according to some embodiments, one WT-ITR may be from one AAV serotype, and the other WT-ITR may be from a different AAV serotype. In such embodiments, the WT-ITR pair is substantially symmetrical, as defined herein, that is, it may have one or more conservative nucleotide modifications, while still retaining a symmetrical three-dimensional spatial organization.
[0310] Thus, as disclosed herein, a ceDNA vector contains a transgene or nucleic acid sequence located between two flanking wild-type inverted terminal repeat (WT-ITR) sequences that are reverse complements of each other (inverted), or alternatively are substantially symmetrical relative to each other - that is, the WT-ITR pair has a symmetrical three-dimensional spatial organization. According to some embodiments, the wild-type ITR sequence (e.g., AAV WT-ITR) includes a functional Rep binding site (RBS; e.g., 5'-GCGCGCTCGCTCGCTC-3' of AAV2, SEQ ID NO:__) and a functional terminal resolution site (TRS; e.g., 5'-AGTT-3', SEQ ID NO:__).
[0311] According to some aspects, a ceDNA vector for expressing a peptide (e.g., an antigen) may be obtained from a vector polynucleotide encoding a nucleic acid operably positioned between two WT inverted terminal repeats (WT-ITRs) (e.g., AAV WT-ITRs). That is, the two ITRs have wild-type sequences, but do not necessarily have to be WT-ITRs from the same AAV serotype. That is, according to some embodiments, one WT-ITR may be from one AAV serotype, and the other WT-ITR may be from a different AAV serotype. In such embodiments, as defined herein, the WT-ITR pair is substantially symmetrical, that is, it may have one or more conservative nucleotide modifications while still retaining a symmetrical three-dimensional spatial organization. According to some embodiments, the 5'WT-ITR is from one AAV serotype, and the 3'WT-ITR is from the same or different AAV serotype. According to some embodiments, the 5'WT-ITR and the 3'WT-ITR are mirror images of each other, i.e., they are symmetrical. According to some embodiments, the 5'WT-ITR and the 3'WT-ITR are from the same AAV serotype.
[0312] WT ITR is well known. According to some embodiments, two ITRs are from the same AAV2 serotype. In certain embodiments, WT from other serotypes can be used. There are many homologous serotypes, such as AAV2, AAV4, AAV6, AAV8. According to some embodiments, closely homologous ITRs (e.g., ITRs with similar loop structures) can be used. In another embodiment, more diverse AAV WT ITRs can be used, for example, AAV2 and AAV5, and in still another embodiment, ITRs that are essentially WT can be used-that is, they have the basic loop structure of WT, but some conservative nucleotide changes do not change or affect the properties. When using WT-ITRs from the same viral serotype, one or more regulatory sequences can be further used. In certain embodiments, the regulatory sequence is a regulatory switch that allows modulation of ceDNA activity, such as the expression of encoded antigens or immunogenic peptides.
[0313] According to some embodiments, one aspect of the technology described herein relates to a ceDNA vector for expressing a peptide (e.g., an antigen), wherein the ceDNA vector comprises at least one nucleic acid sequence encoding, for example, a HC and / or LC operably positioned between two wild-type inverted terminal repeats (WT-ITRs), wherein the WT-ITRs may be from the same serotype, different serotypes, or substantially symmetrical relative to each other (i.e., having a symmetrical three-dimensional spatial organization such that their structures have the same shape in geometric space, or have the same A, C-C', and B-B' loops in 3D space). According to some embodiments, the symmetrical WT-ITRs comprise a functional terminal resolution site and a Rep binding site. According to some embodiments, the nucleic acid sequence encodes a transgene, and wherein the vector is not in a viral capsid.
[0314] According to some embodiments, the WT-ITRs are identical but are reverse complementary to each other. For example, the sequence AACG in the 5'ITR can be the CGTT (i.e., the reverse complementary sequence) in the 3'ITR at the corresponding site. According to some examples, the 5'WT-ITR sense strand includes a sequence of ATCGATCG, and the corresponding 3'WT-ITR sense strand includes CGATCGAT (i.e., the reverse complementary sequence of ATCGATCG). According to some embodiments, the WT-ITR ceDNA further includes an end resolution site and a replication protein binding site (RPS) (sometimes referred to as a replication protein binding site), such as a Rep binding site.
[0315] Exemplary WT-ITR sequences for use in ceDNA vectors for expressing peptides (eg, antigens) comprising WT-ITRs are shown in Table 8 herein, which shows WT-ITR pairs (5' WT-ITR and 3' WT-ITR).
[0316] As an illustrative example, the present disclosure provides a ceDNA vector for expressing a peptide (e.g., an antigen), the ceDNA vector comprising a promoter operably linked to a transgene (e.g., a nucleic acid sequence), with or without a regulatory switch, wherein the ceDNA lacks a capsid protein and: (a) is produced from a ceDNA-plasmid encoding a WT-ITR (e.g., see International Publication No. WO / 2019 / 051255); Figure 1 F-1G, which is incorporated herein by reference in its entirety), wherein each WT-ITR has the same number of intramolecular duplex base pairs in its hairpin secondary configuration (preferably excluding the absence of any AAA or TTT terminal loops in this configuration compared to these reference sequences), and (b) is identified as ceDNA in Example 1 using the assay for identifying ceDNA by agarose gel electrophoresis under native gel and denaturing conditions.
[0317] According to some embodiments, the flanking WT-ITRs are substantially symmetrical to each other. In this embodiment, the 5' WT-ITR can be from one AAV serotype and the 3' WT-ITR is from a different AAV serotype, such that the WT-ITRs are not the same reverse complement. For example, the 5' WT-ITR can be from AAV2 and the 3' WT-ITR is from a different serotype (e.g., AAV1, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12). According to some embodiments, the WT-ITRs may be selected from two different parvoviruses, the two different parvoviruses being selected from any of the following: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (e.g., python parvovirus), bovine parvovirus, caprine parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus, or insect AAV. According to some embodiments, such a combination of WT ITRs is a combination of WT-ITRs from AAV2 and AAV6. According to some embodiments, when one ITR is reversed relative to the other, the substantially symmetrical WT-ITRs are at least 90% identical, at least 95% identical, at least 96% ... 97% ... 98% ... 99% ... 99.5% and all points in between, and have the same symmetrical three-dimensional spatial organization. According to some embodiments, the WT-ITR pair is substantially symmetrical in that it has a symmetrical three-dimensional spatial organization, for example, a 3D structure with identical A, C-C', B-B', and D arms. According to some embodiments, the substantially symmetrical WT-ITR pair is inverted relative to one another and is at least 95% identical to one another, at least 96% ... 97% ... 98% ... 99% ... 99.5% and all points in between, and one WT-ITR retains the Rep binding site (RBS) and terminal resolution site (trs) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO: 60). According to some embodiments, the substantially symmetrical WT-ITR pair is inverted relative to each other and is at least 95% identical to each other, at least 96% ... 97% ... 98% ... 99% ... 99.5% and all points in between, and one WT-ITR retains the Rep binding site (RBS) and terminal resolution site (trs) of 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO:__), and in addition to the variable palindromic sequence that allows for the formation of hairpin secondary structures. Homology can be determined by standard means well known in the art such as BLAST (Basic Local Alignment Search Tool), BLASTN under default settings, etc.
[0318] According to some embodiments, the structural element of the ITR can be any structural element involved in the functional interaction of the ITR with the large Rep protein (e.g., Rep 78 or Rep68). In certain embodiments, the structural element provides selectivity for the interaction of the ITR with the large Rep protein, that is, at least partially determines which Rep protein interacts with the ITR functionally. In other embodiments, when the Rep protein binds to the ITR, the structural element physically interacts with the large Rep protein. Each structural element can be, for example, the secondary structure of the ITR, the nucleic acid sequence of the ITR, the interval between two or more elements, or a combination of any of the above. According to some embodiments, the structural element is selected from the group consisting of: A and A' arms, B and B' arms, C and C' arms, D arms, Rep binding sites (RBE) and RBE' (i.e., complementary RBE sequences) and terminal resolution sites (trs).
[0319] By way of example only, Table 8 indicates exemplary combinations of WT-ITRs.
[0320] Table 8: Exemplary combinations of WT-ITRs from the same serotype or different serotypes or different parvoviruses. The order shown does not indicate the ITR position, for example, "AAV1, AAV2" indicates that the ceDNA can include a WT-AAV1 ITR in the 5' position and a WT-AAV2 ITR in the 3' position, or vice versa, a 5' position WT-AAV2 ITR and a WT-AAV1 ITR in the 3' position. Abbreviations: AAV serotype 1 (AAV1), AAV serotype 2 (AAV2), AAV serotype 3 (AAV3), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11), or AAV serotype 12 (AAV12); AAVrh8, AAVrh10, AAV-DJ, and AAV-DJ8 genomes (e.g., NCBI: NC 002077; NC 001401; NC 001729; NC 001829; NC 006152; NC 006260; NC 006261), ITRs from warm-blooded animals (avian AAV (AAAV), bovine AAV (BAAV), canine, equine and ovine AAV), ITRs from B19 parvovirus (GenBank Accession No. NC 000883), minute virus from mice (MVM) (GenBank Accession No. NC 001510); geese: goose parvovirus (GenBank Accession No. NC 001701); snakes: snake parvovirus 1 (GenBank Accession No. NC 006148).
[0321] Table 8: Exemplary combinations of WT-ITR
[0322]
[0323]
[0324]
[0325] By way of example only, Table 9 shows the sequences of exemplary WT-ITRs from several different AAV serotypes.
[0326] Table 9: Exemplary WT-ITRs
[0327]
[0328]
[0329] According to some embodiments, the nucleic acid sequence of the WT-ITR sequence can be modified (e.g., by modifying 1, 2, 3, 4 or 5 or more nucleotides or any range therein), whereby the modification is a substitution of complementary nucleotides, e.g., G replaces C, and vice versa, and T replaces A, and vice versa.
[0330] In certain embodiments of the present disclosure, the ceDNA vector for expressing a peptide (e.g., an antigen) does not have a WT-ITR consisting of a nucleic acid sequence selected from any one of the following: SEQ ID NO: 1, 2, 5-14. In alternative embodiments of the present disclosure, if the ceDNA vector has a WT-ITR comprising a nucleic acid sequence selected from any one of the following: SEQ ID NO: 1, 2, 5-14, the flanking ITRs are also WT, and the ceDNA vector includes a regulatory switch, for example, as disclosed herein and in International Application PCT / US18 / 49996 (e.g., see Table 11 of PCT / US18 / 49996, which is incorporated herein by reference in its entirety). According to some embodiments, the ceDNA vector for expressing a peptide (e.g., an antigen) includes a regulatory switch as disclosed herein and a WT-ITR having a nucleic acid sequence selected from any one of the group consisting of: SEQ ID NO: 1, 2, 5-14.
[0331] A ceDNA vector for expressing a peptide (eg, an antigen) as described herein may comprise a WT-ITR structure that retains operable RBE, trs, and RBE' portions. Figure 2 A and Figure 2B illustrates a possible operating mechanism of the trs site within the wild-type ITR structure portion of a ceDNA vector using wild-type ITR as an exemplary embodiment. According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) contains one or more functional WT-ITR polynucleotide sequences, which include a Rep binding site (RBS; 5'-GCGCGCTCGCTCGCTC-3' (SEQ ID NO:__) of AAV2 and a terminal resolution site (TRS; 5'-AGTT (SEQ ID NO:__)). According to some embodiments, at least one WT-ITR is functional. In an alternative embodiment in which the ceDNA vector for expressing a peptide (e.g., an antigen) includes two WT-ITRs that are substantially symmetrical to each other, at least one WT-ITR is functional and at least one WT-ITR is non-functional.
[0332] Generally, for a modified ITR (mod-ITR) of a ceDNA vector comprising an asymmetric ITR pair or a symmetric ITR pair,
[0333] As discussed herein, ceDNA vectors for expressing peptides (e.g., antigens) can include symmetrical ITR pairs or asymmetrical ITR pairs. In both cases, one or both of the ITRs can be modified ITRs—the difference being that in the first case (i.e., symmetrical mod-ITRs), the mod-ITRs have the same three-dimensional spatial organization (i.e., have the same A-A', C-C', and B-B' arm configurations), while in the second case (i.e., asymmetrical mod-ITRs), the mod-ITRs have different three-dimensional spatial organizations (i.e., have different A-A', C-C', and B-B' arm configurations).
[0334] According to some embodiments, the modified ITR is an ITR modified by deletion, insertion and / or substitution compared to a wild-type ITR sequence (e.g., AAV ITR). According to some embodiments, at least one of the ITRs in the ceDNA vector includes a functional Rep binding site (RBS; e.g., 5'-GCGCGCTCGCTCGCTC-3' of AAV2) and a functional terminal resolution site (TRS; e.g., 5'-AGTT-3'). According to some embodiments, at least one of the ITRs is a non-functional ITR. According to some embodiments, the different or modified ITRs are not each wild-type ITR from a different serotype.
[0335] Specific changes and mutations in ITRs are described in detail herein, but in the context of ITRs, "altered" or "mutated" or "modified" indicates that nucleotides have been inserted, deleted and / or substituted relative to the wild-type, reference or original ITR sequence. The altered or mutated ITR can be an engineered ITR. As used herein, "engineered" refers to aspects that have been manipulated by the hand of man. For example, a polypeptide is considered to be "engineered" when at least one aspect of the polypeptide, such as its sequence, has been manipulated by the hand of man and differs from that which occurs in nature.
[0336] According to some embodiments, the mod-ITR may be synthetic. According to some embodiments, the synthetic ITR is based on ITR sequences from more than one AAV serotype. In another embodiment, the synthetic ITR does not contain sequences based on AAV. In yet another embodiment, the synthetic ITR retains the ITR structure described above despite having only some or no sequences derived from AAV. According to some aspects, the synthetic ITR may preferentially interact with wild-type Rep or Rep of a specific serotype, or according to some cases, the wild-type Rep will not recognize and will only be recognized by the mutated Rep.
[0337] The skilled person can determine the corresponding sequence of other serotypes by known means. For example, determine whether the change is in region A, A', B, B', C, C' or D, and determine the corresponding region in another serotype. (Basic Local Alignment Search Tool) or other homology alignment programs to determine the corresponding sequences. The present disclosure further provides a population of ceDNA vectors and multiple ceDNA vectors comprising mod-ITRs from combinations of different AAV serotypes, that is, one mod-ITR can be from one AAV serotype and another mod-ITR can be from a different serotype. Without wishing to be bound by theory, according to some embodiments, one ITR can be from or based on an AAV2 ITR sequence, and another ITR of the ceDNA vector can be from or based on any one or more of the following ITR sequences: AAV serotype 1 (AAV1), AAV serotype 4 (AAV4), AAV serotype 5 (AAV5), AAV serotype 6 (AAV6), AAV serotype 7 (AAV7), AAV serotype 8 (AAV8), AAV serotype 9 (AAV9), AAV serotype 10 (AAV10), AAV serotype 11 (AAV11) or AAV serotype 12 (AAV12).
[0338] Any parvovirus ITR can be used as an ITR or as a modified base ITR. Preferably, the parvovirus is a dependent virus. More preferably, it is AAV. The selected serotype can be based on the tissue tropism of the serotype. AAV2 has a broad tissue tropism, AAV1 preferentially targets neurons and skeletal muscle, while AAV5 preferentially targets neurons, retinal pigment epithelium and photoreceptors. AAV6 preferentially targets skeletal muscle and lungs. AAV8 preferentially targets liver, skeletal muscle, heart and pancreatic tissue. AAV9 preferentially targets liver, bone and lung tissue. According to some embodiments, the modified ITR is based on AAV2 ITR.
[0339] More specifically, the ability of a structural element to interact with a specific large Rep protein function can be altered by modifying the structural element. For example, the nucleic acid sequence of the structural element can be modified compared to the wild-type sequence of the ITR. According to some embodiments, the structural elements of the ITR (e.g., A arm, A' arm, B arm, B' arm, C arm, C' arm, D arm, RBE, RBE' and trs) can be removed and replaced with wild-type structural elements from different parvoviruses. For example, the replacement structure can be from: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, snake parvovirus (e.g., python parvovirus), bovine parvovirus, goat parvovirus, avian parvovirus, canine parvovirus, equine parvovirus, shrimp parvovirus, porcine parvovirus or insect AAV. For example, the ITR can be an AAV2 ITR, and the A or A' arm or RBE can be replaced with a structural element from AAV5. In another example, the ITR can be an AAV5 ITR, and the C or C' arms, RBE and trs can be replaced with structural elements from AAV2. In another example, the AAV ITR can be an AAV5 ITR with the B and B' arms replaced with the AAV2 ITR B and B' arms.
[0340] Merely by way of example, Table 10 indicates exemplary modifications (e.g., deletions, insertions, and / or substitutions) of at least one nucleotide in a region of a modified ITR, wherein X indicates a modification (e.g., deletions, insertions, and / or substitutions) of at least one nucleic acid in the portion relative to the corresponding wild-type ITR. According to some embodiments, any modification (e.g., deletions, insertions, and / or substitutions) of at least one nucleotide in any region of the regions of C and / or C' and / or B and / or B' retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. For example, if the modification results in any of the following: a single-arm ITR (e.g., a single C-C' arm or a single B-B' arm) or a modified C-B' arm or C'-B arm, or a two-arm ITR with at least one truncated arm (e.g., a truncated C-C' arm and / or a truncated B-B' arm), then at least one of the arms of the single-arm, or two-arm ITR (one of which may be truncated) retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. According to some embodiments, the truncated C-C' arm and / or the truncated B-B' arm has three consecutive T nucleotides (ie, TTT) in the terminal loop.
[0341] Table 10: Exemplary combinations of modifications (e.g., deletions, insertions and / or substitutions) of at least one nucleotide in different BB' and CC' regions or arms of ITRs (X indicates a nucleotide modification, e.g., addition, deletion or substitution of at least one nucleotide in the region).
[0342] Zone B B' Zone Zone C C' Zone X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
[0343] According to some embodiments, mod-ITRs for use in ceDNA vectors for expressing peptides (e.g., antigens) include asymmetric ITR pairs, or symmetric mod-ITR pairs as disclosed herein may include any of the combinations of modifications shown in Table 10, and modifications of at least one nucleotide in any one or more of the regions selected from: between A' and C, between C and C', between C' and B, between B and B', and between B' and A. According to some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in the C or C' or B or B' region still retains the terminal loop of the stem-loop. According to some embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide between C and C' and / or B and B' retains three consecutive T nucleotides (i.e., TTT) in at least one terminal loop. In alternative embodiments, any modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide between C and C' and / or B and B' retains three consecutive A nucleotides (i.e., AAA) in at least one terminal loop. According to some embodiments, the modified ITR used herein may include any one of the combinations of modifications shown in Table 10, and further include modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in any one or more of the following regions selected from: A', A and / or D. For example, according to some embodiments, the modified ITR used herein may include any one of the combinations of modifications shown in Table 10, and further include modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in region A. According to some embodiments, the modified ITR used herein may include any one of the combinations of modifications shown in Table 10, and further include modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in region A'. According to some embodiments, the modified ITR used herein may include any one of the combinations of modifications shown in Table 10, and further include modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in region A and / or A'. According to some embodiments, the modified ITR used herein may include any one of the combinations of modifications shown in Table 10, and further include modification (e.g., deletion, insertion, and / or substitution) of at least one nucleotide in region D.
[0344] According to some embodiments, the nucleotide sequence of the structural element can be modified (e.g., by modifying 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more nucleotides or any range therein) to produce a modified structural element. According to some embodiments, specific modifications to ITRs (e.g., SEQ ID NO: 3, 4, 15-47, 101-116 or 165-187, or International Patent Application No. PCT / US2018 / 064242 filed on December 6, 2018) are exemplified herein. Figure 7 A-7B (e.g., SEQ ID NOs: 97-98, 101-103, 105-108, 111-112, 117-134, 545-54 in PCT / US2018 / 064242). According to some embodiments, the ITRs can be modified (e.g., by modifying 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more nucleotides or any range thereof). In other embodiments, the ITR can have at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more sequence identity to one of the modified ITRs of SEQ ID NO: 3, 4, 15-47, 101-116 or 165-187; or the A-A' arm and the C-C' and B-B' arm-containing RBE portion of SEQ ID NO: 3, 4, 15-47, 101-116 or 165-187; or as shown in Table 2-9 of International Patent Application No. PCT / US18 / 49996 (i.e., SEQ ID NO: 110-112, 115-190, 200-468), which is incorporated herein by reference in its entirety.
[0345] According to some embodiments, the modified ITR may, for example, include removal or deletion of all of a particular arm, such as all or a portion of the A-A' arm, or all or a portion of the B-B' arm, or all or a portion of the C-C' arm, or alternatively, removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs of the stem forming the loop, as long as the final loop terminating the stem (e.g., a single arm) still exists (e.g., see PCT / US2018 / 064242 filed on December 6, 2018). Figure 7According to some embodiments, the modified ITR may include removing 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the B-B' arm. According to some embodiments, the modified ITR may include removing 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the C-C' arm (see, e.g., International Patent Application No. PCT / US2018 / 064242 filed on December 6, 2018). Figure 3 ITR-1 in B or Figure 7 According to some embodiments, the modified ITRs may include removal of 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the C-C' arm and 1, 2, 3, 4, 5, 6, 7, 8, 9 or more base pairs from the B-B' arm. Any combination of base pair removals is contemplated, for example, 6 base pairs may be removed from the C-C' arm and 2 base pairs may be removed from the B-B' arm. As an illustrative example, Figure 3 B shows an exemplary modified ITR, which has at least 7 base pairs deleted from each of the C and C' portions, nucleotides in the loop between the C and C' regions are substituted, and at least one base pair is deleted from each of the B and B' regions, so that the modified ITR includes two arms with at least one arm (e.g., C-C') truncated. According to some embodiments, the modified ITR also includes at least one base pair deleted from each of the B and B' regions, so that the B-B' arm is also truncated relative to the WT ITR.
[0346] According to some embodiments, the modified ITR may have between 1 and 50 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotide deletions relative to the full-length wild-type ITR sequence. According to some embodiments, the modified ITR may have 1 to 30 nucleotide deletions relative to the full-length WT ITR sequence. According to some embodiments, the modified ITR has 2 to 20 nucleotide deletions relative to the full-length wild-type ITR sequence.
[0347] According to some embodiments, the modified ITR does not contain any nucleotide deletions in the RBE-containing portion of the A or A' region so as not to interfere with DNA replication (e.g., by binding of the Rep protein to the RBE, or nicking at the terminal resolution site). According to some embodiments, it is contemplated that the modified ITR used herein has one or more deletions in the B, B', C and / or C regions as described herein.
[0348] According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) comprising a symmetric ITR pair or an asymmetric ITR pair comprises a regulatory switch as disclosed herein and at least one modified ITR of a nucleotide sequence selected from any one of the following groups consisting of: SEQ ID NO: 3, 4, 15-47, 101-116 or 165-187.
[0349] In another embodiment, the structure of the structural element can be modified.For example, the structural element changes the height of the stem and / or the number of the nucleotides in the ring.For example, the height of the stem can be about 2,3,4,5,6,7,8 or 9 or more nucleotides or any range therein.According to some embodiments, the stem height can be about 5 nucleotides to about 9 nucleotides and functionally interact with Rep.In another embodiment, the stem height can be about 7 nucleotides and functionally interact with Rep.In another embodiment, the ring can have 3,4,5,6,7,8,9 or 10 or more nucleotides or any range therein.
[0350] In another embodiment, the number of GAGY binding sites or GAGY-related binding sites within the RBE or extended RBE can be increased or decreased. According to some examples, the RBE or extended RBE can include 1, 2, 3, 4, 5 or 6 or more GAGY binding sites or any range therein. Each GAGY binding site can independently be an exact GAGY sequence or a sequence similar to GAGY, as long as the sequence is sufficient to bind to the Rep protein.
[0351] In another embodiment, the spacing between two elements (such as but not limited to RBE and hairpin) can be altered (e.g., increased or decreased) to alter the functional interaction with the large Rep protein. For example, the spacing can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 or more nucleotides or any range therein.
[0352] A ceDNA vector for expressing a peptide (eg, an antigen) as described herein may comprise an ITR structure that is modified relative to the wild-type AAV2 ITR structure disclosed herein, but still retains operable RBE, trs, and RBE' portions. Figure 2 A and Figure 2 B shows a possible mechanism for manipulating trs sites within the wild-type ITR structure portion of a ceDNA vector for expressing an antigen or immunogenic peptide. According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) contains one or more functional ITR polynucleotide sequences, including a Rep binding site (RBS; 5'-GCGCGCTCGCTCGCTC-3' of AAV2) and a terminal resolution site (TRS; 5'-AGTT). According to some embodiments, at least one ITR (wt or modified ITR) is functional. In alternative embodiments where the ceDNA vector for expressing a peptide (e.g., an antigen) includes two modified ITRs that are different or asymmetric from each other, at least one modified ITR is functional and at least one modified ITR is non-functional.
[0353] According to some embodiments, a modified ITR (eg, left or right ITR) of a ceDNA vector for expressing a peptide (eg, an antigen) as described herein has a modification within a loop arm, a truncated arm, or a spacer. Exemplary sequences of ITRs with loop arms, truncated arms, or modifications within the spacer are listed in Table 2 (i.e., SEQ ID NOs: 135-190, 200-233); Table 3 (e.g., SEQ ID NOs: 234-263); Table 4 (e.g., SEQ ID NOs: 264-293); Table 5 (e.g., SEQ ID NOs: 294-318 herein); Table 6 (e.g., SEQ ID NOs: 319-468); and Tables 7-9 (e.g., SEQ ID NOs: 101-110, 111-112, 115-134) or Tables 10A or 10B (e.g., SEQ ID NOs: 9, 100, 469-483, 484-499) of International Patent Application No. PCT / US18 / 49996, which are incorporated herein by reference in their entirety.
[0354] According to some embodiments, the modified ITRs for use in a ceDNA vector for expressing a peptide (e.g., an antigen) comprising an asymmetric ITR pair or a symmetric mod-ITR pair are selected from any or a combination of those shown in Tables 2, 3, 4, 5, 6, 7, 8, 9, and 10A-10B of International Patent Application No. PCT / US18 / 49996, which is incorporated herein by reference in its entirety.
[0355] Additional exemplary modified ITRs for use in ceDNA vectors for expressing peptides (e.g., antigens) comprising asymmetric ITR pairs or symmetric mod-ITR pairs in each of the above categories are provided in Tables 11A and 11B. The predicted secondary structure of the right modified ITR in Table 11A is as described in International Patent Application No. PCT / US2018 / 064242 filed on December 6, 2018. Figure 7 The predicted secondary structure of the left modified ITR shown in A and in Table 11B is in International Patent Application No. PCT / US2018 / 064242 filed on December 6, 2018 Figure 7 B, which is incorporated herein by reference in its entirety.
[0356] Table 11A and Table 11B list the SEQ ID NOs of exemplary right and left modified ITRs.
[0357] Table 11A: Exemplary modified right ITRs These exemplary modified right ITRs may include RBE of GCGCGCTCGCTCGCTC-3' (a spacer of ACTGAGGC), a spacer complement of GAGCGAGCG AGCGCGC, GCCTCAGT, and RBE' (ie, the complement to RBE).
[0358]
[0359]
[0360] Table 11B: Exemplary modified left ITRs These exemplary modified left ITRs may include an RBE of GCGCGCTCGCTCGCTC-3', a spacer of ACTGAGGC, a spacer complement of GAGCGAGCGA GCGCGC, GCCTCAGT, and an RBE complement (RBE').
[0361]
[0362]
[0363] According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) includes, in the 5' to 3' direction: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleic acid sequence of interest (e.g., an expression cassette as described herein), and a second AAV ITR, wherein the first ITR (5' ITR) and the second ITR (3' ITR) are asymmetric relative to each other - that is, they have different 3D spatial configurations from each other. As an exemplary embodiment, the first ITR can be a wild-type ITR and the second ITR can be a mutated or modified ITR, or vice versa, wherein the first ITR can be a mutated or modified ITR and the second ITR can be a wild-type ITR. According to some embodiments, both the first ITR and the second ITR are mod-ITRs, but have different sequences, or have different modifications, and are therefore not the same modified ITR, and have different 3D spatial configurations. In other words, ceDNA vectors with asymmetric ITRs include ITRs, wherein any changes in some ITRs relative to the WT-ITRs are not reflected in the other ITRs; or alternatively, wherein the asymmetric ITRs have modified asymmetric ITR pairs that may have different sequences and different three-dimensional shapes relative to each other. Exemplary asymmetric ITRs in ceDNA vectors for expressing peptides (e.g., antigens) and for generating ceDNA-plasmids are shown in Tables 11A and 11B.
[0364] In an alternative embodiment, a ceDNA vector for expressing a peptide (e.g., an antigen) includes two symmetrical mod-ITRs—that is, the two ITRs have the same sequence, but are reverse complementary (reverse) to each other. According to some embodiments, the symmetrical mod-ITR pair includes at least one or any combination of deletions, insertions, or substitutions relative to the wild-type ITR sequence from the same AAV serotype. The additions, deletions, or substitutions in the symmetrical ITRs are identical, but are reverse complementary to each other. For example, the insertion of 3 nucleotides in the C region of the 5'ITR will be reflected in the insertion of 3 reverse complementary nucleotides in the corresponding segment in the C' region of the 3'ITR. For illustration purposes only, if the addition is AACG in the 5'ITR, the addition is CGTT in the 3'ITR of the corresponding site. For example, if the 5'ITR sense strand is ATCGATCG, AACG is added between G and A to produce the sequence ATCGAACGATCG. The corresponding 3' ITR sense strand is CGATCGAT (the reverse complement of ATCGATCG), and CGTT (ie, the reverse complement of AACG) is added between T and C to generate the sequence CGATCGTTCGAT (the reverse complement of ATCGAACGATCG).
[0365] In alternative embodiments, the modified ITR pair is substantially symmetrical, as defined herein, that is, the modified ITR pair may have different sequences, but have corresponding or identical symmetrical three-dimensional shapes. For example, one modified ITR may be from one serotype, and another modified ITR from a different serotype, but have the same mutation (e.g., nucleotide insertion, deletion, or substitution) in the same region. In other words, for illustrative purposes only, the 5'mod-ITR may be from AAV2 and have a deletion in the C region, and the 3'mod-ITR may be from AAV5 and have a corresponding deletion in the C' region, and if the 5'mod-ITR and the 3'mod-ITR have the same or symmetrical three-dimensional spatial organization, then it is contemplated that they are used as modified ITR pairs herein.
[0366] According to some embodiments, a substantially symmetric mod-ITR pair has identical A, C-C', and B-B' loops in 3D space, e.g., if a modified ITR in a substantially symmetric mod-ITR pair lacks the C-C' arm, then the homologous mod-ITR correspondingly lacks the C-C' loop and also has a similar 3D structure with the remaining A and B-B' loops being the same shape in the geometric space of its homologous mod-ITR. By way of example only, substantially symmetric ITRs can have a symmetrical spatial organization such that their structures have the same shape in geometric space. For example, this can occur when, for example, a GC pair is modified to a CG pair or vice versa, or an AT pair is modified to a TA pair or vice versa. Thus, using the illustrative example above of a modified 5' ITR being ATCGAACGATCG, and a modified 3' ITR being CGATCGTCGAT (i.e., the reverse complement of ATCGAACGATCG), if, for example, the 5' ITR has ATCGAAC C ATCG, wherein the added G is modified to C, and the substantially symmetrical 3' ITR has the sequence of CGATCGTCGAT, without correspondingly modifying the added T to A, then these modified ITRs are still symmetrical. According to some embodiments, such modified ITR pairs are substantially symmetrical because the modified ITR pairs have symmetrical stereochemistry.
[0367] Table 12 shows exemplary symmetrical modified ITR pairs (i.e., left modified ITRs and symmetrical right modified ITRs) for use in ceDNA vectors for expressing antigens or immunogenic peptides. The bold (red) portion of the sequence identifies partial ITR sequences (i.e., sequences of the A-A', C-C', and B-B' loops), also shown in Figures 31A-46B. These exemplary modified ITRs can include an RBE of GCGCGCTCGCTCGCTC-3', a spacer of ACTGAGGC, a spacer complement of GAGCGAGCGAGCGCGC, and RBE' (i.e., the complement of RBE).
[0368] Table 12: Exemplary symmetrical modified ITR pairs for expression of antigens or immunogenic peptides in ceDNA vectors.
[0369]
[0370]
[0371]
[0372]
[0373] According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) comprising an asymmetric ITR pair may include an ITR having a modification corresponding to any one of the following modifications: an ITR sequence or an ITR partial sequence shown in any one or more of Tables 11A-11B herein; or an ITR sequence described in International Patent Application No. PCT / US2018 / 064242 filed on December 6, 2018. Figure 7 The sequences shown in A-7B are incorporated herein in their entirety; or the sequences disclosed in Tables 2, 3, 4, 5, 6, 7, 8, 9 or 10A-10B of International Patent Application No. PCT / US18 / 49996 filed on September 7, 2018, which are incorporated herein by reference in their entirety.
[0374] Exemplary ceDNA Vectors
[0375] As described above, the present disclosure relates to recombinant ceDNA expression vectors and ceDNA vectors encoding peptides (e.g., antigens), the recombinant ceDNA expression vectors and ceDNA vectors comprising any of the following: asymmetric ITR pairs, symmetric ITR pairs, or substantially symmetric ITR pairs as described above. In certain embodiments, the present disclosure relates to recombinant ceDNA vectors for expressing peptides (e.g., antigens) having flanking ITR sequences and a transgene, wherein the ITR sequences are asymmetric, symmetric, or substantially symmetric relative to each other as defined herein, and the ceDNA further comprises a nucleic acid sequence of interest (e.g., an expression cassette comprising a nucleic acid of a transgene) located between the flanking ITRs, wherein the nucleic acid molecule lacks a viral capsid protein coding sequence.
[0376] The ceDNA expression vector for expressing a peptide (e.g., an antigen) can be any ceDNA vector that can be conveniently subjected to a recombinant DNA procedure comprising a nucleic acid sequence as described herein, provided that at least one ITR is altered. The ceDNA vector for expressing the peptide (e.g., an antigen) of the present disclosure is compatible with the host cell into which the ceDNA vector is introduced. In certain embodiments, the ceDNA vector can be linear. In certain embodiments, the ceDNA vector can exist as an extrachromosomal entity. In certain embodiments, the ceDNA vector of the present disclosure can contain elements that allow the donor sequence to be integrated into the genome of the host cell. As used herein, "transgene", "nucleic acid sequence" and "heterologous nucleic acid sequence" are synonymous and encode a peptide (e.g., an antigen) as described herein.
[0377] Now refer to International Publication No. WO / 2019 / 051255 Figure 1 A-1G, a schematic diagram showing the functional components of two non-restrictive plasmids that can be used to prepare ceDNA vectors for expressing peptides (e.g., antigens), is incorporated herein by reference in its entirety. Figure 1A, 1B, 1D, 1F show the corresponding sequences of the constructs of ceDNA vectors or ceDNA plasmids for expressing antigens or immunogenic peptides. The ceDNA vector is capsid-free and can be obtained from a plasmid encoding in this order: a first ITR, an expressible transgene cassette, and a second ITR, wherein the first and second ITR sequences are asymmetric, symmetrical or substantially symmetrical relative to each other as defined herein. The ceDNA vector for expressing a peptide (e.g., an antigen) is capsid-free and can be obtained from a plasmid encoding in this order: a first ITR, an expressible transgene (protein or nucleic acid), and a second ITR, wherein the first and second ITR sequences are asymmetric, symmetrical or substantially symmetrical relative to each other as defined herein. According to some embodiments, the expressible transgene cassette comprises, as desired: an enhancer / promoter, one or more homology arms, a donor sequence, a post-transcriptional regulatory element (e.g., WPRE, e.g., SEQ ID NO: 67), and a polyadenylation and termination signal (e.g., BGHpolyA, e.g., SEQ ID NO: 68).
[0378] International Publication No. WO / 2019 / 051255 Figure 5 is a gel confirming the generation of ceDNA from multiple plasmid constructs using the methods described in the Examples, which are incorporated herein by reference in their entirety. ceDNA is confirmed by characteristic band patterns in the gel, as described in connection with International Publication No. WO / 2019 / 051255. Figure 4 A, which is incorporated herein by reference in its entirety.
[0379] Regulatory elements
[0380] The ceDNA vectors as described herein for expressing peptides (e.g., antigens) comprising asymmetric ITR pairs or symmetric ITR pairs as defined herein may further comprise a specific combination of cis-regulatory elements. Cis-regulatory elements include, but are not limited to, promoters, riboswitches, insulators, mir-regulatable elements, post-transcriptional regulatory elements, tissue and cell type specific promoters, and enhancers.
[0381] According to some embodiments, the sequences of various cis-regulatory elements can be selected from any cis-regulatory element disclosed in International Application No. PCT / US2021 / 023891, filed on March 24, 2021, which is incorporated herein by reference in its entirety.
[0382] In an embodiment, the second nucleic acid sequence comprises a regulatory sequence and a nucleic acid sequence encoding a nuclease. In certain embodiments, a gene regulatory sequence is operably connected to a nucleic acid sequence encoding a nuclease. In certain embodiments, a regulatory sequence is suitable for controlling the expression of a nuclease in a host cell. In certain embodiments, a regulatory sequence comprises a suitable promoter sequence, and the suitable promoter sequence can guide the transcription of a gene operably connected to a promoter sequence, such as a nucleic acid sequence encoding a nuclease of the present disclosure. In certain embodiments, the second nucleic acid sequence comprises an intron sequence connected to the 5' end of the nucleic acid sequence encoding a nuclease. In certain embodiments, an enhancer sequence is arranged upstream of the promoter to increase the efficacy of the promoter. In certain embodiments, a regulatory sequence comprises an enhancer and a promoter, wherein the second nucleic acid sequence comprises an intron sequence upstream of a nucleic acid sequence encoding a nuclease, wherein the intron comprises one or more nuclease cleavage sites, and wherein the promoter is operably connected to a nucleic acid sequence encoding a nuclease.
[0383] Suitable promoters may be derived from viruses and may therefore be referred to as viral promoters, or they may be derived from any organism, including prokaryotic or eukaryotic organisms. Suitable promoters may be used to drive expression by any RNA polymerase (e.g., pol I, pol II, pol III). Exemplary promoters include, but are not limited to, the SV40 early promoter, the mouse mammary tumor virus long terminal repeat (LTR) promoter, the adenovirus major late promoter (Ad MLP), the herpes simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE), the Rous sarcoma virus (RSV) promoter, the human U6 small nuclear promoter (U6, e.g., SEQ ID NO: 80) (Miyagishi et al., Nature Biotechnology 20, 497-500 (2002)), the enhanced U6 promoter (e.g., Xia et al., Nucleic Acids Res. 2003 Sep 1; 31 (17)), the human H1 promoter (H1) (e.g., SEQ ID NO: 81 or SEQ ID NO: 155), the CAG promoter, the human alpha 1-antitrypsin (HAAT) promoter (e.g., SEQ ID NO: 82), and the like. In certain embodiments, these promoters are altered at their downstream intron-containing ends to include one or more nuclease cleavage sites. In certain embodiments, the DNA containing the nuclease cleavage site is foreign to the promoter DNA.
[0384] According to some embodiments, the promoter may also be a promoter from a human gene, such as human ubiquitin C (hUbC), human actin, human myosin, human hemoglobin, human muscle creatine, or human metallothionein.
[0385] According to some embodiments, the promoter is a tissue-specific promoter. According to further embodiments, the tissue-specific promoter is a liver-specific promoter. According to some embodiments, the antigen or immunogenic protein is targeted to the liver and / or produced in the liver by a liver-specific promoter.
[0386] Any liver-specific promoter known in the art is contemplated for use in the present disclosure. According to some embodiments, the liver-specific promoter is selected from, but not limited to, natural or synthetic human α1-antitrypsin (HAAT). According to some embodiments, delivery to the liver can be achieved by specifically targeting a composition comprising a ceDNA vector to hepatocytes using endogenous ApoE, through low-density lipoprotein (LDL) receptors present on the surface of hepatocytes.
[0387] Non-limiting examples of suitable promoters for use in accordance with the present disclosure include, but are not limited to, any of the following: CAG promoter, EF1a promoter, IE2 promoter, and rat EF1-alpha promoter, mEF1 promoter, or 1E1 promoter fragment.
[0388] According to some embodiments, the promoter can be selected from any promoter sequence disclosed in International Application No. PCT / US2021 / 023891, filed on March 24, 2021, which is incorporated herein by reference in its entirety.
[0389] Polyadenylation sequence:
[0390] A sequence encoding a polyadenylation sequence can be included in a ceDNA vector for expressing a peptide (e.g., an antigen) to stabilize the mRNA expressed from the ceDNA vector and to facilitate nuclear export and translation. According to some embodiments, the ceDNA vector does not include a polyadenylation sequence. In other embodiments, the ceDNA vector for expressing a peptide (e.g., an antigen) includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 45, at least 50 or more adenine dinucleotides. According to some embodiments, the polyadenylation sequence includes about 43 nucleotides, about 40-50 nucleotides, about 40-55 nucleotides, about 45-50 nucleotides, about 35-50 nucleotides, or any range therebetween.
[0391] The expression cassette may comprise any polyadenylation sequence known in the art or variants thereof. Some expression cassettes may also comprise an SV40 late polyA signal upstream enhancer (USE) sequence. According to some embodiments, the USE sequence may be used in combination with SV40pA or a heterologous poly-A signal. The polyA sequence is located 3' of the transgenic encoding the antigen or immunogenic peptide.
[0392] According to some embodiments, the polyadenylation sequence can be selected from any polyadenylation sequence disclosed in International Application No. PCT / US2021 / 023891, filed on March 24, 2021, which is incorporated herein by reference in its entirety.
[0393] The expression cassette may also contain post-transcriptional elements to increase the expression of the transgene. According to some embodiments, the woodchuck hepatitis virus (WHP) post-transcriptional regulatory element (WPRE) is used to increase the expression of the transgene. Other post-transcriptional processing elements, such as the thymidine kinase gene from herpes simplex virus or the post-transcriptional element of hepatitis B virus (HBV) may be used.
[0394] According to some embodiments, the post-transcriptional regulatory element can be selected from any post-transcriptional regulatory element sequence disclosed in International Application No. PCT / US2021 / 023891 filed on March 24, 2021, which is incorporated herein by reference in its entirety.
[0395] According to some embodiments, one or more nucleic acid sequences encoding an antigen or immunogenic protein may also encode a secretory sequence so that the protein is directed to the Golgi apparatus and the endoplasmic reticulum and is folded into the correct conformation by chaperones as it passes through the ER and leaves the cell. Exemplary secretory sequences include, but are not limited to, VH-02 and VK-A26 and IgK signal sequences, as well as Gluc secretion signals that allow the labeled protein to be secreted from the cytosol, TMD-ST secretion sequences that direct the labeled protein to the Golgi apparatus.
[0396] According to some embodiments, the secretory sequence can be selected from any secretory sequence disclosed in International Application No. PCT / US2021 / 023891, filed on March 24, 2021, which is incorporated herein by reference in its entirety.
[0397] nuclear localization sequence
[0398] According to some embodiments, the ceDNA vector for expressing a peptide (e.g., an antigen) includes one or more nuclear localization sequences (NLS), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more NLS. According to some embodiments, the one or more NLSs are located at or near the amino terminus, at or near the carboxyl terminus, or a combination of these (e.g., one or more NLSs at the amino terminus and / or one or more NLSs at the carboxyl terminus). When more than one NLS is present, each NLS can be selected independently of one another so that a single NLS is present in more than one copy and / or is combined with one or more other NLSs present according to some or more copies.
[0399] According to some embodiments, the NLS can be selected from any NLS disclosed in International Application No. PCT / US2021 / 023891 filed on March 24, 2021, which is incorporated herein by reference in its entirety.
[0400] V. Methods for Producing ceDNA Vectors
[0401] General Generation
[0402] Methods for producing ceDNA vectors for expressing peptides (e.g., antigens) comprising asymmetric ITR pairs or symmetric ITR pairs as defined herein are described in Part IV of International Application PCT / US18 / 49996, filed September 7, 2018, which is incorporated herein by reference in its entirety. According to some embodiments, ceDNA vectors for expressing peptides (e.g., antigens) as disclosed herein can be produced using insect cells, as described herein. In alternative embodiments, ceDNA vectors for expressing peptides (e.g., antigens) as disclosed herein can be produced synthetically and, according to some embodiments, produced in a cell-free method, as disclosed in International Application PCT / US19 / 14122, filed January 18, 2019, which is incorporated herein by reference in its entirety.
[0403] As described herein, according to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) can be obtained, for example, by a method comprising the following steps: a) incubating a population of host cells (e.g., insect cells) carrying a vector polynucleotide expression construct template (e.g., ceDNA-plasmid, ceDNA-bacmid and / or ceDNA-baculovirus) under effective conditions in the presence of Rep protein for a time sufficient to induce ceDNA production in the host cells, the host cell population lacking a viral capsid encoding sequence, and wherein the host cells do not include a viral capsid encoding sequence; and b) harvesting and isolating the ceDNA vector from the host cells. The presence of the Rep protein induces replication of the vector polynucleotide having a modified ITR, thereby producing a ceDNA vector in the host cell. However, no viral particles (e.g., AAV virions) are expressed. Therefore, there is no size restriction, such as the size restriction naturally imposed in AAV or other virus-based vectors.
[0404] The presence of the ceDNA vector isolated from the host cells can be confirmed by digesting the DNA isolated from the host cells with a restriction enzyme that has a single recognition site on the ceDNA vector and analyzing the digested DNA material on a non-denaturing gel to confirm the presence of the characteristic bands of linear and continuous DNA compared to linear and non-continuous DNA.
[0405] In yet another aspect, the present disclosure provides the use of a host cell line that stably integrates a DNA vector polynucleotide expression template (ceDNA template) into its own genome, the cell line being used to produce a non-viral DNA vector, for example, as described in Lee, L. et al. (2013) PLOS ONE 8(8): e69879. Preferably, Rep is added to the host cell at an MOI of about 3. When the host cell line is a mammalian cell line, such as HEK293 cells, the cell line can have a stably integrated polynucleotide vector template, and a second vector, such as a herpes virus, can be used to introduce the Rep protein into the cell, so that the ceDNA is excised and amplified in the presence of Rep and a helper virus.
[0406] According to some embodiments, the host cell used to prepare the ceDNA vector for expressing a peptide (e.g., an antigen) as described herein is an insect cell, and a baculovirus is used to deliver a polynucleotide encoding a Rep protein and a non-viral DNA vector polynucleotide expression construct template of the ceDNA, e.g., as described in Example 1. According to some embodiments, the host cell is engineered to express a Rep protein.
[0407] Then collect and separate ceDNA vectors from host cells. The time for harvesting and collecting ceDNA vectors described herein from cells can be selected and optimized to achieve high yield production of ceDNA vectors. For example, harvesting time can be selected according to cell viability, cell morphology, cell growth, etc. According to some embodiments, cells are grown and harvested for enough time to produce ceDNA vectors after baculovirus infection, but before most cells begin to die due to baculovirus toxicity. Plasmid purification kits such as Qiagen Endo-Free Plasmid kits can be used to separate DNA vectors. Other methods developed for separating plasmids are also applicable to DNA vectors. Generally, any nucleic acid purification method can be used.
[0408] The DNA vector can be purified by any means known to those skilled in the art for purifying DNA. According to some embodiments, the ceDNA vector is purified into a DNA molecule. In another embodiment, the ceDNA vector is purified into exosomes or microparticles.
[0409] The presence of a ceDNA vector for expressing a peptide (e.g., an antigen) can be confirmed by digesting vector DNA isolated from cells with a restriction enzyme that has a single recognition site for the DNA vector and analyzing the digested and undigested DNA material by gel electrophoresis to confirm the presence of characteristic bands of linear and continuous DNA compared to linear and non-continuous DNA.
[0410] According to some embodiments, ceDNA is synthetically produced in a cell-free environment.
[0411] ceDNA Plasmid
[0412] The ceDNA-plasmid is a plasmid used to later generate a ceDNA vector for expressing a peptide (e.g., an antigen) as described herein. According to some embodiments, the ceDNA-plasmid can be constructed using known techniques to provide at least the following components as operably linked in the transcription direction: (1) a modified 5'ITR sequence; (2) an expression cassette containing cis-regulatory elements such as a promoter, an inducible promoter, a regulatory switch, an enhancer, and (3) a modified 3'ITR sequence, wherein the 3'ITR sequence is symmetrical relative to the 5'ITR sequence. According to some embodiments, the expression cassette flanked by the ITRs includes a cloning site for introducing an exogenous sequence. The expression cassette replaces the rep and cap coding regions of the AAV genome.
[0413] According to some aspects, the ceDNA vector for expressing a peptide (e.g., an antigen) is obtained from a plasmid, referred to herein as a "ceDNA-plasmid", which encodes, in order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), an expression cassette comprising a transgene, and a mutated or modified AAV ITR, wherein the ceDNA-plasmid lacks an AAV capsid protein coding sequence. In an alternative embodiment, the ceDNA-plasmid encodes, in this order: a first (or 5') modified or mutated AAV ITR, an expression cassette comprising a transgene, and a second (or 3') modified AAV ITR, wherein the ceDNA-plasmid lacks an AAV capsid protein coding sequence, and wherein the 5' and 3' ITRs are symmetrical relative to each other. In alternative embodiments, the ceDNA-plasmid encodes in sequence: a first (or 5') modified or mutated AAV ITR, an expression cassette comprising a transgene, and a second (or 3') mutated or modified AAV ITR, wherein the ceDNA-plasmid lacks an AAV capsid protein coding sequence, and wherein the 5' and 3' modified ITRs have the same modification (i.e., they are reverse complements or symmetric with respect to each other).
[0414] In other embodiments, the ceDNA-plasmid system lacks viral capsid protein coding sequences (i.e., it lacks the AAV capsid gene and also lacks the capsid genes of other viruses). In addition, in specific embodiments, the ceDNA-plasmid also lacks the AAVRep protein coding sequence. Therefore, in a preferred embodiment, the ceDNA-plasmid lacks the functional AAV cap and the AAV rep gene GG-3' for AAV2 plus a variable palindromic sequence that allows the formation of a hairpin.
[0415] The ceDNA-plasmids of the present disclosure can be generated using the natural nucleic acid sequence of the genome of any AAV serotype well known in the art. According to some embodiments, the ceDNA-plasmid backbone is derived from AAV1, AAV2, AAV3, AAV4, AAV5, AAV5, AAV7, AAV8, AAV9, AAV10, AAV 11, AAV12, AAVrh8, AAVrh10, AAV-DJ and AAV-DJ8 genomes. For example, NCBI: NC 002077; NC 001401; NC001729; NC001829; NC006152; NC 006260; NC 006261; Kotin and Smith, Springer Index of Viruses, available at a URL maintained by Springer (website: oesys.springer.de / viruses / database / mkchapter.asp?virID=42.04.) (Note - references to URLs or databases refer to the contents of the URLs or databases as of the effective filing date of this application). In a specific embodiment, the ceDNA-plasmid backbone is derived from the AAV2 genome. In another specific embodiment, the ceDNA-plasmid backbone is a synthetic backbone that is genetically engineered to contain at its 5' and 3' ITRs a backbone derived from one of these AAV genomes.
[0416] The ceDNA-plasmid may optionally include a selectivity or selection marker for establishing a cell line producing a ceDNA vector. According to some embodiments, the selection marker may be inserted downstream of the 3'ITR sequence (i.e., 3'). In another embodiment, the selection marker may be inserted upstream of the 5'ITR sequence (i.e., 5'). Suitable selection markers include, for example, those that confer drug resistance. The selection marker may be, for example, a blasticidin S resistance gene, kanamycin, geneticin, etc. In a preferred embodiment, the drug selection marker is a blasticidin S resistance gene.
[0417] An exemplary ceDNA (e.g., rAAV0) vector for expressing a peptide (e.g., an antigen) is produced from a rAAV plasmid. A method for producing a rAAV vector may include: (a) providing a host cell with a rAAV plasmid as described above, wherein neither the host cell nor the plasmid contains a capsid protein encoding gene, (b) culturing the host cell under conditions that allow the production of a ceDNA genome; and (c) harvesting the cell and isolating the AAV genome produced from the cell.
[0418] Exemplary method for preparing ceDNA vectors from ceDNA plasmids
[0419] Also provided herein are methods for preparing capsid-free ceDNA vectors for expressing peptides (eg, antigens), particularly methods with sufficiently high yields to provide sufficient vector for in vivo experiments.
[0420] According to some embodiments, a method for producing a ceDNA vector for expressing a peptide (e.g., an antigen) comprises the following steps: (1) introducing a nucleic acid construct comprising an expression cassette and two symmetrical ITR sequences into a host cell (e.g., Sf9 cell); (2) optionally, establishing a clonal cell line, for example, by using a selection marker present on a plasmid; (3) introducing a Rep encoding gene into the insect cell (by transfection or infection with a baculovirus carrying the gene); and (4) harvesting the cells and purifying the ceDNA vector. The nucleic acid construct comprising an expression cassette and two ITR sequences described above for producing a ceDNA vector can be in the form of a ceDNA-plasmid, or in the form of a bacmid or baculovirus produced using a ceDNA-plasmid as described below. The nucleic acid construct can be introduced into a host cell by transfection, viral transduction, stable integration, or other methods known in the art.
[0421] Cell lines
[0422] Host cell lines for producing ceDNA vectors for expressing peptides (e.g., antigens) may include insect cell lines derived from Spodoptera frugiperda, such as Sf9 Sf21, or Trichoplusiani cells, or other invertebrate, vertebrate or other eukaryotic cell lines, including mammalian cells. Other cell lines known to those of ordinary skill may also be used, such as HEK293, Huh-7, HeLa, HepG2, HeplA, 911, CHO, COS, MeWo, NIH3T3, A549, HT1 180, monocytes, and mature and immature dendritic cells. Host cell lines may be transfected to stably express ceDNA-plasmids, thereby producing ceDNA vectors in high yields.
[0423] CeDNA-plasmids can be introduced into Sf9 cells by transient transfection using reagents known in the art (e.g., liposomes, calcium phosphate) or physical means (e.g., electroporation). Alternatively, a stable Sf9 cell line that stably integrates ceDNA-plasmids into the genome can be established. Such stable cell lines can be established by incorporating selection markers into ceDNA-plasmids as described above. If the ceDNA-plasmids used for transfecting cell lines include selection markers such as antibiotics, then cells that have been transfected with ceDNA-plasmids and ceDNA-plasmid DNA integrated into the genome can be selected by adding antibiotics to the cell growth medium. The resistant clones of cells can then be isolated and propagated by single cell dilution or colony transfer techniques.
[0424] Isolation and purification of ceDNA vectors
[0425] Examples of methods for obtaining and isolating ceDNA vectors are described in International Publication No. WO / 2019 / 051255. Figure 4 A-4E, which is incorporated herein by reference in its entirety. ceDNA vectors for expressing peptides (e.g., antigens) used as prime vaccines in the prime-boost compositions and methods described herein can be obtained from producer cells expressing AAV Rep proteins, which are further transformed with ceDNA-plasmids, ceDNA-bacmids, or ceDNA-baculoviruses. Plasmids that can be used to generate ceDNA vectors include plasmids encoding peptides (e.g., antigens) or plasmids encoding one or more REP proteins.
[0426] According to some aspects, the polynucleotide encodes an AAV Rep protein (Rep 78 or 68) delivered to a production cell in a plasmid (Rep-plasmid), a bacmid (Rep-bacmid) or a baculovirus (Rep-baculovirus). Rep-plasmids, Rep-bacmids and Rep-baculoviruses can be produced by the methods described above.
[0427] Methods for producing ceDNA vectors for expressing peptides (e.g., antigens) used as priming vaccines in the prime-boost compositions and methods described herein are described herein. The expression construct for producing a ceDNA vector for expressing a peptide (e.g., antigen) as described herein can be a plasmid (e.g., ceDNA-plasmid), a bacmid (e.g., ceDNA-bacmid) and / or a baculovirus (e.g., ceDNA-baculovirus). By way of example only, a ceDNA-vector can be produced by cells co-infected with a ceDNA-baculovirus and a Rep-baculovirus. The Rep protein produced by the Rep-baculovirus can replicate the ceDNA-baculovirus to produce a ceDNA-vector. Alternatively, a ceDNA vector for expressing a peptide (e.g., antigen) can be produced from cells stably transfected with a construct comprising a sequence encoding an AAV Rep protein (Rep78 / 52), the protein being delivered in a Rep-plasmid, a Rep-bacmid, or a Rep-baculovirus. CeDNA-baculovirus can be transiently transfected into cells, replicate through Rep protein and produce ceDNA vector.
[0428] Bacmids (e.g., ceDNA-bacmids) can be transfected into permissive insect cells, such as Sf9, Sf21, Tni (Trichoplusia ni) cells, High Five cells, and ceDNA-baculoviruses are generated, which are recombinant baculoviruses comprising sequences including asymmetric ITRs and expression cassettes. The ceDNA-baculoviruses can be reinfected into insect cells to obtain the next generation of recombinant baculoviruses. Optionally, the steps can be repeated one or more times to produce larger quantities of recombinant baculoviruses.
[0429] The time for harvesting and collecting ceDNA vectors for expressing peptides (e.g., antigens) as described herein from cells can be selected and optimized to achieve high yield production of ceDNA vectors. For example, the harvesting time can be selected based on cell viability, cell morphology, cell growth, etc. Typically, cells can be harvested after a sufficient time after baculovirus infection to produce ceDNA vectors (e.g., ceDNA vectors), but before most cells begin to die due to viral toxicity. Using a Qiagen ENDO-FREE Plasmid purification kits such as kits can be used to isolate ceDNA-vectors from Sf9 cells. Other methods developed for isolating plasmids may also be suitable for ceDNA vectors. Generally, any nucleic acid purification method known in the art, as well as commercially available DNA extraction kits, can be used.
[0430] Alternatively, purification can be performed by subjecting the cell pellet to an alkaline lysis process, centrifuging the resulting lysate, and performing chromatography. As a non-limiting example, the method can be performed as follows: The supernatant is loaded onto an ion exchange column that retains nucleic acids (e.g., SARTOBIND ), then eluted (e.g., using 1.2 M NaCl solution) and further chromatographically purified on a gel filtration column (e.g., 6 fast-flow GE). The capsid-free AAV vector is then recovered by, for example, precipitation.
[0431] According to some embodiments, ceDNA vectors for expressing peptides (e.g., antigens) can also be purified in the form of exosomes or microparticles. It is known in the art that many cell types release not only soluble proteins, but also complex protein / nucleic acid cargoes by shedding of membrane microvesicles (Cocucci et al., 2009; EP 10306226.1). Such vesicles include microvesicles (also referred to as microparticles) and exosomes (also referred to as nanovesicles), both of which include proteins and RNA as cargoes. Microvesicles are produced by direct budding of the plasma membrane, while exosomes are released into the extracellular environment after fusion of multivesicular endosomes with the plasma membrane. Therefore, microvesicles and / or exosomes containing ceDNA vectors can be isolated from cells that have been transduced with ceDNA-plasmids or from bacmids or baculoviruses produced with ceDNA-plasmids.
[0432] Microvesicles can be isolated by filtering the culture medium or by ultracentrifugation at 20,000 x g, while exosomes can be isolated by ultracentrifugation at 100,000 x g. The optimal duration of ultracentrifugation can be determined experimentally and will depend on the specific cell type from which the vesicles are isolated. Preferably, the culture medium is first cleared by low speed centrifugation (e.g., 5-20 minutes at 2000 x g) and the culture medium is centrifuged using, for example, Centrifugal concentration is performed using centrifugal columns (Millipore, Watford, UK). Microvesicles and exosomes can be further purified by FACS or MACS using specific antibodies that recognize specific surface antigens present on microvesicles and exosomes. Other microvesicle and exosome purification methods include, but are not limited to, immunoprecipitation, affinity chromatography, filtration, and magnetic beads coated with specific antibodies or aptamers. After purification, the vesicles are washed with, for example, phosphate-buffered saline. One advantage of using microvesicles or exosomes to deliver vesicles containing ceDNA is that these vesicles can be targeted to various cell types by containing proteins on their membranes that are recognized by specific receptors on the corresponding cell types. (See also EP 10306226)
[0433] Another aspect disclosed herein relates to a method for purifying a ceDNA vector from a host cell line that has stably integrated the ceDNA construct into its own genome. According to some embodiments, the ceDNA vector is purified into a DNA molecule. In another embodiment, the ceDNA vector is purified into exosomes or microparticles.
[0434] International Application PCT / US18 / 49996 Figure 5 Shown is a gel confirming the production of ceDNA from multiple ceDNA-plasmid constructs.
[0435] VI. Application
[0436] Heterologous prime-boost method
[0437] It is reported that multiple doses of immunization for therapy or disease prevention are generally more effective than single doses. It is generally believed that after vaccination, a large number of antigen-specific memory CD8 + T cells are a desired target for vaccine design for a variety of animal and human diseases, as the number is closely related to host immunity and protection. One method of generating these large numbers of cells is to use prime-boost immunity, which relies on restimulation of antigen-specific immune cells after primary memory formation. In such a process, there is a "prime" composition that is first administered to the subject and a "boost" composition that is subsequently administered one or more times.
[0438] The disclosure also contemplates multiple administrations of one (primary immunization vaccine) in the composition, followed by multiple administrations of another composition (enhancement). In one embodiment, the primary immunization composition is administered to the subject at least once or multiple times before the booster composition is administered. Thereafter, the booster composition is subsequently administered to the subject at least once or multiple times. It is widely believed that the vaccine booster immune response produces more effector cells required for mediating the protection of pathogens when infected.
[0439] According to aspects of the present disclosure, the methods described herein employ heterologous prime-boost immunization, or use two different modalities or platforms to administer antigens or immunogenic peptides. According to embodiments, such methods advantageously elicit an improved immune response in a subject. According to some embodiments, the improved immune response produced by the described heterologous prime-boost immunization comprises an improved memory response, including but not limited to CD8 + The magnitude of the T cell response is higher, the T cell epitopes recognized by the immune system are expanded, and the multifunctionality of the T cells is increased. According to some embodiments, CD8 +The higher magnitude of T cell response can be an increase of at least 20%, or at least 25%, or at least 30%, or at least 50%, or at least 75%, or at least 100%, or at least 150%, or at least 200%, or at least 250%, or at least 300% relative to a single dose administration or relative to a homologous primary immunization-boosting regimen. According to some embodiments, the heterologous primary immunization-boosting strategy described herein can result in a synergistic enhancement of immune responses, wherein the ceDNA platform is used as a primary immunization vaccine. According to other embodiments, the synergistic enhancement of immune responses can be seen in the magnitude of the increase in the number of antigen-specific T cells, the length of the immune memory response, and the immune memory response.
[0440] According to some embodiments, the present disclosure provides a method for inducing an immune response of a subject against a first peptide and a second peptide, the method comprising: administering a primary vaccine to the subject, the primary vaccine comprising deoxyribonucleic acid (DNA) DNA, wherein the DNA encodes the first peptide; and administering a booster vaccine to the subject, the booster vaccine comprising (i) ribonucleic acid (RNA) or (ii) a second peptide, wherein the RNA encodes the second peptide, thereby inducing an immune response of the subject against the first peptide and the second peptide. A vaccine regimen is also provided, the vaccine regimen comprising: a primary vaccine, the primary vaccine comprising deoxyribonucleic acid (DNA) DNA, wherein the DNA encodes the first peptide; and a booster vaccine, the booster vaccine comprising (i) ribonucleic acid (RNA) or (ii) a second peptide, wherein the RNA encodes the second peptide. According to some embodiments, the first peptide and the second peptide are derived from bacteria, viruses, fungi or parasitic infectious agents. According to some embodiments, the first peptide and the second peptide are from the same pathogenic organism. According to some embodiments, the first peptide and the second peptide are the same in the primary vaccine and the booster vaccine. According to some embodiments, at least one of the epitopes of the first peptide and the second peptide is different in the primary vaccine and the booster vaccine.
[0441] Some embodiments disclosed herein relate to a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject at least one dose of a priming vaccine, wherein the priming vaccine comprises a ceDNA vector encoding the first peptide; and subsequently administering to the subject at least one dose of a boosting vaccine, wherein the boosting vaccine does not comprise a ceDNA vector.
[0442] Some embodiments disclosed herein relate to a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject at least one dose of a priming vaccine, wherein the priming vaccine comprises a ceDNA vector encoding the first peptide; and subsequently administering to the subject at least one dose of a boosting vaccine, wherein the boosting vaccine comprises the second peptide.
[0443] Some embodiments disclosed herein relate to a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject at least one dose of a priming vaccine, wherein the priming vaccine comprises a ceDNA vector encoding the first peptide; and subsequently administering to the subject at least one dose of a boosting vaccine, wherein the boosting vaccine comprises ribonucleic acid (RNA) encoding the second peptide.
[0444] Some embodiments disclosed herein relate to a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject at least one dose of a priming vaccine, wherein the priming vaccine comprises a ceDNA vector encoding the first peptide; and subsequently administering to the subject at least one dose of a boosting vaccine, wherein the boosting vaccine comprises a ceDNA vector encoding the second peptide.
[0445] Some embodiments disclosed herein relate to a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject at least one dose of a priming vaccine, wherein the priming vaccine comprises ribonucleic acid (RNA) encoding the first peptide; and subsequently administering to the subject at least one dose of a boosting vaccine, wherein the boosting vaccine comprises a ceDNA vector encoding the second peptide.
[0446] Some embodiments disclosed herein relate to a method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject at least one dose of a priming vaccine, wherein the priming vaccine comprises the first peptide; and subsequently administering to the subject at least one dose of a boosting vaccine, wherein the boosting vaccine comprises a ceDNA vector encoding the second peptide.
[0447] In some embodiments, the first peptide and the second peptide are identical to each other. In some embodiments, the amino acid sequences of the first peptide and the second peptide are homologous to each other. In some embodiments, the amino acid sequence of the first peptide exhibits at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence of the second peptide. In some embodiments, the first and second immunogenic peptides include at least one cross-reactive antigenic determinant. In some embodiments, the first and second immunogenic peptides or antigens induce substantially the same immune response in a subject.
[0448] In some embodiments, the priming composition is administered to the subject in a single dose. In some embodiments, the priming composition is administered to the subject in multiple doses. In some embodiments, the boosting composition is administered to the subject in a single dose. In some embodiments, the boosting composition is administered to the subject in multiple doses.
[0449] In some embodiments, the subject is administered a priming composition and / or a boosting composition for at least 2, at least 3, at least 4, at least 5, or at least 10 consecutive doses, or any number of doses therebetween. In some embodiments, the subject is administered a priming composition and / or a boosting composition for at least 10, at least 12, at least 14, at least 16, or at least 20 consecutive doses, or any number of doses therebetween.
[0450] In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 1 week, or 2, 3, 4, 5, 6, 7, or 8, or 1-2, or 2-4, or 3-4 weeks. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 4 weeks. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 6 weeks. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 8 weeks. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 10 weeks.
[0451] In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 28 days. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 35 days. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 42 days. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 49 days. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 56 days. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 63 days. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals of about 70 days or longer. In some embodiments of the methods disclosed herein, at least one dose of the priming composition and the boosting composition are administered to the subject at intervals between 28 and 56 days.
[0452] It will be further understood by those skilled in the art that for any particular subject, a specific dosing regimen may be adjusted over time according to individual needs and the professional judgment of the person administering or supervising the administration of the composition. For example, the dosage may be adjusted based on the clinical effects of the administered composition, such as toxic effects and / or laboratory values. The dosing regimen may be adjusted to provide the best desired effect. For example, as discussed above, a single dose may be administered, several divided doses may be administered over time, or the dosage may be proportionally reduced or increased as indicated by the urgency of the treatment situation. Determining the appropriate dosage and regimen for administering the compositions disclosed herein is well known in the relevant art, and once the teachings disclosed herein are provided, it will be understood to be covered by the skilled person.
[0453] Therefore, it will be appreciated by those skilled in the art that based on the disclosure provided herein, dosage and administration regimens are adjusted according to methods well known in the therapeutic field. That is, the maximum tolerated dose can be easily determined, and the effective amount for providing a detectable therapeutic benefit to the subject can also be determined, as well as the time requirement for administering each medicament to provide a detectable therapeutic benefit to the patient. Therefore, although certain dosages and administration regimens are illustrated herein, when practicing the present disclosure, these examples in no way limit the dosages and administration regimens that can be provided to the patient.
[0454] The administration of the primary immunity and booster compositions disclosed herein can be carried out by any method that enables the compositions to be delivered to the site of action. These methods include oral routes, intraduodenal routes, parenteral injections (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical administration and rectal administration. Infusion can be administered by drip, continuous infusion, infusion pump, metering pump, reservoir preparation or any other suitable manner. In some embodiments, at least one dose of the primary immunity composition is administered intramuscularly to the subject. In some embodiments, at least one dose of the booster composition is administered intramuscularly to the subject.
[0455] In some embodiments disclosed herein, the method of the present disclosure further comprises one or more subsequent booster administrations. In some embodiments, the method of the present disclosure further comprises at least 2, at least 3, at least 4, at least 5, or at least 10 consecutive booster administrations or any number of administrations therebetween. In some embodiments, the subsequent booster administration is performed with a dose that gradually increases over time. In some embodiments, the subsequent booster administration is performed with a dose that gradually decreases over time.
[0456] VII. Pharmaceutical Compositions
[0457] In another aspect, a pharmaceutical composition is provided. The pharmaceutical composition includes a ceDNA vector for expressing a peptide (eg, antigen) used as a prime vaccine in the prime-boost composition and method described herein, and a pharmaceutically acceptable carrier or diluent.
[0458] The ceDNA vectors for expressing peptides (e.g., antigens) as disclosed herein can be incorporated into pharmaceutical compositions suitable for administration to a subject for in vivo delivery to cells, tissues or organs of the subject. Typically, the pharmaceutical composition comprises a ceDNA-vector as disclosed herein and a pharmaceutically acceptable carrier.
[0459] The pharmaceutical formulations disclosed herein include liquids, e.g., aqueous solutions that can be administered directly, and lyophilized powders that can be reconstituted into solutions by adding diluents prior to administration. In certain embodiments, formulations including ceDNA vectors as disclosed herein with or without at least one additional therapeutic agent can be formulated into lyophilisates using appropriate excipients. Lyophilization can be performed on a commercially available lyophilizer (e.g., a VirTis laboratory-scale lyophilizer) using a universal lyophilization cycle.
[0460] Pharmaceutical compositions for therapeutic purposes must generally be sterile and stable under the conditions of preparation and storage. The compositions can be formulated as solutions, microemulsions, dispersions, liposomes or other ordered structures suitable for high ceDNA carrier concentrations. Sterile injectable solutions can be prepared by incorporating the desired amount of the ceDNA carrier compound into an appropriate buffer along with one or a combination of the ingredients listed above, as desired, followed by filtration sterilization.
[0461] In certain embodiments, formulations for parenteral administration may be stored in lyophilized form or in solution.In certain embodiments, parenteral formulations are typically placed in a container with a sterile access port, such as an intravenous solution bag or vial with a stopper pierceable by a hypodermic injection needle.
[0462] According to some aspects, the methods provided herein include delivering one or more ceDNA vectors for expressing peptides (e.g., antigens) used as primary vaccines in the primary-boost compositions and methods described herein to host cells. Cells produced by such methods are also provided herein, as well as organisms (e.g., animals, plants, or fungi) including such cells or produced by such cells. The delivery method of nucleic acids may include lipofection, nuclear transfection, microinjection, biolistics, liposomes, immunoliposomes, polycations or lipids: nucleic acid conjugates, naked DNA, and agents for enhancing uptake of DNA. Lipofection is described, for example, in U.S. Patents Nos. 5,049,386; 4,946,787; and 4,897,355, and liposome transfection reagents are commercially available (e.g., Transfectam TM Lipofectin TM ). Delivery can be to cells (eg, in vitro administration or ex vivo administration) or to target tissues (eg, in vivo administration).
[0463] Various techniques and methods for delivering nucleic acid to cells are known in the art. For example, nucleic acids such as ceDNA for expressing peptides (e.g., antigens) can be formulated into lipid nanoparticles (LNPs), lipidoids, liposomes, lipid nanoparticles, lipoplexes or core-shell nanoparticles. Typically, LNPs are composed of nucleic acid (e.g., ceDNA) molecules, one or more ionizable or cationic lipids (or their salts), one or more nonionic or neutral lipids (e.g., phospholipids), molecules that prevent aggregation (e.g., PEG or PEG-lipid conjugates), and optionally sterols (e.g., cholesterol).
[0464] Another method of delivering nucleic acids such as ceDNA for expressing peptides (e.g., antigens) to cells is to conjugate nucleic acids to ligands internalized by the cells. For example, ligands can bind to receptors on the cell surface and be internalized by endocytosis. Ligands can be covalently linked to nucleotides in nucleic acids. Exemplary conjugates for delivering nucleic acids to cells are described in, for example, WO2015 / 006740, WO2014 / 025805, WO2012 / 037254, WO2009 / 082606, WO2009 / 073809, WO2009 / 018332, WO2006 / 112872, WO2004 / 090108, WO2004 / 091515, and WO2017 / 177326.
[0465] Nucleic acids such as ceDNA vectors for expressing peptides (e.g., antigens) can also be delivered to cells by transfection. Useful transfection methods include, but are not limited to, lipid-mediated transfection, cationic polymer-mediated transfection, or calcium phosphate precipitation. Transfection reagents are well known in the art and include, but are not limited to, TurboFect transfection reagent (Thermo Fisher Scientific), Pro-Ject reagent (Thermo Fisher Scientific), TRANSPASS TM P protein transfection reagent (New England Biolabs), CHARIOT TM Protein delivery reagents (Active Motif), PROTEOJUICE TM Protein transfection reagent (EMD Millipore), 293fectin, LIPOFECTAMINE TM 2000、LIPOFECTAMINE TM 3000(Thermo Fisher Scientific), LIPOFECTAMINE TM (Thermo Fisher Scientific), LIPOFECTIN TM(Thermo Fisher Scientific), DMRIE-C, CELLFECTIN TM (Thermo Fisher Scientific), OLIGOFECTAMINE TM (Thermo Fisher Scientific), LIPOFECTACE TM FUGENE TM (Roche, Basel, Switzerland), FUGENE TM HD (Roche), TRANSFECTAM TM (Transfectamine, Promega, Madison, Wis.), TFX-10 TM (Promega Corporation), TFX-20 TM (Promega Corporation), TFX-50 TM (Promega Corporation), TRANSFECTIN TM (BioRad, Hercules, Calif.), SILENTFECT TM (Bole Company), Effectene TM (Qiagen, Valencia, Calif.), DC-chol (Avanti Polar Lipids), GENEPORTER TM (Gene Therapy Systems, San Diego, Calif.), DHARMAFECT 1 TM (Dharmacon, Lafayette, Colo.), DHARMAFECT 2 TM (Dalmarken), DHARMAFECT 3 TM (Dalmarken), DHARMAFECT 4 TM (Dalmacan), ESCORT TM III (Sigma, St. Louis, Mo.) and ESCORT TM IV (Sigma Chemical Co.) Nucleic acids such as ceDNA can also be delivered to cells by microfluidic methods known to those skilled in the art.
[0466] ceDNA vectors for expressing peptides (e.g., antigens) as described herein can also be directly applied to an organism to transduce cells in vivo. Administration is by any route normally used to introduce molecules into final contact with blood or tissue cells, including but not limited to injection, infusion, topical application, and electroporation. Suitable methods for administering such nucleic acids are available and well known to those skilled in the art, and although more than one approach can be used to administer a particular composition, a particular approach can often provide a more direct and more effective response than another approach.
[0467] According to the disclosure, ceDNA vectors for expressing peptides (e.g., antigens) can be added to liposomes for delivery to cells or target organs of subjects. Liposomes are vesicles with at least one lipid bilayer. In the context of pharmaceutical research and development, liposomes are generally used as carriers for drug / therapeutic agent delivery. It works by fusing with the cell membrane and repositioning its lipid structure to deliver drugs or active pharmaceutical ingredients (APIs). Liposome compositions for such delivery are composed of phospholipids, especially compounds with phosphatidylcholine groups, but these compositions can also include other lipids. Exemplary liposomes and liposome formulations, including but not limited to compounds containing polyethylene glycol (PEG) functional groups, are disclosed in international applications PCT / US2018 / 050042 filed on September 7, 2018 and PCT / US2018 / 064242 filed on December 6, 2018, for example, see the section entitled "Pharmaceutical Formulations".
[0468] Various delivery methods known in the art or their modified methods can be used to deliver ceDNA vectors in vitro or in vivo. For example, according to some embodiments, ceDNA vectors for expressing peptides (e.g., antigens) are delivered by mechanical, electrical, ultrasonic, fluid dynamic, or laser-based energy to allow instantaneous penetration of cell membranes so that DNA can enter targeted cells. For example, ceDNA vectors can be delivered by squeezing cells through a size-restricted channel or by other means known in the art to instantaneously destroy cell membranes. According to some embodiments, a single ceDNA vector is directly injected into any of the following as naked DNA: any one or more tissues selected from the following: lung, liver, kidney, gallbladder, prostate, adrenal gland, heart, intestine, stomach, skin, thymus, myocardium, or skeletal muscle. According to some embodiments, ceDNA vectors are delivered by gene guns. Gold or tungsten spherical particles (1-3 μm in diameter) coated with a capsid-free AAV vector can be accelerated to high speed by pressurized gas and penetrate into target tissue cells.
[0469] According to some embodiments, ceDNA carriers are formulated with lipid delivery systems, for example, liposomes as described herein. According to some embodiments, such compositions are administered by any route desired by the technician. The composition can be administered to the subject by different routes including: oral, parenteral, sublingual, transdermal, rectal, transmucosal, topical, by inhalation, buccal administration, intrapleural, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intranasal, intrathecal and intraarticular or a combination thereof. For veterinary use, the composition can be administered as a suitably acceptable formulation according to normal veterinary practice. Veterinarians can easily determine the dosage regimen and route of administration that is most suitable for a particular animal. The composition can be administered by conventional syringes, needleless injection devices, "microparticle bombardment gene guns" or other physical methods such as electroporation ("EP"), "fluid dynamic methods" or ultrasound.
[0470] According to some embodiments, ceDNA vectors for expressing peptides (eg, antigens) are delivered by hydrodynamic injection, which is a simple and efficient method for the intracellular delivery of any water-soluble compounds and particles directly into visceral organs and skeletal muscles throughout the limbs.
[0471] According to some embodiments, nanopores are created in the membrane by ultrasound to facilitate intracellular delivery of DNA particles into cells of internal organs or tumors to deliver ceDNA vectors for expressing peptides (e.g., antigens), so the size and concentration of the plasmid DNA plays an important role in the efficiency of the system. According to some embodiments, ceDNA vectors are delivered by magnetofection using a magnetic field to concentrate particles containing nucleic acids into target cells.
[0472] According to some embodiments, a chemical delivery system can be used, such as by using a nanocomplex comprising a polycationic nanoparticle that is a cationic liposome / micelle or a cationic polymer to compact the negatively charged nucleic acid. Cationic lipids used in the delivery method include, but are not limited to, monovalent cationic lipids, multivalent cationic lipids, guanidine-containing compounds, cholesterol-derived compounds, cationic polymers, (e.g., poly(ethyleneimine), poly-L-lysine, protamine, other cationic polymers) and lipid-polymer hybrids.
[0473] exosomes
[0474] According to some embodiments, the ceDNA vector for expressing peptides (e.g., antigens) as disclosed herein is delivered by packaging in exosomes. Exosomes are small membrane vesicles of endocytic origin, which are released into the extracellular environment after the fusion of multivesicular bodies with the plasma membrane. Its surface is composed of a lipid bilayer from the cell membrane of donor cells, which contains the cytosol from the cells producing exosomes and displays membrane proteins from parent cells on the surface. Exosomes are produced by various cell types including epithelial cells, B and T lymphocytes, mast cells (MCs), and dendritic cells (DCs). According to some embodiments, it is envisioned to use exosomes with a diameter between 10nm and 1 μm, between 20nm and 500nm, between 30nm and 250nm, and between 50nm and 100nm. Using donor cells of exosomes or by introducing specific nucleic acids into exosomes, exosomes can be isolated for delivery to target cells. Various methods known in the art can be used to produce exosomes containing the capsid-free AAV vector disclosed herein.
[0475] Microparticles / Nanoparticles
[0476] According to some embodiments, the ceDNA carrier for expressing peptide (e.g., antigen) as disclosed herein is delivered by lipid nanoparticles. Generally, lipid nanoparticles include ionizable amino lipids (e.g., 4-(dimethylamino)butyric acid 37 carbon-6,9,28,31-tetraene-19-yl ester, DLin-MC3-DMA, phosphatidylcholine (1,2-distearoyl-sn-glycero-3-phosphocholine, DSPC), cholesterol and outer lipids (polyethylene glycol-dimyristoyl glycerol, PEG-DMG), for example, such as Tam et al. (2013). Advances in lipid nanoparticles for delivering siRNA (Advances in LipidNanoparticles for siRNA delivery). "Pharmaceuticals (Pharmaceuticals)" 5 (3): disclosed in 498-507.
[0477] According to some embodiments, the average diameter of the lipid nanoparticles is between about 10nm and about 1000nm. According to some embodiments, the diameter of the lipid nanoparticles is less than 300nm. According to some embodiments, the diameter of the lipid nanoparticles is between about 10nm and about 300nm. According to some embodiments, the diameter of the lipid nanoparticles is less than 200nm. According to some embodiments, the diameter of the lipid nanoparticles is between about 25nm and about 200nm. According to some embodiments, the lipid nanoparticle preparation (e.g., a composition comprising a plurality of lipid nanoparticles) has a size distribution in which the average size (e.g., diameter) is about 70nm to about 200nm, more typically the average size is about 100nm or less.
[0478] Various lipid nanoparticles known in the art can be used to deliver ceDNA vectors for expressing peptides (e.g., antigens) as disclosed herein. For example, various delivery methods using lipid nanoparticles are described in U.S. Patents Nos. 9,404,127, 9,006,417, and 9,518,272.
[0479] Conjugate
[0480] According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) as disclosed herein is conjugated (e.g., covalently bound) to an agent that increases cellular uptake. "Agents that increase cellular uptake" are molecules that promote the transport of nucleic acids across lipid membranes. For example, nucleic acids can be conjugated to lipophilic compounds (e.g., cholesterol, tocopherol, etc.), cell penetrating peptides (CPP) (e.g., transmembrane peptides, TAT, Syn1B, etc.) and polyamines (e.g., spermine). Other examples of agents that enhance cellular uptake are disclosed in, for example, Winkler (2013). Oligonucleotide conjugates for therapeutic applications. Ther. Deliv. 4 (7); 791-809.
[0481] According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) as disclosed herein is conjugated to a polymer (e.g., a polymer molecule) or a folic acid molecule (e.g., a folic acid molecule). Typically, delivery of nucleic acids conjugated to polymers is known in the art, for example, as described in WO2000 / 34343 and WO2008 / 022309. According to some embodiments, a ceDNA vector for expressing a peptide (e.g., an antigen) as disclosed herein is conjugated to a poly(amide) polymer, for example, as described in U.S. Patent No. 8,987,377. According to some embodiments, a nucleic acid described in the present disclosure is conjugated to a folic acid molecule, as described in U.S. Patent No. 8,507,455.
[0482] According to some embodiments, a ceDNA vector for expressing a peptide (eg, an antigen) as disclosed herein is conjugated to a carbohydrate, eg, as described in US Pat. No. 8,450,467.
[0483] Nanocapsules
[0484] Alternatively, nanocapsule formulations of ceDNA vectors for expressing peptides (e.g., antigens) as disclosed herein can be used. Nanocapsules can generally entrap substances in a stable and reproducible manner. In order to avoid side effects due to intracellular polymer overload, such ultrafine particles (about 0.1 μm in size) should be designed using polymers that can degrade in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are expected to be used.
[0485] Liposomes
[0486] According to the disclosure, ceDNA vectors for expressing peptides (e.g., antigens) can be added to liposomes for delivery to cells or target organs of subjects. Liposomes are vesicles with at least one lipid bilayer. In the context of pharmaceutical research and development, liposomes are generally used as carriers for drug / therapeutic agent delivery. It works by fusing with the cell membrane and repositioning its lipid structure to deliver drugs or active pharmaceutical ingredients (API). Liposome compositions for such delivery are composed of phospholipids, especially compounds with phosphatidylcholine groups, but these compositions can also include other lipids.
[0487] The formation and use of liposomes are generally known to those skilled in the art. Liposomes with improved serum stability and circulation half-life have been developed (U.S. Pat. No. 5,741,516). Further, various methods of liposomes and liposome-like formulations as potential drug carriers have been described (U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).
[0488] Exemplary Liposome and Lipid Nanoparticle (LNP) Compositions
[0489] According to the disclosure, ceDNA vectors for expressing peptides (e.g., antigens) can be added to liposomes for delivery to cells, such as cells that need to express transgenics. Liposomes are vesicles with at least one lipid bilayer. In the context of pharmaceutical research and development, liposomes are generally used as carriers for drug / therapeutic agent delivery. It works by fusing with the cell membrane and repositioning its lipid structure to deliver drugs or active pharmaceutical ingredients (API). Liposome compositions for such delivery are composed of phospholipids, particularly compounds with phosphatidylcholine groups, but these compositions may also include other lipids.
[0490] Lipid nanoparticles (LNPs) comprising ceDNA vectors are disclosed in International Applications PCT / US2018 / 050042, filed September 7, 2018, and PCT / US2018 / 064242, filed December 6, 2018, which are incorporated herein in their entirety and are contemplated for use in methods and compositions of ceDNA vectors for expressing peptides (e.g., antigens) as disclosed herein.
[0491] According to some aspects, the present disclosure provides a liposome formulation comprising one or more compounds having a polyethylene glycol (PEG) functional group (so-called "PEGylated compound"), which can reduce the immunogenicity / antigenicity of one or more of the compounds, provide hydrophilicity and hydrophobicity thereto, and reduce dosage frequency. Alternatively, the liposome formulation comprises only a polyethylene glycol (PEG) polymer as an additional component. In such aspects, the molecular weight of the PEG or PEG functional group can be 62 Da to about 5,000 Da.
[0492] According to some aspects, the present disclosure provides a liposome formulation that delivers an API with an extended release or controlled release profile over a period of hours to weeks. According to some related aspects, the liposome formulation may include an aqueous cavity bound by a lipid bilayer. In other related aspects, the liposome formulation encapsulates the API with components that undergo physical transformations at elevated temperatures to release the API over a period of hours to weeks.
[0493] According to some aspects, the liposomal formulation comprises sphingomyelin and one or more lipids disclosed herein. According to some aspects, the liposomal formulation comprises a photosensitizer.
[0494] According to some aspects, the present disclosure provides a liposome formulation comprising one or more lipids selected from the following: N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, (distearoyl-sn-glycero-phosphoethanolamine), MPEG (methoxypolyethylene glycol) conjugated lipids, HSPC (hydrogenated soybean phosphatidylcholine); PEG (polyethylene glycol); DSPE (distearoyl-sn-glycero-phosphoethanolamine); DSPC (distearoyl phosphatidylcholine); DOPC (dioleoyl phosphatidylcholine); DPPG (dipalmitoyl phosphatidylcholine); acylglycerol); EPC (ovine phosphatidylcholine); DOPS (dioleoylphosphatidylserine); POPC (palmitoyloleoylphosphatidylcholine); SM (sphingomyelin); MPEG (methoxypolyethylene glycol); DMPC (dimyristoylphosphatidylcholine); DMPG (dimyristoylphosphatidylglycerol); DSPG (distearoylphosphatidylglycerol); DEPC (dieserucylphosphatidylcholine); DOPE (dioleoyl-sn-glycero-phosphoethanolamine), cholesterol sulfate (CS), dipalmitoylphosphatidylglycerol (DPPG), DOPC (dioleoyl-sn-glycero-phosphatidylcholine), or any combination thereof.
[0495] According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprising phospholipids, cholesterol and PEGylated lipids in a molar ratio of 56:38:5. According to some aspects, the total lipid content of the liposome formulation is 2-16 mg / mL. According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprises lipids containing phosphatidylcholine functional groups, lipids containing ethanolamine functional groups and PEGylated lipids. According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprises lipids containing phosphatidylcholine functional groups, lipids containing ethanolamine functional groups and PEGylated lipids, and the molar ratios are 3:0.015:2, respectively. According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprises lipids containing phosphatidylcholine functional groups, cholesterol and PEGylated lipids. According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprises lipids containing phosphatidylcholine functional groups and cholesterol. According to some aspects, the PEGylated lipid is PEG-2000-DSPE. According to some aspects, the present disclosure provides a liposome formulation comprising DPPG, soybean PC, MPEG-DSPE lipid conjugate and cholesterol.
[0496] According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprising one or more lipids containing phosphatidylcholine functional groups and one or more lipids containing ethanolamine functional groups. According to some aspects, the present disclosure provides a liposome formulation, the liposome formulation comprising one or more: lipids containing phosphatidylcholine functional groups, lipids containing ethanolamine functional groups and sterols, such as cholesterol. According to some aspects, the liposome formulation comprises DOPC / DEPC; and DOPE.
[0497] According to some aspects, the present disclosure provides a liposomal formulation further comprising one or more pharmaceutical excipients, such as sucrose and / or glycine.
[0498] According to some aspects, the present disclosure provides a liposom...
Claims
1. A method for inducing an immune response in a subject against a first peptide and a second peptide, the method comprising: administering to the subject a priming vaccine comprising deoxyribonucleic acid (DNA), wherein the DNA encodes a first peptide; as well as administering to the subject a booster vaccine comprising (i) ribonucleic acid (RNA), wherein the RNA encodes the second peptide, or (ii) a second peptide, Thereby, the immune response of the subject is induced against the first peptide and the second peptide.
2. The method of claim 1, wherein the priming vaccine comprises DNA encoding the first peptide and the boosting vaccine comprises RNA encoding the second peptide.
3. The method of claim 1, wherein the priming vaccine comprises DNA encoding the first peptide and the boosting vaccine comprises the second peptide.
4. The method according to any one of claims 1 to 3, wherein the DNA comprises a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (a linear covalently closed DNA vector), a linear duplex DNA (CELiD or ceDNA) with closed ends, a doggybone (dbDNA), TM ) DNA, dumbbell DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector.
5. The method according to any one of claims 1 to 4, wherein the first peptide and the second peptide are derived from a bacterial, viral, fungal or parasitic infectious agent.
6. The method according to any one of claims 1 to 5, wherein the first peptide and the second peptide are derived from the same pathogenic organism.
7. The method according to any one of claims 1 to 6, wherein the first peptide and the second peptide are identical in the prime vaccine and the boost vaccine.
8. The method according to any one of claims 1 to 6, wherein at least one of the epitopes of the first peptide and the second peptide is different in the priming vaccine and the boosting vaccine.
9. The method of any one of claims 1 to 8, wherein the DNA comprises a capsid-free end-closed DNA (ceDNA) vector comprising at least one nucleic acid sequence located between flanking inverted terminal repeats (ITRs), wherein the at least one nucleic acid sequence encodes the peptide.
10. The method according to any one of claims 1 to 9, wherein the first peptide and / or the second peptide is a tumor associated antigen or is associated with an autoimmune condition.
11. The method according to any one of claims 1 to 10, wherein the first peptide and / or the second peptide is selected from the group consisting of the peptides shown in Tables 1-8.
12. The method according to any one of claims 1 to 11, wherein the DNA comprises a promoter sequence linked to the at least one nucleic acid sequence.
13. The method according to any one of claims 4 to 12, wherein the ceDNA vector comprises at least one polyA sequence.
14. The method according to any one of claims 4 to 13, wherein the ceDNA vector comprises a 5'UTR and / or an intron sequence.
15. The method according to any one of claims 4 to 14, wherein the ceDNA vector comprises a 3'UTR sequence.
16. The method according to any one of claims 4 to 15, wherein the ceDNA vector comprises an enhancer sequence.
17. The method of any one of claims 9 to 16, wherein at least one of the flanking ITRs comprises a functional terminal resolution site and a Rep binding site.
18. The method of any one of claims 9 to 17, wherein one or both of the flanking ITRs are derived from a virus selected from the group consisting of a parvovirus, a dependovirus, and an adeno-associated virus (AAV).
19. The method of any one of claims 9 to 18, wherein the flanking ITRs are symmetric or asymmetric relative to each other.
20. The method of any one of claims 9 to 19, wherein the flanking ITRs are symmetrical or substantially symmetrical.
21. The method of any one of claims 9 to 19, wherein the flanking ITRs are asymmetric.
22. The method of any one of claims 9 to 21, wherein one of the flanking ITRs is wild-type, or wherein two of the flanking ITRs are wild-type ITRs.
23. The method according to any one of claims 9 to 22, wherein the flanking ITRs are from different viral serotypes.
24. The method according to any one of claims 9 to 23, wherein the flanking ITRs are selected from the group consisting of the viral serotype pairs shown in Table 8.
25. The method according to any one of claims 9 to 24, wherein one or both of the flanking ITRs comprise a sequence selected from the group consisting of the sequences shown in Table 9.
26. The method of any one of claims 9 to 25, wherein at least one of the flanking ITRs is altered from a wild-type AAV ITR sequence by a deletion, addition or substitution that affects the overall three-dimensional conformation of the ITR.
27. The method of any one of claims 9 to 26, wherein one or both of the flanking ITRs are derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12.
28. The method of any one of claims 9 to 27, wherein one or both of the flanking ITRs are synthetic.
29. The method of any one of claims 9 to 28, wherein one of the flanking ITRs is not a wild-type ITR, or wherein two of the ITRs are not a wild-type ITR.
30. The method according to any one of claims 9 to 29, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D and D'.
31. The method according to claim 30, wherein the deletion, insertion and / or substitution results in the deletion of all or part of the stem-loop structure formed by the A, A', B, B', C or C' region.
32. The method according to any one of claims 9 to 31, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of all or part of the stem-loop structure formed by the B and B' regions.
33. The method according to any one of claims 9 to 32, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of all or part of the stem-loop structure formed by the C and C' regions.
34. The method according to any one of claims 9 to 33, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of part of the stem-loop structure formed by the B and B' regions and / or part of the stem-loop structure formed by the C and C' regions.
35. A method according to any one of claims 9 to 34, wherein one or both of the flanking ITRs comprise a single stem-loop structure in the region, which in a wild-type ITR would comprise a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.
36. A method according to any one of claims 9 to 35, wherein one or both of the flanking ITRs comprises a single stem and two loops in the region, which in a wild-type ITR would comprise a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.
37. A method according to any one of claims 9 to 36, wherein one or both of the flanking ITRs comprise a single stem and a single loop in the region, which in a wild-type ITR would comprise a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.
38. A method according to any one of claims 9 to 37, wherein when flanking ITRs are inverted relative to each other, both of the ITRs are altered in a manner that produces overall three-dimensional symmetry.
39. The method of any one of claims 1 to 38, wherein the DNA is delivered in lipid nanoparticles (LNPs).
40. The method of any one of claims 1 to 39, wherein the RNA is delivered in LNP.
41. The method of any one of claims 1 to 40, wherein the RNA is messenger RNA (mRNA).
42. The method of any one of claims 1 to 41, wherein the RNA comprises at least one nucleotide analogue.
43. The method of any one of claims 1 to 42, wherein the immune response is an antibody response.
44. The method of any one of claims 1 to 43, wherein the immune response is a T cell response.
45. The method according to any one of claims 1 to 44, wherein the immune response is a memory (CD8 + )T cell response.
46. The method of any one of claims 1 to 45, wherein the method comprises administering the booster vaccine at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 9 weeks, at least about 10 weeks, at least about 11 weeks, at least about 12 weeks, at least about 14 weeks, at least about 16 weeks, at least about 1-2 weeks, at least about 2-3 weeks, at least about 3-4 weeks, at least about 4-5 weeks, at least about 5-6 weeks, at least about 6-7 weeks, at least about 7-8 weeks, at least about 8-9 weeks, at least about 9-10 weeks, at least about 10-11 weeks, at least about 11-12 weeks, at least about 12-13 weeks, at least about 13-14 weeks, at least about 14-15 weeks, or at least about 15-16 weeks after administering the priming vaccine.
47. The method of any one of claims 1 to 46, wherein the method comprises administering the booster vaccine about 8 weeks after administering the priming vaccine.
48. The method of any one of claims 1 to 47, wherein the time interval between the administration of the priming vaccine and the administration of the booster vaccine is at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, at least about 31 days, at least about 32 days, at least about 33 days, at least about 34 days, at least about 35 days, at least about 36 days, at least about 37 days, at least about 38 days, at least about 39 days, at least about 40 days, at least about 41 days, at least about 42 days, at least about 43 days, at least about 44 days, at least about 45 days, at least about 46 days, at least about 47 days, at least about 48 days, at least about 49 days, at least about 50 days, at least about 51 days, at least about 52 days, at least about 53 days, at least about 54 days, at least about 55 days, at least about 56 days, at least about 57 days, at least about 58 days 28 days, at least about 29 days, at least about 30 days, at least about 31 days, at least about 32 days, at least about 33 days, at least about 34 days, at least about 35 days, at least about 36 days, at least about 37 days, at least about 38 days, at least about 39 days, at least about 40 days, at least about 41 days, at least about 42 days, at least about 43 days, at least about 44 days, at least about 45 days, at least about 46 days, at least about 47 days, at least about 48 days, at least about 49 days, at least about 50 days, at least about 51 days, at least about 52 days, at least about 53 days, at least about 54 days, at least about 55 days, at least about 56 days, at least about 57 days about 57 days, at least about 58 days, at least about 59 days, at least about 60 days, at least about 61 days, at least about 62 days, at least about 63 days, at least about 64 days, at least about 65 days, at least about 66 days, at least about 67 days, at least about 68 days, at least about 69 days, at least about 70 days, at least about 71 days, at least about 72 days, at least about 73 days, at least about 74 days, at least about 75 days, at least about 76 days, at least about 77 days, at least about 78 days, at least about 79 days, at least about 80 days, at least about 81 days, at least about 82 days, at least about 83 days, at least about 84 days, at least about 85 days, At least about 86 days, at least about 87 days, at least about 88 days, at least about 89 days, at least about 90 days, at least about 91 days, at least about 92 days, at least about 93 days, at least about 94 days, at least about 95 days, at least about 96 days, at least about 97 days, at least about 98 days, at least about 99 days, at least about 100 days, at least about 101 days, at least about 102 days, at least about 103 days, at least about 104 days, at least about 105 days, at least about 106 days, at least about 107 days, at least about 108 days, at least about 109 days, at least about 110 days, at least about 111 days, or at least about 112 days.
49. The method of any one of claims 1 to 48, wherein the time interval between said administering of said priming vaccine and said administering of said boosting vaccine is about 64 days.
50. The method of any one of claims 1 to 49, wherein the method comprises administering two or more doses of the booster vaccine to the subject.
51. The method of any one of claims 1 to 50, wherein the method comprises administering each dose of a booster vaccine at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 9 weeks, at least about 10 weeks, at least about 11 weeks, at least about 12 weeks, at least about 14 weeks, at least about 16 weeks, at least about 1-2 weeks, at least about 2-3 weeks, at least about 3-4 weeks, at least about 4-5 weeks, at least about 5-6 weeks, at least about 6-7 weeks, at least about 7-8 weeks, at least about 8-9 weeks, at least about 9-10 weeks, at least about 10-11 weeks, at least about 11-12 weeks, at least about 12-13 weeks, at least 13-14 weeks, at least about 14-15 weeks, or at least about 15-16 weeks after administration of a prior vaccine.
52. The method of any one of claims 1 to 51, wherein the time interval between administering each dose of the booster vaccine and administering the prior vaccine is at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days , at least about 28 days, at least about 29 days, at least about 30 days, at least about 31 days, at least about 32 days, at least about 33 days, at least about 34 days, at least about 35 days, at least about 36 days, at least about 37 days, at least about 38 days, at least about 39 days, at least about 40 days, at least about 41 days, at least about 42 days, at least about 43 days, at least about 44 days, at least about 45 days, at least about 46 days, at least about 47 days, at least about 48 days, at least about 49 days, at least about 50 days, at least about 51 days, at least about 52 days, at least about 53 days, at least about 54 days, at least about 55 days, at least about 56 days , at least about 57 days, at least about 58 days, at least about 59 days, at least about 60 days, at least about 61 days, at least about 62 days, at least about 63 days, at least about 64 days, at least about 65 days, at least about 66 days, at least about 67 days, at least about 68 days, at least about 69 days, at least about 70 days, at least about 71 days, at least about 72 days, at least about 73 days, at least about 74 days, at least about 75 days, at least about 76 days, at least about 77 days, at least about 78 days, at least about 79 days, at least about 80 days, at least about 81 days, at least about 82 days, at least about 83 days, at least about 84 days, at least about 85 days , at least about 86 days, at least about 87 days, at least about 88 days, at least about 89 days, at least about 90 days, at least about 91 day, at least about 92 days, at least about 93 days, at least about 94 days, at least about 95 days, at least about 96 days, at least about 97 days, at least about 98 days, at least about 99 days, at least about 100 days, at least about 101 days, at least about 102 days, at least about 103 days, at least about 104 days, at least about 105 days, at least about 106 days, at least about 107 days, at least about 108 days, at least about 109 days, at least about 110 days, at least about 111 days, or at least about 112 days.
53. The method of any one of claims 1 to 52, wherein the subject has a bacterial infection, a viral infection, a parasitic infection, or a fungal infection.
54. The method of any one of claims 1 to 53, wherein the subject has cancer.
55. The method of any one of claims 1 to 54, wherein the subject has an autoimmune disease or disorder.
56. The method of any one of claims 1 to 55, wherein one or more of the priming vaccine or the boosting vaccine comprises a pharmaceutically acceptable carrier.
57. The method of claim 56, wherein at least one of the priming vaccine and boosting vaccine compositions further comprises an adjuvant.
58. The method of any one of claims 1 to 57, wherein at least one of the priming vaccine and the boosting vaccine is administered by a route selected from the group consisting of intramuscular, intraperitoneal, buccal, inhaled, intranasal, intrathecal, intravenous, subcutaneous, intradermal, and intratumoral, or administered to the interstitial space of a tissue.
59. A vaccine regimen comprising: A priming vaccine comprising deoxyribonucleic acid (DNA), wherein the DNA encodes a first peptide; This is followed by a booster vaccine comprising (i) ribonucleic acid (RNA) encoding the second peptide or (ii) the second peptide.
60. The vaccine regimen of claim 59, wherein the priming vaccine comprises an amount of DNA encoding an immunologically effective amount of the first peptide, and the boosting vaccine comprises an amount of RNA encoding an immunologically effective amount of the second peptide.
61. The vaccine regimen of claim 59, wherein the priming vaccine comprises an amount of DNA encoding an immunologically effective amount of the first peptide, and the boosting vaccine comprises an immunologically effective amount of the second peptide.
62. The vaccine regimen according to any one of claims 59 to 61, wherein the DNA comprises a minicircle, a plasmid, a bacmid, a minigene, a ministring DNA (linear covalently closed DNA vector), an end-closed linear duplex DNA (CELiD or ceDNA), a doggybone (dbDNA TM ) DNA, dumbbell DNA, minimalistic immunologically defined gene expression (MIDGE) vector, viral vector or non-viral vector.
63. The vaccine regimen of any one of claims 59 to 62, wherein the first peptide and the second peptide are derived from a bacterial, viral, fungal, or parasitic infectious agent.
64. The vaccine regimen of any one of claims 59 to 63, wherein the first peptide and the second peptide are derived from the same pathogenic organism.
65. The vaccine regimen of any one of claims 59 to 64, wherein the first peptide and the second peptide are identical in the prime vaccine and the boost vaccine.
66. The vaccine regimen of any one of claims 59 to 64, wherein at least one of the epitopes of the first peptide and the second peptide is different in the prime vaccine and the boost vaccine.
67. The vaccine regimen of any one of claims 59 to 66, wherein the DNA comprises a capsid-free end-closed DNA (ceDNA) vector comprising at least one nucleic acid sequence located between flanking inverted termini (ITRs), wherein the at least one nucleic acid sequence encodes the first peptide.
68. The vaccine regimen of any one of claims 59 to 62 or 65 to 67, wherein the first peptide and / or the second peptide is a tumor associated antigen or is associated with an autoimmune condition.
69. The vaccine regimen according to any one of claims 59 to 68, wherein the first peptide and / or the second peptide is selected from the group consisting of the peptides shown in Tables 1-8.
70. The vaccine regimen of any one of claims 59 to 69, wherein the DNA comprises a promoter sequence linked to the at least one nucleic acid sequence.
71. The vaccine regimen of any one of claims 62 to 70, wherein the ceDNA vector comprises at least one poly A sequence.
72. The vaccine regimen of any one of claims 62 to 71, wherein the ceDNA vector comprises a 5'UTR and / or intron sequences.
73. The vaccine regimen of any one of claims 62 to 72, wherein the ceDNA vector comprises a 3'UTR sequence.
74. The vaccine regimen of any one of claims 62 to 73, wherein the ceDNA vector comprises an enhancer sequence.
75. The vaccine regimen of any one of claims 67 to 74, wherein at least one of the flanking ITRs comprises a functional terminal resolution site and a Rep binding site.
76. The vaccine regimen of any one of claims 67 to 75, wherein one or both of the flanking ITRs are derived from a virus selected from the group consisting of: a parvovirus, a dependovirus, and an adeno-associated virus (AAV).
77. The vaccine regimen of any one of claims 67 to 76, wherein the flanking ITRs are symmetrical or asymmetrical relative to each other.
78. The vaccine regimen of any one of claims 67 to 77, wherein the flanking ITRs are symmetrical or substantially symmetrical.
79. The vaccine regimen of any one of claims 67 to 77, wherein the flanking ITRs are asymmetric.
80. The vaccine regimen of any one of claims 67 to 79, wherein one of the flanking ITRs is wild-type, or wherein two of the ITRs are wild-type ITRs.
81. The vaccine regimen of any one of claims 67 to 80, wherein the flanking ITRs are derived from different viral serotypes.
82. The vaccine regimen of any one of claims 67 to 81, wherein the flanking ITRs are selected from the group consisting of the viral serotypes shown in Table 8.
83. The vaccine regimen of any one of claims 67 to 82, wherein one or both of the flanking ITRs comprise a sequence selected from the group consisting of the sequences shown in Table 9.
84. The vaccine regimen of any one of claims 67 to 83, wherein at least one of the flanking ITRs is altered from a wild-type AAV ITR sequence by a deletion, addition or substitution that affects the overall three-dimensional conformation of the ITR.
85. The vaccine regimen of any one of claims 67 to 84, wherein one or both of the flanking ITRs are derived from an AAV serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12.
86. The vaccine regimen of any one of claims 67 to 85, wherein one or both of the flanking ITRs are synthetic.
87. The vaccine regimen of any one of claims 67 to 86, wherein one of the flanking ITRs is not a wild-type ITR, or wherein two of the flanking ITRs are not a wild-type ITR.
88. The vaccine regimen of any one of claims 67 to 87, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution in at least one of the ITR regions selected from A, A', B, B', C, C', D and D'.
89. The vaccine regimen of claim 88, wherein the deletions, insertions and / or substitutions result in the deletion of all or part of the stem-loop structure formed by the A, A', B, B', C or C' regions.
90. The vaccine regimen according to any one of claims 67 to 89, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of all or part of the stem-loop structure formed by the B and B' regions.
91. The vaccine regimen according to any one of claims 67 to 90, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of all or part of the stem-loop structure formed by the C and C' regions.
92. The vaccine regimen according to any one of claims 67 to 91, wherein one or both of the flanking ITRs are modified by deletion, insertion and / or substitution resulting in the deletion of part of the stem-loop structure formed by the B and B' regions and / or part of the stem-loop structure formed by the C and C' regions.
93. The vaccine regimen of any one of claims 67 to 92, wherein one or both of the flanking ITRs comprise a single stem-loop structure in the region, which in a wild-type ITR would comprise a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.
94. The vaccine regimen of any one of claims 67 to 93, wherein one or both of the flanking ITRs comprise a single stem and two loops in the region, which in a wild-type ITR would comprise a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.
95. The vaccine regimen of any one of claims 67 to 94, wherein one or both of the flanking ITRs comprise a single stem and a single loop in the region, which in a wild-type ITR would comprise a first stem-loop structure formed by the B and B' regions and a second stem-loop structure formed by the C and C' regions.
96. The vaccine regimen of any one of claims 67 to 95, wherein when the flanking ITRs are inverted relative to each other, both of the ITRs are altered in a manner that produces overall three-dimensional symmetry.
97. A method of treating a subject having a bacterial, viral, parasitic or fungal infection, the method comprising performing the method of any one of claims 1 to 58 or administering to the subject a vaccine regimen of any one of claims 59 to 96.
98. A method of treating a subject having cancer, the method comprising performing the method of any one of claims 1 to 58 or administering to the subject the vaccine regimen of any one of claims 59 to 96.
99. A method of treating a subject having an autoimmune disease or disorder, the method comprising performing the method of any one of claims 1 to 58 or administering to the subject a vaccine regimen of any one of claims 59 to 96.
100. A method of preventing a bacterial infection, a viral infection, a parasitic infection or a fungal infection in a subject, the method comprising performing the method of any one of claims 1 to 58 or administering to the subject a vaccine regimen of any one of claims 59 to 96.
101. A method of preventing cancer in a subject, the method comprising performing the method of any one of claims 1 to 58 or administering to the subject the vaccine regimen of any one of claims 59 to 96.
102. A method of preventing an autoimmune disease in a subject, the method comprising performing the method of any one of claims 1 to 58 or administering to the subject a vaccine regimen of any one of claims 59 to 96.
103. The method of any one of claims 97 to 102, wherein the method comprises administering two or more doses of the booster vaccine to the subject.
104. The method of any one of claims 97 to 103, wherein the method comprises administering the booster vaccine about 8 weeks after administration of the priming vaccine.
105. The method of any one of claims 97 to 104, further comprising administering one or more additional therapeutic agents to the subject.
106. The vaccine regimen of any one of claims 59 to 96, wherein the priming vaccine and the boosting vaccine are each formulated in a pharmaceutical composition.
107. The vaccine regimen of claim 106, wherein one or both of the priming vaccine and the boosting vaccine further comprises one or more additional therapeutic agents.
108. The vaccine regimen of any one of claims 59 to 96 or 106 to 107, wherein one or both of the priming vaccine and the boosting vaccine further comprises a lipid.
109. The vaccine regimen of claim 108, wherein the lipid is a lipid nanoparticle (LNP).
110. The vaccine regimen of any one of claims 106 to 109, wherein one or both of the priming vaccine and the boosting vaccine are lyophilized.
111. A kit comprising the vaccine regimen according to any one of claims 59 to 96 or 106 to 110 and instructions for use.
